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CHAPTER 1
Introduction
and
Aims of the study
8Preface
The term mastocytosis can be summarized as an accumu-
lation of mast cells without an apparent cause. In the ma-
jority of the cases the disease is manifest in the skin and 
can be diagnosed on clinical suspicion and skin biopsy. 
Mastocytosis has a wide clinical spectrum and it is not a 
disease limited to the skin. As cutaneous manifestations of 
mastocytosis form one of the key features of this rare dis-
ease, the dermatological aspects of this disease continue 
to be relevant.
History of the mast cell and mastocytosis
In 1878 Paul Ehrlich was the first investigator to describe 
cells that stained reddish—purple with aniline dyes in 
connective tissues. He called them “mästzellen”1, 2. Net-
tleship and Tay described mastocytosis in the skin in 1869 
as a symmetrical maculopapular eruption with urtication 
of lesions after rubbing3. In 1878 Sangster proposed the 
term ‘urticaria pigmentosa’ (UP) for such lesions 4 a term 
now replaced by maculopapular mastocytosis. Mast cells 
were recognized as the cellular substrate of skin lesions 
by Unna in 18875. The term mastocytosis was first used 
by Sézary et al in 19366. Multiple organ involvement in 
a patient with mastocytosis in the skin was reported by 
Ellis in an autopsied patient in 19497. Bony changes in 
patients with UP were observed by Sagher in 1957 and a 
malignant form of mastocytosis presenting as leukemia 
was reported in 1957 by Efrati8,9.
Biology of the mast cell
Mast cells (MCs) originate from CD34+ hemopoietic pro-
genitor cells (stem cells) in the bone marrow (BM) 10,11. 
Stem cells are self-regenerating and may differentiate into 
various types of committed progenitors. Commitment of 
differentiation is considered to be determined randomly 
by intrinsic mechanisms. Erythroid, mast cell, eosinophil 
and neutrophil progenitors can survive, differentiate, and 
proliferate only in the presence of the appropriate growth 
factors12. Human MCs require a much longer period to 
develop compared with other cell lineages12. Generally, 
MCs mature in tissues in which they are normally present. 
Mature MCs are not present in peripheral blood. Mature 
MCs have the capacity to proliferate11.
 Studies in rodents showed that the life span of MCs var-
ied from weeks to months. Mast cells are normally present 
in all connective tissues where they may be particularly 
numerous beneath the epithelial surfaces of the skin, in 
the respiratory system, in the gastrointestinal and the gen-
itourinary tracts, adjacent to blood or lymphatic vessels, 
and near or within the peripheral nerves13. 
 There are two types of MCs in tissue—the mucosal 
(MC
T
) and the connective tissue (MC
TC
) MCs. The two 
types are distinguished on the basis of structural, bio-
chemical, and functional differences and have been well 
characterized. The connective tissue MCs are the predom-
inant type in the normal skin and in the skin of patients 
suffering from maculopapular mastocytosis.
Staining of mast cells
Mast cells are identified in tissue sections by their charac-
teristic granules that stain metachromatic after exposure 
to basic dyes11,14. A distinct array of cytoplasmic and cell 
surface antigens are also expressed in MCs15. The surface 
antigen stem cell factor receptor (KIT/CD117) is the most 
important growth factor receptor in MCs. It is typically 
expressed on MCs in various organs independently of the 
maturation stage of MCs or cell activation15. Mast cells 
differ from each other in the expression of mediators, the 
response to diverse stimuli and the expression of cell sur-
face antigens depending on the environmental and other 
factors16-19.
 Staining of tissue sections with hematoxylin & eosin, 
which is routinely used in pathology laboratories is nei-
ther specific nor reliable for establishing the presence 
of MCs. Other histochemical and immunohistochemical 
stains, such as toluidine blue, mast cell tryptase and chy-
mase, Leder stain, and CD117 are more specific for MCs. 
The classic histochemical stain used to demonstrate MCs 
is the metachromatic stain toluidine blue. The membrane-
bound granules in the MC cytoplasm contain biologically 
active mediators including acidic proteoglycans, which 
bind basic dyes such as toluidine blue. Since the stained 
granules typically acquire the color that is different from 
that of the native dye, they are referred to as metachro-
matic granules20. 
 The most specific method for identifying MCs in tis-
sues is by immunohistochemical staining for mast cell 
tryptase. During the past 10 years, a number of useful 
techniques for the enumeration and phenotypic analysis 
of MCs in the bone marrow have been developed. Most 
of these techniques are based on the unique expression of 
the stem cell factor receptor KIT on these cells. In fact, in 
the bone marrow, KIT is expressed on MCs and CD34+ 
hemopoietic progenitors, but not on other mature hemo-
poietic cells 21-27. 
Stem cell factor
Stem cell factor (SCF) is a major migration, proliferation, 
maturation and survival factor. It is a cytokine produced 
by a variety of cells including mesenchymal cells and 
fibroblasts. It is synthesized as a transmembrane protein 
and is proteolytically cleaved to generate a soluble form28. 
Soluble SCF molecules exist as homodimers in the plas-
ma and cross-link two KIT receptor molecules when they 
bind to the cell surface. Cross-linking of KIT results in the 
activation of the tyrosine kinase enzymatic activity29.
 Stem cell factor is expressed in various tissue microen-
vironments in which MCs normally develop. Precursors 
9of MCs require the expression of the proto oncogene c-kit, 
which gives rise to KIT a transmembrane receptor with 
intrinsic tyrosine kinase activity, for the normal response 
to SCF30-32.
 In normal cells, KIT has been shown to play a major 
role in hematopoiesis (in the differentiation of erythroid, 
lymphoid, megakaryocytic and myeloid precursors)33, 
gametogenesis34, MC development and function35, mela-
nogenesis33 and gastrointestinal function36. Activation of 
the SCF/KIT signaling pathway in MCs is associated with 
multiple biological effects depending on the activated cell. 
Among others, these effects include cell proliferation, 
maturation/differentiation, and suppression of apoptosis, 
degranulation and changes in the adhesion properties and 
motility of the activated cells37. Expression of the KIT 
protein has been reported in both normal progenitors, on 
normal mature MCs and various other cell types as well 
as neoplastic cells from the gastrointestinal tract, lung, 
breast and myeloid and lymphatic origin38. In humans, the 
encoding gene for KIT (c-kit) is located on chromosome 
4q12. Genomic DNA of human c-kit spans approximately 
89 kb and contains 21 exons which are transcribed/trans-
lated into a receptor molecule with a molecular mass of 
145 kD and 976 amino acids in length39,40.
Figure 1. KIT structure and effects.
Adapted from Orfao A, Garcia-Montero AC, Sanchez L, Escribano L; REMA. 
Recent advances in the understanding of mastocytosis: the role of KIT 
mutations. Br J Haematol 2007, 138(1):12-30
The following domains are recognized; the extracellular 
domain: five immunoglobulin-like loops of the extracel-
lular domain of KIT. The first three immunoglobulin (Ig)-
like loops of the extracellular domain form the binding 
site for SCF41,43. The fourth and fifth loops play a role in 
stabilizing the SCF-induced KIT dimer44,45. The trans-
membrane domain, the juxtamembrane domain; this auto 
inhibitory juxtamembrane domain contains alpha-helical 
elements whose proper configuration is essential for the 
down regulation of tyrosine phosporylation44,46,47. The TK 
domain, this domain is the kinase portion of KIT is com-
posed of two domains which are separated by a kinase 
insert: (1) the TK1 domain contains the ATP binding site, 
and; (2) the TK2 domain containing the phosphotransfer-
ase site and the activation loop (Fig 1)38. Based on the lo-
calization of the phospho (p)-tyrosine binding sites, three 
preferential regulatory sites of KIT have been identified 
with activating and/or inhibitory effects on one or more 
downstream signaling transduction pathways: (1) the jux-
tamembrane domain; (2) the tyrosine kinase insert; and 
(3) the activation loop in the TK2 domain38. 
Figure 2. Sites of most common points of mutation in masto-
cytosis in KIT.
Adapted from: Yanagihori H, Oyama N, Nakamura K, Kaneko F. c-kit Muta-
tions in patients with childhood-onset mastocytosis and genotype-pheno-
type correlation. J Mol Diagn 2005, 7(2):252-7
Occurrence of different point mutations and frame dele-
tions/insertions of KIT have been shown to cause altera-
tions of the downstream KIT signaling pathways that 
convert the KIT proto-oncogene into an active, dysregu-
lated (ligand independent) oncoprotein capable of induc-
ing neoplastic transformation of normal KIT expressing 
cells48. The more frequently observed gain of function 
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mutations in the KIT sequence, in association to a specific 
disease or group of diseases include acute myeloid leuke-
mia; gastrointestinal stromal tumor; nasal and nasal-type 
NK/T-cell lymphoma; mastocytosis; melanoma; myelo-
proliferative disorder; seminoma/germinoma. Known loss 
of function mutation in C-kit in human leads to piebald-
ism which in fact is inherited in an autosomal manner49. 
Figure 2 shows a scheme of the most common sites of 
mutation in mastocytosis.
C-kit mutations
Multiple KIT mutations have been reported in patients 
with mastocytosis; many of these mutations are associat-
ed with KIT phosphorylation and downstream activation, 
independent of SCF binding50. In order to better under-
stand the impact of KIT mutations Longley et al (2001) 
proposed that the activating KIT mutations be classified 
into two major groups based on their topological localiza-
tion51. 
 The ‘regulatory	 type’ mutations that typically affect 
regulation of the kinase activity of the KIT molecule by 
disrupting the auto inhibitory a-helix at the juxtamem-
brane domain of KIT. These mutations affect the binding 
of signal transducing or regulatory molecules to KIT and/
or inducing ligand-independent dimerisation and activa-
tion; most frequently these ‘regulatory type’ mutations 
occur at the juxtamembrane domain of KIT52.
The second type are the ‘enzymatic	pocket	type’ mutations 
which directly affect the enzymatic site at the TK2 activa-
tion loop and induce activation of KIT in the absence of 
dimerisation of the receptor51. 
 The large majority (>90%) of adult cases with systemic 
mastocytosis (SM), mutations in the activation loop of KIT 
(most frequently D816V) are detected in MC in associa-
tion with an aberrant CD25+ phenotype53. Despite the fact 
that the D816V KIT mutation is present in >90% of SM, 
with the exception of rare cases of SM and MCL the exact 
frequency of this mutation in patients with cutaneous mas-
tocytosis (CM) remains unknown53. Accordingly, while a 
significant proportion of CM cases with a childhood onset 
do not show the D816V KITmutation54 KIT mutations at 
codons 509, 533, 815, 816 and 839 have been reported in 
adult CM patients 55-58. Interestingly an analysis of c-kit 
mutation in skin biopsy specimens from a large group of 
adults with mastocytosis in the skin showed a significantly 
different proportion of D816V mutation depending on the 
age of onset. The patients with disease starting at child-
hood had D816V in 44% of the cases versus 77% in adult 
onset mastocytosis59. Altogether, the greatest frequency of 
KIT mutation is found at codon 816 and is consistent with 
Domain Exon Mutation Consequense Frequency
of mutation
Comments Reference
Extracellular  8  delD419  Unknown <5  Familial SM Hartmann et al (2005)
 9  K509I  Unknown <5  Familial SM Zhang et al (2006)
Transmembrane  100  F522C  Activating <5  SM Akin et al (2004)
 10  A533D  Activating <5  Familial CM Tang et al (2004)
Juxtamembrane  11  V559I  Activating <5  ASM Nakagomi and Hirota (2007)
 11  V560G  Activating <5  ISM, MCL Furitsu etal (1993);
Buttner etal (1998)
Activation loop  17  R815K  Unknown <5  Paediatric up Sotlar et al (2003)
 17  D816V  Activating >90  Adult SM, Paediatric UP Garcia-Montero et al (2006)
 17  D816V  Activating …  Paediatric up, Paediatric UP Yanagihori et al (2005)
 17  D816Y  Activating <5  SM Longley etal (1999)
 17  D816H  Unknown <5  SM-AML Pullarkat etal (2003)
 17  D816F  Activating <5  SM Longley etal (1999) 
 17  I817V  Unknown <5  WDSM Garcia-Montero et al (2006)
 17 insV815I 816  Unknown <5  SM Garcia-Montero et al (2006)
 17  D820G  Unknown <5  ASM Pignon etal (1997)
 17  E839K  Inactivating <5  UP Longley etal (1999)
CM, cutaneous mastocytosis; SM, systemic mastocytosis; AML, acute myeloblastic leukemia; ISM, indolent systemic mastocytosis; UP, urticaria pig-
mentosa (=maculopapular mastocytosis); CML, chronic myeloid leukemia; MCL , mast cell leukemia MF, myelofibrosis; MPD, myeloproliferative 
disorder; ASM, aggressive systemic mastocytosis; WDSM, well-differentiated systemic mastocytosis 
Adapted from Orfao A, Garcia-Montero AC, Sanchez L, Escribano L; REMA. Recent advances in the understanding of mastocytosis: the role of KIT muta-
tions.Br J Haematol. 2007, 138(1):12-30 
Table 1. Known KIT mutations in mastocytosis 
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systemic mastocytosis53,59. These observations support the 
notion that genetic examination of the KIT mutational sta-
tus of MCs from lesional skin, BM or other extracutaneous 
organs (peripheral blood, spleen, liver, lymph nodes and 
pleural fluid), is of great help for the differential diagnosis 
of CM versus SM60. Furthermore the CD25 expression on 
cutaneous mast cells in mastocytosis in the skin appears to 
be predictive of systemic mastocytosis61.
Impact of KIT mutation/activation 
One of the most frequent and evident clinical manifesta-
tions of mastocytosis is the increased proliferation and ac-
cumulation of neoplastic MCs in different organs and tis-
sues. This increased proliferation and survival of MCs is 
because of constitutive activation of KIT. Although, there 
is an increased numbers of MCs in the skin, BM and other 
tissues in patients with SM, a large variation in the overall 
MC burden is encountered in individual patients. KIT mu-
tations have been identified not only in MCs from SM pa-
tients, but they may also be found in other BM hemopoi-
etic cell compartments, particularly among CD34+ hemo-
poietic progenitor and precursor cells (HPC), eosinophil , 
neutrophil and monocytic precursors53. Interestingly, the 
frequency of patients with involvement of KIT mutation 
in BM cell compartments other than MCs is significantly 
lower among patients included within those types of mas-
tocytosis associated with a good prognosis, in comparison 
with cases of aggressive systemic mastocytosis (ASM), 
mast cell leukemia (MCL) and systemic mastocytosis 
with an associated clonal hematologic non-mast cell lin-
eage disease (SM-AHNMD). C-Kit mutation may involve 
the mast cell progenitors at different levels of commit-
ment with varying potentials for expansion. The D816V 
KIT mutation may affect a committed MC progenitor in 
patients with limited indolent disease. In contrast, patients 
with more extensive disease variants, such as smoldering 
systemic mastocytosis or aggressive mastocytosis, may 
have an earlier pluripotential progenitor cell affected, re-
sulting in multilineage hemopoietic involvement similar 
to other myeloproliferative disorders ( Fig. 3 )62-64.
 Altogether, these results suggest that SM patients show-
ing multilineage involvement of BM hemopoietic cells 
may represent more advanced stages of the disease. How-
ever, the relatively stable course of the disease in most 
SM patients and the observation that the same KIT muta-
tion (e.g. D816V) may be associated with indolent (good 
prognosis) and malignant tumors53 underline the potential 
role of other genetic and/or epigenetic factors in determin-
ing the progression/outcome of the disease64. It is recently 
suggested that KIT D816V alone is sufficient to cause 
indolent systemic mastocytosis with a favorable course. 
Additional defects may be required to cause severe types 
of systemic mastocytosis65. 
Classification of mastocytosis
The rapidly accumulating knowledge on mastocytosis has 
led to a speedy evolution in the classification of masto-
cytosis:
1. The Kiel classification (Lennert & Parwaresch, 1979) 
was followed by others in which mastocytosis was di-
vided into well defined clinico-biological entities66.
2. The first consensus classification of mastocytosis was 
proposed by Metcalfe in 199167.
Figure 3. Explanation of varying clonal expansion
Hypothetical explanation of varying clonal expansion patterns in 
mastocytosis. The D816V c-kit mutation (denoted by ‘x’) may occur 
in a mast cell lineage-committed progenitor (a) or a multipotential 
progenitor (b) resulting in single or multilineage involvement, respec-
tively. The mutation would be detectable in peripheral blood in the 
latter but not in the former scenario. Patients with systemic smol-
dering mastocytosis or those with an associated myeloproliferative 
disorder often carry the D816V c-kit mutation in multiple peripheral 
blood lineages, while patients with limited systemic indolent disease 
have this mutation detectable only in lesional tissue mast cells.
Taken from Akin C. Clonality and Molecular Pathogenesis of Mastocytosis. 
Acta Haematol 2005, 114:61-69
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The associations between mastocytosis and increased se-
rum Tryptase levels68 , the presence of the D816V-activat-
ing KIT mutation69-71 and an aberrant CD25+ and CD2+ 
immunophenotype of BM MCs 21 were most relevant. The 
identification of these new biological markers has facili-
tated a better understanding of the molecular mechanisms 
involved in mastocytosis and has also contributed towards 
improving the classification and the diagnosis of the dis-
ease and promotes the search for effective molecular-tar-
geted therapies64,72,73.
3.  The World Health Organization (WHO) proposed new 
criteria for the classification and the diagnosis of mas-
tocytosis in 200174. An International Working Confer-
ence proposed new standards last year 75. In addition, 
this International Working Conference discussed the 
differential diagnosis of new poorly defined subgroups 
of patients with increased and/or altered MCs.
Over the years, the descriptive types of classification have 
been of lost in value but may be applicable in the cutaneous 
mastocytosis. 
 The WHO classification published in 2001 defines 7 dis-
ease-variants: cutaneous mastocytosis (CM), indolent sys-
temic mastocytosis (ISM), SM with an associated clonal 
hematological non-MC-lineage disease (SM-AHNMD), 
aggressive SM (ASM), MC leukemia (MCL, leukemic 
SM-variant), MC sarcoma (MCS), and extracutaneous 
mastocytoma (Table 2) 74,76.
Systemic mastocytosis is defined using major and minor 
SM-criteria in this classification system. The diagnosis is 
SM if at least one major and one minor or at least three 
minor SM-criteria are fulfilled. Criteria defining the MC-
burden, involvement of non-MC-lineages, and aggres-
siveness of disease (C-Findings), are to sub classify SM. 
In addition, a thorough hematological evaluation is under-
taken to reveal or exclude an AHNMD74-76. 
Table 3. Diagnostic WHO criteria for systemic mastocytosis: 
SM criteria
If at least one major and one minor criterion or three minor criteria are 
fulfilled, the diagnosis SM can be established. 1Other activating mutations 
at codon 816 of c-kit also count as a minor criterion.
Taken from Horny H-P, Sotlar K, Valent P: Mastocytosis: State of the Art. Patho-
biology 2007;74:121-132
In the recently published “Standards and standardization 
in mastocytosis: Consensus Statements on Diagnostics, 
Treatment Recommendations and Response Criteria” by 
Valent, Akin, Metcalfe et al. diagnostic algorithms and 
procedures are highlighted in great details. However, it is 
beyond the scope of this dissertation to present an in depth 
description of hematological, pathological and diagnostic 
issues in systemic mastocytosis75.
Management of mastocytosis
There is no curative treatment for mastocytosis. However, 
since the clinical picture and the severity of the disease 
are widely varied, the management of the disease also 
varies accordingly. The large majority of the patients re-
quire no more than reassurance and advice, while other 
fatal systemic cases may be candidates for cytoreductive 
therapies. The treatment in all cases is tailored to alleviate 
patient discomfort.
 Treatment targets include constitutional symptoms, cu-
taneous symptoms, skeletal complaints, gastrointestinal 
symptoms and neurological symptoms. Constitutional 
1. Cutaneous mastocytosis
Maculopapular CM1
Diffuse CM
Mastocytoma of skin
(Mast cell sarcoma of skin)
CM
MPCM
DCM
2. Indolent systemic mastocytosis
Smouldering SM
Isolated bone marrow mastocytosis
ISM
SSM
BMM
3. Systemic mastocytosis with an 
associated clonal hematologic 
non-mast cell lineage disease
SM-AHNMD2
4. Aggressive systemic mastocytosis
Lymphadenopathic SM with eosinophilia3 ASM
5. Mast cell leukemia
Typical MCL
Aleukemic MCL4
MCL
6. (Extracutaneous) mast cell sarcoma MCS
7. Extracutaneous mastocytoma
Table 2. WHO classification of mastocytosis
Major
Multifocal compact infiltrates of MCs in bone marrow or 
other extracutaneous organ(s) (>15 MCs)
Minor
a MCs in bone marrow or other extracutaneous 
organ(s) show an abnormal spindle-shaped 
morphology (>25%)
b c-kit mutation D816V in extracutaneous organ(s)1
c MCs in the bone marrow express CD2 or/and CD25
d Serum tryptase >20 ng/ml (does not count in 
patients who have an associated hemopoietic clonal 
non-MC lineage disease (= AHNMD)
1 Also termed urticaria pigmentosa; 
2 The subtype of the ‘AHNMD’ has to be defined by WHO criteria as well; 
3 In a subgroup of these patients, the FIPL1-PDGFRA fusion gene is detectable; 
4 Circulating mast cells are <10%.  
Taken from Horny H-P, Sotlar K, Valent P: Mastocytosis: State of the Art. Patho-
biology 2007;74:121-132
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symptoms manifest as dizziness, hypotension, flushing, 
headache and shock. Cutaneous symptoms are pruritus, 
wheals, and redness, swelling and cosmetic disturbances 
such as nodules, macules. Skeletal complaints include 
osteoporosis, osteopenia and bone pain. Gastrointestinal 
symptoms constist of peptic ulcer, bleeding, cramping, 
nausea, vomiting and diarrhea. Neurological symptoms 
include headaches and specific IgE-mediated allergic re-
actions. 
 In case of systemic mastocytosis other than indolent 
forms choice of targeted and cytoreductive therapy de-
pends on the presence of B- or C-findings. B-findings 
include signs of multilineage-involvement (hypercellular 
marrow, dysplasia), a massive MC burden (huge MC mar-
row infiltration, serum Tryptase level > 200 ng mL-1), and 
organomegaly (spleen, liver, lymph nodes). C-Findings 
are the result of a clinically relevant impairment or loss 
of organ function caused by local infiltrates of MCs. The 
diagnosis is “smoldering SM” if B-Findings are present. 
The prognosis and the natural course in SSM are varied. 
Many patients remain in a smoldering state for decades. 
Response criteria to cytoreductive drugs strictly relate to 
C-findings. These have been generally agreed upon and 
should be applied in all patients and thus are only appli-
cable to patients with ASM or MCL77. A detailed discus-
sion of cytoreductive therapy in mastocytosis is beyond 
the scope of this dissertation. 
In conclusion, the present insight into the operative mech-
anisms in mastocytosis has led to the understanding that 
mastocytosis is a clonal systemic disease in most if not in 
all of the adult cases as well as a part of the juvenile cases. 
The dermatological aspects of mastocytosis are refined or 
even redefined with this notion in mind. Mastocytosis in 
the skin is considered to be the starting point from which 
systemic mastocytosis must be excluded. The diagnostic 
end point is either called systemic mastocytosis, in case 
mastocytosis is diagnosed elsewhere in the body or cuta-
neous mastocytosis, if this is not the case. Published data 
or data that were collected in the period before this algo-
rithm was in practice are included in this thesis. From this 
point of view, it is now also possible to re-write already 
published articles using a different classification of mas-
tocytosis in the skin.
In this thesis, a collection of already published articles on 
dermatologically oriented work dealing with practical is-
sues concerning patients with mastocytosis is presented. 
Therefore, the main theme of this thesis is the dermato-
logical aspects of mastocytosis with particular attention to 
the differences between childhood onset mastocytosis and 
adult onset mastocytosis.
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Aims of the thesis
The aims of the studies described in this thesis were:
1. To provide an overview and an update of the clinical aspects of mastocytosis from a dermatologist’s 
perspective with focus on the differences between pediatric and adult onset of the disease.
2. To describe current diagnostic methods for mastocytosis in dermatological practice.
3. To present a method on the clinical evaluation of the disease severity in cutaneous mastocytosis.
4. To update the already existing diagnostic and therapeutic guidelines in pediatric mastocytosis.
Various approaches described in the various chapters were pursued in order to achieve these objectives.
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Mast cells have a prominent, although not completely understood, participation in both
immunity and disease. Well-known disorders in which mast cells play a prominent and
undisputed role are mastocytosis and urticaria. Mastocytosis has been classified more clearly,
based on international consensus meetings and reports of the European Network on
Mastocytosis (Consensus Mastocytosis 2007) in the last 5 years. Urticaria is elicited by a great
diversity of factors and entities. Treatment points at avoidance, elimination or treatment of the
eliciting stimulus or cause, inhibition of mast cell mediator release or therapy of target tissues
of mast cell mediators (Consensus Urticaria 2006). Chronic urticaria is believed to have an
underlying autoimmune pathogenesis in almost 50% of cases. In a disease such as atopic
dermatitis, the role of mast cells is probably underexposed, but is beyond the main scope of
this review. In this review; we stress the important differences between children and adults
with these disorders. Recent advances in mast cell-mediated skin diseases, such as
mastocytosis and urticaria, and differences based on age are subject of discussion, with focus
on the literature published in the last 5 years.
KEYWORDS: mast cell  mastocytosis  ur ticaria
Our understanding of the contribution of mast
cells (MCs) in skin diseases, particularly in
wound healing, angiogenesis and prolifera-
tion, is still in its infancy. The exact role of
MCs in different tissues is poorly understood
with varying characteristics of MCs in different
tissues. MCs play a prominent role in several
inflammatory and proliferative disorders.
The most important MC disease is mastocy-
tosis, which can be roughly distinguished into
cutaneous mastocytosis (CM) and systemic
mastocytosis (SM). Mastocytosis is character-
ized by a deviant MC proliferation. MC prolif-
eration may be limited to the skin, which is
called CM. It may also involve one or more
extracutaneous organs, such as the bone mar-
row, when it is called SM, which is considered
to be a clonal disease.
The most well-known inflammatory condi-
tions in which MCs play a role are urticaria
and atopic dermatitis (AD), although its role
in the latter is underexposed and probably
underappreciated (FIGURE 1 & BOX 1) [1].
MCs originate from pluripotent hematopoietic
bone marrow stem cells. Precursor cells leave
the bone marrow and migrate into the blood
and invade the tissue, where they proliferate and
differentiate into mature MCs.
MCs are most abundantly present in the der-
mis close to the epidermis where they may stim-
ulate or enhance neoangiogenesis in normal and
pathological conditions. These new vessels facil-
itate increased transport of complement com-
ponents and antibodies, although complement
and antibodies reach all tissues, particularly via
normal blood vessels. Both complement com-
ponents and antibodies play a role against pene-
trating antigens [1]. MCs are not only increased
in number in lesions of AD, but also in num-
mular eczema. In both conditions, MCs are able
to maintain neurogenic inflammation [2]. Urti-
caria is a common disorder with various patho-
genic mechanisms, but the result is cutaneous
MC activation with release of histamine and
other vasoactive or proinflammatory mediators
being a central process [3 5].
This review focuses on recent developments in
the last 5 years in MC-mediated skin diseases,
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such as mastocytosis and urticaria. Other diseases with a possible
or suspected role of MCs will only be mentioned briefly.
Disorders in which MCs play a role
Disorders in which MCs play an established role are listed in
BOX 1. These disorders can be broadly divided into dermatoses,
proliferative processes and others.
Effective measures against MCs or against mediators
released by MCs are the cornerstone in the treatment of mas-
tocytosis and urticaria. Other diseases in which the MC may
be important are AD (most presumably), hemangioma
(speculative), scars (speculative) and keloid (speculative).
Mastocytosis
Mastocytosis consists of a heterogeneous group of diseases
characterized by abnormal proliferation and accumulation of
MCs in one or more organs, particularly the skin [6]. A cuta-
neous form of mastocytosis with different variants and sev-
eral systemic forms of mastocytosis are distinguished. For
practical pediatric and general dermatology aspects, we rec-
ognize differences between pediatric and adult-onset mani-
festations. However, in the recent consensus, this difference
was not highlighted as such [6]. Pediatric mastocytosis is con-
sidered in most cases to be reactive, whereas the adult form is
clonal and tends to progress slowly. Pediatric mastocytosis
can also be persistent and progressive. The adult variants
may more frequently develop into serious conditions, such as
malignant MC processes [6]. However, most adult variants
may stay indolent for decades. Malignant forms of the dis-
ease are generally apparent at the initial diagnosis and rarely
evolve from the common indolent variants. By contrast,
pediatric mastocytosis is also not always reactive, as reported
in some recent studies in which D816V c-kit mutation was
demonstrated in a significant number of cutaneous lesions in
pediatric patients [7]. Clinically, CM expresses as maculopa-
pular mastocytosis (solitary mastocytoma, urticaria pigmen-
tosa, diffuse CM and telangiectasia macularis eruptive per-
stans). Rubbing and trauma of the affected skin results in a
wheal with a flare (Dariers sign). SM can occur with and
without skin lesions and symptoms. It is known as indolent
SM when there are no symptoms. If there are symptoms,
then they are primarily of systemic origin. Based on Tryptase
serum values, presence of hematological aberrations and
presence of c-kit mutations in non-MC lines and other
investigations, one can stage the disease severity of
mastocytosis (FIGURE 2).
There is no specific treatment for mastocytosis. For treat-
ment options, roughly three practical categories can be gener-
ally recognized: pediatric, adult cutaneous and (adult and
pediatric) SM [2]. For a more detailed classification, we recom-
mend the 2003 WHO classification of mastocytosis recogniz-
ing more than three categories of mastocytosis, which are fur-
ther defined by the presence of B and/or C findings, which
determine the indicated therapeutic modality in each case.
However, this review is limited to skin manifestations only
(FIGURE 3 & BOX 2) [1] .
Treatment of mastocytosis
Treatment of mastocytosis in childhood is usually unnecessary.
In general, treatment of mastocytosis, both in children and
adults, is only indicated when symptoms are present [8 1 0].
Similar to that in other diseases,
patient education is an important tool for
guiding the patients and affected children
and their parents. Affected children and
their parents are advised to avoid agents
such as aspirin, NSAIDs, codeine, mor-
phine, alcohol, thiamine, quinine, opi-
ates, gallamine, decamethonium, pro-
caine, radiographic dyes, dextran,
polymyxin B, scopolamine and
D-tubocurarine. All these agents precipi-
tate the release of MC mediators. This
list is especially important for adults,
because several of the agents are not used
in children. Diets are of little value in
patients in whom food allergy or intoler-
ance are suspected. However, histamine-
liberating foods, such as banana, kiwi
and others, should be avoided.
Therapy is aimed at alleviating clinical
symptoms of mastocytosis. If mastocyto-
sis presents in children aged younger
Figure 1. Functions of mast cells in physiological and pathological states.
Mast cells may play crucial roles in various disease states, including vascular disease, fibrotic 
states, rheumatological disease, certain malignancies and in host defense against infectious 
pathogens. The probable roles of the mast cell in human diseases are summarized.
PG: Prostaglandin.
Adapted from [28].
Chronic inflammation
Cytokines–chemokines Tryptase, histamine, 
leukotrienes, PG
Atherogenesis
Plaque rupture
Vascular remodeling
Wound repair-remodeling processes Phagocytosis and killing of bacteria
Primary immune defense
• Leukocyte recruitment
• TNF-α secretion
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than 5 years, most cases of maculopapular mastocytosis (urti-
caria pigmentosa and mastocytoma) follow a benign course.
Maculopapular childhood mastocytosis often spares the sun-
light-exposed areas, indicating why UV light is a therapeutic
option. Therapy is often limited to reas-
surance of the parents and consists of
advice on avoiding factors known to
stimulate or induce MC degranulation
and to prevent serious events. 
Bullae may be present in the first 2 years
of life, and can be treated by local general
care and preventing infection. This presen-
tation mimics staphylococcal scalded skin
syndrome [8]. Bullae formation may occur
in active mastocytosis, as well as maculo-
papular mastocytosis (formerly known as
urticaria pigmentosa) and diffuse CM.
The first step of treatment is relief of
pruritus, urtication and flushing, which
can be achieved by H1 receptor antago-
nists (e.g., dimentidene 0.05 mg/kg daily
in three doses, hydroxyzine 2 mg/kg daily
in three doses, cetirizine 0.250 mg/kg
daily in two doses) or levocetirizine
0.125 mg/kg daily, which have proved to
be very safe. Higher doses than registered
are probably required for effectiveness.
H2 receptor antagonists (e.g., raniti-
dine 4 mg/kg daily) may be added, espe-
cially if H1 receptor antagonists have
insufficient effect or when gastrointesti-
nal symptoms of hyperacidity or ulcera-
tion are present. Patients with diarrhea
may also benefit from treatment with an
H2 receptor antagonist. 
For gastrointestinal symptoms, disodium chromoglycate may
be a useful addition, especially for diarrhea. Ketotifen, another
MC stabilizer, was reported not to have more advantages when
compared with hydroxyzine. 
Treatment of children with maculopapular mastocytosis
(formerly urticaria pigmentosa) may also include topical ster-
oids (diluted to 25%) under wet dry wraps (double wraps
application, rewetted every 2 h) [10,11]. Strict monitoring of
cortisol levels, weight and growth are essential. This treat-
ment is contraindicated in puberty for reasons of develop-
ment of striae. Isolated mastocytomas may be treated with
topical steroids with occlusive dressings. This is especially
indicated if there are persistent severe symptoms. If this fails,
excision may be considered on rare occasions. 
Children with a history of anaphylaxis must be equipped
with an epinephrine autoinjector and parents and (older)
children should be instructed on self medication (for instruc-
tions also see [102]). Taking preventive measures in patients
with mastocytosis undergoing anesthesia is controversial. 
When flushing or pruritus is prominent, antihistamines
are used, but the current generation has limited affectivity.
In the case of chronic diarrhea, sodium cromoglycate is
indicated [12].
Box 1. Cutaneous inflammatory and proliferative 
disorders in which mast cells play an established 
or a speculative role.
Allergy, drug eruptions
Dermatitis, exanthemas
Atopic dermatitis
Urticaria
P soriasis
Proliferative disorders
Mastocytosis
Hemangioma?
Malignant skin processes?
Others
S cars?
Keloid?
Figure 2. Algorithm of disease staging.
CM: Cutaneous mastocytosis; SM: Systemic mastocytosis.
Mastocytosis in the skin
Mastocytosis in the skin
Childhood Adult
Serum Tryptase Tryptase
<20 ng/ml >20 ng/ml >100 ng/ml
+ other signs of 
systemic disease
No No Yes
Yes
CM
Monitoring until adolescence (18 years)
Check once yearly
Skin lesions regress Persist
+ +
Tryptase < 20 ng/ml >20 ng/ml
No
Monitoring?
Complete staging after
systemic mastocytosis
No Yes
Diagnosis
CM SM
Monitoring once yearly
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In most adults, the disease is more severe and progressive.
The percentage of SM is higher, but less common in dermatol-
ogy practice. Internal medicine physicians often see more com-
plicated cases. National or international registration would
improve knowledge on mastocytosis. However, many cases are,
or at least begin as cutaneous forms, in which there is special
danger for wasp stings. Infrequently, cases are first encountered
after anaphylaxis following a wasp sting [13,14].
Adults with a history of anaphylaxis are treated in the same
way as children (see earlier).
Taking preventive measures in patients with mastocytosis
undergoing anesthesia is indicated in those with serum Tryptase
values of 20  g/ml and more. We recommend the following
perioperative measures, but evidence-based data are lacking:
Close monitoring of all patients, the
avoidance of known histamine-releasing
drugs and a continuous availability of
emergency drugs;
Patients are hospitalized 1 day before
anesthesia and surgery;
Prednisolone at a stress dosage and anti-
histamines are started 1 day before and
continued 1 day after. 
Treatment with drugs, such as pred-
nisone (short courses) or UV therapy with
UVA or psoralen and UVA (PUVA), may
have a place in adults (they do not have a
place in first-line treatment of pediatric
mastocytosis) [8].
Systemic mastocytosis
Systemic mastocytosis is only dealt with
briefly, because it is not within the scope
of this review.
Systemic mastocytosis (diagnosis based on WHO criteria) is a
disease characterized by multifocal MC proliferation in the bone
marrow or other extracutaneous organs. It is a rare condition
that often involves the bone marrow. Many patients with SM
exhibit the D816V point mutation in the tyrosine kinase
domain of the transmembrane receptor protein c-kit. Therefore,
if a codon 816 c-kit mutation is detected, it counts as a minor
diagnostic criterion in the WHO diagnostic criteria for SM.
Mutational status of the c-kit gene has also pharmacogenomic
implications for the best future therapy options [14,15]. Currently,
there is no standard cure for SM. Prolonged courses of systemic
corticosteroids have been used. Others have tried to influence
SM by systemic treatment with IFN-D combined with systemic
corticosteroids [16]. Recently, cladribine was effectively used in
Box 2. Diagnostic WHO criteria for systemic mastocytosis: criteria also adjusted for children.
Major criteria
Multifocal compact infiltrates of MCs in bone marrow or other extracutaneous organ(s) (>15 MCs)
Minor criteria
MCs in bone marrow or other extracutaneous organ(s) show an abnormal spindle-shaped morphology (>25%)
Mutation D816V in C-kit in extracutaneous organ(s)*
MCs in the bone marrow express CD2 and/or CD25
Serum Tryptase > 20 ng/ml (does not count in two categories: children aged < 15 years and in patients who have an associated 
hematopoietic clonal non-MC lineage Disease
Diagnosis systemic mastocytosis, based on two possibilities
At least one major and one minor criterion
Three minor criteria
*Other activating mutations at codon 816 of c-kit also count as a minor criterion.
MC: Mast cell.
Derived from [31].
Figure 3. Algorithm of treatment of mastocytosis.
Mastocytosis
Cutaneous Systemic
Symptomatic
Cosmetic
Diarrhea
Severe manifestations
H1 and if necessary 
H2 antihistaminics
H1 and H2 
antihistaminics
Wet-wrap treatment UVA1 treatment
Sodiumcromoglycate orally
UVA1 treatment, psoralen and UVA
Prednisone (short courses)
Systemic experimental therapy
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patients with SM [17]. In a pilot study, Droogendijk demon-
strated that imatinib mesylate was effective in patients with SM,
including those with and without the D816V mutation. They
studied 14 patients, of whom ten had D816V mutation. Most
responded to therapy [18]. SM is often complicated by early oste-
oporosis; in one study, osteoporosis in mastocytosis was esti-
mated to be present in up to 30% of cases. Mastocytosis is asso-
ciated with skeletal problems, which include a decrease in bone
density and pathological fractures [19].
Urticaria
Urticaria is characterized by the rapid appearance of wheals that
may be accompanied by angioedema (FIGURE 4). A wheal consists
of a central swelling of variable size, almost invariably surrounded
by an erythema, often with associated itching or sometimes a
burning sensation. The individual lesions have a fleeting nature,
with a duration of usually 1 24 h [20 22]. In small children, urti-
caria can have a blue hue, which often leads to misinterpretation
as urticarial vasculitis or erythema multiforme (FIGURE 5).
Urticaria results from a localized capillary vasodilation and
transudation of protein-rich fluid in the superficial dermis.
Besides histamine, other mediators, including prostaglandins,
leukotrienes, cytokines and chemokines produced at different
times following MC activation also contribute to the changing
character of the urticaria. The mechanism by which MC acti-
vation is induced can be either immunological (IgE mediated,
complement activation components, antiFcHRI autoantibodies
and anti-IgE autoantibodies) or nonimmunological (direct
histamine releasers).
Increasing understanding of the pathomechanisms
involved in urticaria has highlighted the heterogeneity of dif-
ferent subtypes. Recent consensus guidelines distinguish
spontaneous urticaria, physical urticaria, different diseases
related to urticaria for historical reasons and syndromes
including urticaria/angioedema. 
In acute spontaneous urticaria, attacks last less than 6 weeks.
Infection, drugs and food allergy are the main known causes;
however, most cases of acute urticaria remain idiopathic. If
attacks last longer, it is referred to as chronic spontaneous urti-
caria. Attacks may last several months to years. One distin-
guishes immunological and nonimmunological urticaria.
Immunological urticaria is a hypersensitivity reaction mediated
by antibodies and/or T cells, which results in MC activation.
IgE-mediated type I hypersensitivity is a major immunological
pathway associated with MC activation, especially in acute urti-
caria. However, it is not the only mechanism. In particular,
chronic urticaria may result from the binding of IgG autoanti-
bodies to IgE and/or to the receptor for IgE molecules on MCs,
thus corresponding to a type II hypersensitivity reaction.
Approximately 50% of patients with chronic urticaria have
histamine-releasing autoantibodies in their blood. The term
autoimmune urticaria  is increasingly being accepted [23]. In
children, autoimmune urticaria has also been described in
chronic cases. The next most frequent form of long-lasting
urticaria is physical urticaria.
Treatment of urticaria can be divided into three basic
approaches based on the recent review by Zuberbier et al. [21,24].
Acute attacks of urticaria can be managed by short courses of
systemic corticosteroids, but preferably as crisis intervention.
Avoidance, elimination or treatment of the eliciting 
stimulus or cause
This approach is most desirable but, in adults and more rarely
in children, only applicable in a minority of cases. It is per-
formed in IgE-mediated urticaria, such as food allergy and
physical urticaria. In children, most urticaria are caused by
infections and food allergy that are acute in origin and can be
treated more easily [22]. 
Another category that can be treated similarly is physical urti-
caria in adults and children. Factors can be eliminated as much
as possible.Figure 4. Urticaria with normal appearance in a child.
Figure 5. Urticaria with a blue hue often misdiagnosed in 
young children.
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It is often impossible to treat chronic urticaria by avoidance,
elimination or by treatment of the eliciting stimulus or cause.
Chronic urticaria in childhood is rare. Possible pediatric causes
are parasitosis, infectious diseases, drugs and physical factors. 
In adults with chronic urticaria, treatment of associated infec-
tions, Helicobacter pylori gastritis, parasitic disease, cancer or drug
allergy can be curative or helpful [21].
A carefully taken history will eliminate most of the causes
in the majority of the cases and one should avoid extensive
investigations or provocations in such patients. The cause of
chronic urticaria often remains undetected.
Inhibition of MC mediator release 
Medicines in this category include steroids and ciclosporine.
PUVA therapy is an alternative. These approaches are not
recommended in children.
The most severe patients may require protracted treatment
with low-dose alternate-day steroid or ciclosporine [21].
Ciclosporine 0.55 mg/kg /day has a confirmed benefit in
more than half of the patients with chronic recalcitrant urti-
caria. It has also been shown to be effective even in autoanti-
body-negative patients [23]. Intravenous immunoglobulin, aza-
thioprine and methotrexate are alternatives if ciclosporine is
not effective [25].
Therapy of target tissues of MC mediators
The mainstay of treatment for urticaria is orally administered
H1 antihistamines as they reduce itch, wheal duration and fre-
quency of attacks. Management is achieved more effectively by
taking antihistamines daily, not only when the patient is symp-
tomatic. The sedating H1 antihistamines are as effective as or
more effective than classical H1 antihistamines. Additional ther-
apy aimed at pruritogenic mediators other than histamine
would be expected to improve urticarial pruritus. It is not
uncommon to exceed the licensed dose in severely affected adult
and pediatric patients. As a general rule, antihistamines are safe,
have few significant adverse effects and interactions with other
drugs are rare. If no symptom control is achieved with H1 anti-
histamines, co-administration of an H2 antihistamine can be
considered. In the next step, a leukotriene receptor antagonist
may be used as add-on therapy. 
If possible, it is best to avoid all antihistamines in preg-
nancy, although none has proven to be teratogenic. If one must
be used, the consensus is that loratadine and chlorphenamine
are among the safest [24].
Hydroxizine and chlorphenamine are the only drugs licensed for
children under the age of 2 years. Other very extensively studied
drugs in children are levocetirizine and cetirizine. Levocetirizine is
L-cetirizine and is the active component of cetirizine. In children
aged 1 5 y ears, the oral clearance of levocetirizine is rapid and will
increase with bodyweight and age. Therefore, levocetirizine dose
should be based on bodyweight and age in children [26].
Rupatadine is a nonsedating, selective and long-acting new
anti H1-drug with an additional potent antagonist activity
towards platelet-activating factor receptors [27]. The use of
rupatadine is currently indicated in adult and adolescent
patients (>12 years of age). It is more effective than the current
drugs, especially in chronic urticaria.
Prognosis of urticaria
The prognosis of acute urticaria is usually excellent and the
symptoms will completely disappear over a short period of
time. However, the prognosis is less favorable in chronic
urticaria, in which the cause is often not found.
Other diseases in which MCs may play a role
Many forms of mucocutaneous drug and other allergic mani-
festations are mediated by MCs. MCs are involved in allergic
and anaphylactic reactions and are also involved in many
inflammatory diseases affecting different organs, including the
heart, joints, lungs and skin. However, their exact role is poorly
understood. In the inflammatory processes involving different
organs, MCs appear to be activated by triggers other than
aggregation of their IgE receptors, such as anaphylatoxins,
immunoglobulin-free light chains, superantigens, heat-shock
proteins, neuropeptides and cytokines, leading to selective
release of mediators without degranulation.
Expert commentary
More therapeutic options directed against MC antigens and medi-
ators with continued research into MC biology and pathophysiol-
ogy will become available. This in turn will facilitate the develop-
ment of more specific therapeutic agents. Oral imatinib and
related drugs are promising new therapeutic agents warranting fur-
ther clinical evaluations. Long-term monitoring of possible side
effects of these new agents will help to develop safer therapeutic
options for diseases in which MCs play a regulatory role.
Five-year view
Mast cell research has provided new insights into a range of dis-
eases. MCs are recognized as important players, and not just
bystanders, in many diseases. As such, targeting MCs will play a
prominent role, which may be relevant in the development of new
therapeutic options in several skin diseases. In mastocytosis, diag-
nostic and therapeutic implications of c-kit mutations as well as
other less common molecular abnormalities may be considered as
possible targets for more specific new therapies. New surface anti-
gens in normal and neoplastic MCs have been discovered, which
may be potential targets for specific molecular biological therapy.
The use of biologicals is currently under critical review and
is expected to lead to more specific treatment modalities for
mastocytosis and urticaria in the near future.
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Key issues
 The contribution of mast cells (MCs) in inflammatory diseases, angiogenesis and other conditions is only partially understood.
MCs play a prominent role in several inflammatory and proliferative disorders, particularly of the skin. Their role is undisputed in 
mastocytosis and urticaria.
At present, there is no causative treatment and no cure for mastocytosis.
Pediatric mastocytosis in most cases is not treated, particularly because it is asymptomatic and limited to the skin. Treatment is only 
indicated for alleviating severe symptoms.
In the majority of cases, chronic urticaria occurs only in adults. Chronic urticaria is believed to have an underlying autoimmune 
pathogenesis in almost 50% of cases. The role of MCs in autoimmune diseases has not yet been completely elucidated.
MCs play a role in several inflammatory and proliferative disorders. The presence of MCs is important for treatment in the 
following diseases:
Mastocytosis: 
For treatment options, three categories must be recognized: pediatric, adult cutaneous and systemic mastocytosis.
Urticaria: acute or chronic.
Atopic dermatitis in which the MCs play a role; although recently an important role of the skin barrier function has also become clear.
The role of MCs in hemangioma is speculative, but may be interesting as a target for future therapeutic options.
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Mastocytosis is a primary, abnormal accumulation
of mast cells in the absence of an apparent cause. Mast
cell infiltrates may be present anywhere in the body. The
skin is the most frequent site of involvement (1,2).
Mastocytosis is associated with a broad range of local
and systemic symptoms primarily caused by the release
of mast cell mediators. Adult-onset mastocytosis and
childhood onset mastocytosis vary in both clinical
symptoms and course. They also differ in association
with genetic mutations of growth factor receptor c-kit.
In this review, attention has been focused on pediatric
mastocytosis.
PATHOGENESIS
The pathogenetic mechanisms leading to mast cell pro-
liferation in cutaneous mastocytosis or systemic masto-
cytosis are still not completely understood. However,
molecular biology techniques have made it possible to
obtain new insights into growth regulation of mast cells
and to allow a better understanding of the variations
in the clinical course of mastocytosis (3). At present,
attention is focused on mutations in proto-oncogene
receptor c-kit (4–7). Systemic mastocytosis and adult-
onset mastocytosis are often linked to Asp-816-Val
mutation of c-kit, while in children, different mutations
have been found. Typical childhood mastocytosis is
linked toGln-839-Lys c-kit mutation.Mutations such as
Asp-816-Tyr and Asp-816-Phe are associated with
atypical childhood mastocytosis. The Asp-816-His mu-
tation is associated with mastocytosis and acute myeloid
leukemia (8). Consequently the classification schemes of
mastocytosis have been revised to incorporate both
molecular-genetic and clinical data (8). C-kit mutation
analyses are extremely important for predicting
sensitivity to therapy and prognosis (8).
CLASSIFICATION
The present classification of mastocytosis is based on the
location of the mast cell infiltrates, the accompanying
symptoms, and the course of the disease. In 1991 Met-
calfe defined a basic classification scheme involving four
prognostic categories: an indolent variant, a variant
associated with hematologic disorders, an aggressive
variant with rapid development of lymphadenopathy
and eosinophilia, and mast cell leukemia (3,9). A des-
criptive classification based on clinical signs is preferable
for practical application and is shown in Table 1 (9).
CLINICAL MANIFESTATION
Childhood onsetmastocytosis is defined as histologically
proven mastocytosis presenting before the age of 15
years.Most of the cases of childhood onset mastocytosis
(60–80%) present during the first year of life, whereas
congenital mastocytosis was reported in 18–31% of the
cases (2,10–13). The sex ratio is equal and data on racial
differences are limited. Mastocytosis is not considered a
hereditary disease, although familial cases have been
described. Children with mastocytosis always have skin
lesions, but only 60% experience mast cell mediator-
related symptoms (11,13).
The most common type of childhood onset masto-
cytosis is urticaria pigmentosa (UP) (Fig. 1), which
represents about 65% of all cases (12,13). The typical
efflorescences consist of red-brown-yellowish macules,
papules, or nodules that vary in size from several
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millimeters to centimeters in diameter. Erythema, swell-
ing, and blister formation as well as itching of the lesions
may occur spontaneously or after stroking or rubbing.
The blistering heals without permanent scarring. The
lesions are generalized and randomly disseminated. The
palms, soles, scalp, and sunlight-exposed areas of the
body are often less affected, especially in older children.
Dermatographism and pruritus may be present, but
these features per se have no diagnostic value.
Complete resolution of the lesions may occur in 10%
of patients and significant improvementmay be expected
in up to 70% of patients by the age of 10 years (9,11,13).
Data on the number of persistent cases of childhood-
onset mastocytosis are limited and range from 25% to
57% (13,14).
The second most common cutaneous presentation of
childhood-onset mastocytosis is solitary mastocytoma
(Fig. 2A) definedby the presence of one to several lesions
(commonly five separate lesions or less) that have char-
acteristics similar to those of urticaria pigmentosa. It is
encountered in 10–35% of the cases of childhood-onset
TABLE 1. Clinical Signs of Mastocytosis
Disease Age predominance Characteristics
Mastocytoma 0–6 months 1–5 red/brown hyperpigmented or skin colored nodules(s)
Urticaria pigmentosa (UP) 3–9 months; most
frequent presentation
Multiple red-brown hyperpigmented macules and papules
Diffuse cutaneous mastocytosis Rare; often at birth Thickened, lichenified skin with papules, rarely without
skin abnormalities; bullae after minimal trauma
Telangiectasia macularis
eruptiva perstans (TMEP)
Adults Numerous hyperpigmented telangiectatic macules
Systemic mastocytosis Adults; rare in children Mast cell infiltrates in skin and internal organs
Mast cell leukemia Adults; rare in children Anemia; mast cells in peripheral blood
Figure 1. Urticaria pigmentosa.
Figure 2. (A) Solitary mastocytoma. (B) Solitary mastocy-
toma, Darier sign positive.
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mastocytosis (11,13,15). However, this figure may be an
underestimate, as an asymptomatic solitary lesion may
be overlooked or mistaken for a mole or juvenile xan-
thogranuloma. Of all clinical subtypes of childhood on-
set mastocytosis, solitary mastocytoma invariably
follows amild course with complete resolution, generally
before adulthood.
Diffuse cutaneous mastocytosis (Fig. 3) is rare and
most patients have been described in single case reports.
By definition, the whole skin is involved, although the
central region and the scalp are primarily affected. The
clinical features become prominent at birth or in early
infancy (1,15,16). These consist of widespread sponta-
neous blisteringwith erosions and crusts, various degrees
of erythroderma, strong dermatographism, and itching.
The diagnosis of mastocytosis must be ruled out in
newborns with blistering and bullae. The blisters may be
hemorrhagic in diffuse cutaneousmastocytosis. The skin
may be leathery and thickened, especially in the flexural
regions. In toddlers the skin becomes less reactive, but
diffuse hyperpigmentation and positive dermatogra-
phism may persist into adulthood.
Telangiectasiamacularis eruptiva perstans (TMEP) is
the least common cutaneous manifestation of mastocy-
tosis. The lesions consist of persistent red telangiectatic
areas without any signs of macules or papules. The le-
sions are poorly demarcated and sometimes difficult to
recognize. Darier sign (swelling and redness induced by
rubbing of the lesion) is generally positive (1). As an
entity, it is said to occur only in adults. The clinical fea-
tures overlap with those of UP. TMEP should be dis-
tinguished from telangiectatic UP in which guttate
telangiectatic macules are observed. Underestimation of
its incidence is plausible, especially in children.
SYMPTOMS
Essentially all types of childhood-onset mastocytosis
may be associated with localized and systemic symp-
toms caused by mast cell mediators (Table 2) (1,17). The
most common symptoms are pruritus, redness, and
swelling. These may occur spontaneously or secondarily
after thermal, mechanical, or chemical stimuli. In in-
fants, blistering is common. On rare occasions these
blisters may have hemorrhagic content, as skin mast
cells have been shown to regulate hemostasis (18).
Gastrointestinal complaints are common and consist
primarily of diarrhea and abdominal pains in up to 40%
of children with mastocytosis (10,11,13,19). Hyperacid-
ity and subsequent peptic ulcers secondary to high his-
tamine levels in pediatric mastocytosis have been
TABLE 2. Mast Cell Mediators
Skin specimens Histamine
Leukotriene B4 (LTB4)
5-hydroxyeicosatetraenoic
acid (5-HETE)
Tryptase
Chymase
Heparin
Cutaneous
blister fluid
Histamine
Prostaglandin D2 (PGD2)
Platelet-activating factor (PAF)
Plasma Histamine
a-Tryptase
Urine Histamine
Histamine metabolites
NT-methylhistamine
NT-methylimidazole acetic acid
PGD2 metabolites
9-a-hydroxy-11, 15-dioxo-2,3,4,
5-tetra-norprostane-1,20-dioic acid
9-a, 11 b-dihidroxy-15-oxo-2,
3,18,19-tetranorprost-5-ene-1,
20-dioic acid (PGD-M)
Chondroitin sulfate B
Hyaluronic acid
Arylsulfatases A and B
Figure 3. Diffuse cutaneous mastocytosis.
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reported (12,19). However, peptic ulcer disease is extre-
mely rare in children with mastocytosis. Constitutional
symptoms ranging from flushing spells in 20–65% to
states of hypotensionand shockmayoccur (10,11,13,19).
Flushing spells are extremely uncommon in solitary
mastocytoma. Reported bone pain, headache, and mild
cognitive changes are easily dismissed as common
complaints (13,19). Peptic ulcer disease, intestinal
bleeding, lymph node swelling, hepatic obstruction, and
anaphylactic reactions to wasp sting venom characterize
childhood-onset mastocytosis with a potentially severe
course. Fatal cases of childhood-onset mastocytosis,
although very rare, have been reported (20–22).
SYSTEMIC MASTOCYTOSIS
Systemic mastocytosis is referred to as mast cell accu-
mulation in one or more organs other than the skin. Its
diagnosis is based on the demonstration of typical mast
cell infiltrates, especially in the bone marrow. It is very
rare in children. Children with urticaria pigmentosa do
not show the typical pattern of bone marrow lesions as
described in adult urticaria pigmentosa and systemic
mastocytosis. Nonspecific mast cell accumulation in the
bone marrow is observed in 17–35% of adult patients
(10,11). Data on intestinal, hepatic, splenic, and lymph
node involvement are sporadic. Nonetheless, hepato-
splenomegaly has been noted in uncomplicated child-
hood-onset mastocytosis (11).
The presence of symptoms that are not limited to the
skin is not predictive for mast cell accumulation else-
where in the body. It is oversimplification to accept the
presence of systemic symptoms as systemicmastocytosis.
Since childhood-onset mastocytosis has a good progno-
sis in almost all patients, the demonstration of mast cell
infiltrates in organs other than the skin is of limited value
in patient management.
DIAGNOSIS
Diagnosis of childhood-onset mastocytosis is based on
clinical suspicion of mast cell accumulation and con-
firmed by histologic demonstration of a significant
increase in mast cell numbers. Clinical suspicion may
be aroused in cases of persistent pigmented lesions with
swelling, redness, blistering, and itching provoked by
thermal,mechanical, or other stimuli. The patient should
always be tested for Darier sign. The test is very
informative if conducted correctly. The procedure con-
sists of rubbing the lesion with a blunt object for
approximately 10 seconds. The lesion is then observed
for swelling and redness for 5 minutes. It is advisable to
repeat the procedure on an adjacent nonlesional area of
the skin. By definition, Darier sign is positive if it can be
provoked only in the lesion but not elsewhere (Fig. 2B).
Dermatographism, tested by drawing a ‘‘train track
crossroad,’’ is not informative as an indicator of masto-
cytosis. It does, however, provide a clinical impression of
the irritability of mast cells in the skin.
In diffuse cutaneous mastocytosis (Fig. 3), it is not
possible to provokeDarier sign on a lesion because large
areas of the skin are affected. The history of spontane-
ously occurring profuse redness, swelling, itching, and
blistering in very young children may point to diffuse
cutaneous mastocytosis. Dermatographism in these
cases is very impressive.
The demonstration of elevated levels of mast cell
mediator histamine or its metabolites in blood or urine is
useful for staging and follow-up of patients with proved
childhood-onset mastocytosis. The levels of mast cell
mediators may be elevated in various conditions associ-
ated with increased mast cell activation (23–25). There-
fore elevated levels of any mast cell mediator may
support, but not establish, the diagnosis of childhood-
onset mastocytosis.
Examination recommendations include complete
blood count with differential, serum chemistry, liver
enzymes, and the levels of mast cell mediator N-methyl
histamine or tryptase at regular intervals. Analysis of
c-kit mutations in skin biopsy specimens by poly-
merase chain reaction (PCR) may differentiate patients
likely to have chronic disease (c-kit mutation positive)
from those likely to have a transient form of masto-
cytosis.
Many authors agree that invasive diagnostic proce-
dures should be reserved for patients with hematologic
aberrations, persistent, localized bone pain, and persist-
ent, severe, gastrointestinal symptoms or biochemical
evidence of hepatic insufficiency (10,11,26).
IMMUNOHISTOCHEMISTRY
The diagnosis of mastocytosis is generally based on the
presence of typical dense or minimal mast cell infiltrates
in the skin and/or bone marrow (27), which are gen-
erally toluidine blue and chloroacetate esterase positive
(28). The mast cell enzyme tryptase is increasingly
used as a serum (29) and as a sensitive and reliable
immunohistologic marker for detecting extremely small
mast cell infiltrates (30), which may be missed after
toluidine blue or chloroacetate esterase staining.
The expression of cell surface membrane phenotype
markers such as the stem cell growth factor (SCF)
receptor c-kit (CD117) (31), CD68 (32), and possibly
CD2 (LFA-2) can be used for confirming the diagno-
sis of mastocytosis. Normal tissue mast cells express
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considerable amounts of c-kit (CD117) on their surface.
It is also expressed on immature normal or neoplastic
mast cells, as well as on multilineage hematopoietic
(CD34+) progenitors, and is useful in distinguishing
mast cells from basophils (31). In recent years c-kit has
been used as a diagnostic marker in patients with sus-
pected mast cell disease (33,34). Bone marrow mast cells
(BMMCs) in normal subjects and patients with mast cell
proliferative disorder can be identified and quantified
using specific antibodies against c-kit (CD117) and
multiparameter flow cytometry (33). Clear immuno-
phenotypic differences were noted between BMMC in
normal or reactive bone marrow and BMMC (c-kit+/
CD34–) in patients with mastocytosis.
A noteworthy finding was that BMMC in patients
with adult-onset indolent or aggressive systemic mast-
ocytosis expressed CD2 (LFA-2) and CD25 (33). The
expression of CD2 (LFA-2) is particularly interesting
because its expression is restricted to T and NK cells. It
is not expressed on normal mast cells. Abnormal
expression of CD2 on neoplastic mast cells may be of
pathophysiologic importance because mast cells also
express a natural ligand LFA-3 (CD58) for CD2 (CD2/
CD58-mediated accumulation of neoplastic mast cells).
The absence of granulocyte antigens (e.g., CD15) also
confirms the presence of a mast cell lineage disease (7).
The clinical significance of new histologic markers for
mastocytosis is currently under investigation and pre-
liminary results indicate that they may be valuable in
defining definite criteria in various forms of masto
cytosis.
CURRENT AND EXPERIMENTAL THERAPY
General Approach
In general, treatment of mastocytosis is only indicated
when symptoms are present (Fig. 4) (9,35,36). If masto-
cytosis presents in children younger than 5 years of age,
most cases of urticaria pigmentosa and mastocytoma
follow a benign course. Therapy is often limited to
reassuring the parents and providing advice on avoiding
factors known to stimulate or induce mast cell degran-
ulation and prevention of serious events. Bullae present
in the first 2 years of life, sometimes mimicking
staphylococcal scalded skin syndrome, can be treated by
local general care and prevention of infection (16,37).
When the presence of symptoms dictates more active
intervention, the following five-step procedure should be
undertaken.
Step 1
Thefirst step in treatment is relievingpruritus, urtication,
and flushing. This may be achieved by H1-receptor
antagonists, such as hydroxyzine and cetirizine (38,39).
Step 2
H2-receptor antagonists such as cimetidine and raniti-
dine may be added, especially if H1-receptor antagonists
have insufficient effect or when gastrointestinal symp-
toms of hyperacidity or ulceration are present (40).
Patients with diarrhea may also benefit from treatment
with an H2-receptor antagonist (41).
Figure 4. Flow chart of pediatric mastocytosis.
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Step 3
For gastrointestinal symptoms, disodiumchromoglycate
may be a useful addition, especially for diarrhea. This is
also effective for flushing and pruritus (42,43), although
conflicting results have been reported (44). Ketotifen is
another mast cell stabilizer, but showed no advantage as
compared with hydroxyzine (10).
Step 4
Treatment of children with urticaria pigmentosa may
also include topical steroids. We have had positive ex-
perience with diluted steroids under wet wraps (double-
wrap applications which are rewetted every 2 hours)
(45,46). Strict checks of cortisol levels, weight, and
growth are indicated. This treatment is contraindicated
in puberty because of the increased risk of development
of striae (47,48).
Solitary mastocytomas may be treated with topical
steroids with occlusive dressings. This is especially indi-
cated if there are persistent, severe symptoms. If this fails,
on rare occasions, excision in toto may be considered
(47).
Step 5
Only patients with a history of anaphylaxis must be
equipped with injectable adrenaline in the form of
Epi-Pen, and parents and (older) children should be
instructed and trained in self-medication (49). Because
the occurrence of anaphylaxis secondary to wasp sting
or other stimuli is unpredictable, all patients and
parents should be informed about this. However, we
do not think it is mandatory to equip patients with
a negative history of anaphylactic reactions with an
Epi-Pen.
Treatment with drugs such as prednisone and aspirin,
or therapy with ultraviolet A (UVA) or psoralen plus
UVA (PUVA) have no place in the management of
childhood-onset mastocytosis (9). Preventive measures
taken in patients with mastocytosis undergoing an-
esthesia are controversial (50). We take the following
perioperative measures: close monitoring of all patients,
avoidance of known histamine-releasing drugs, and the
continuous availability of emergency drugs. Patients are
hospitalized 1 day before anesthesia and surgery.
Prednisolone at a stress dosage and antihistamines are
started 1daybefore and continued1dayafter anesthesia.
FUTURE ASPECTS
Due to advances in molecular biology, information is
becoming available on c-kit mutation-related growth
enhancement of mast cells. As a result, the origin of
some clinical manifestations of mastocytosis may well
be elucidated in the near future. One of the ways to
explain the diversity in the course of mastocytosis may
be by means of the moment of c-kit alteration in the
mast cell lineage.
Cells in early stages in the myeloid (mast cell com-
mitted) cell lineage still have a huge potential to multiply
compared to those cells in late stages of development. If
c-kitmutation arises in these later stages of development,
cells have a limited potential for clonal expansion. Con-
sequently, if c-kit mutations cause increased growth of
mast cells, the duration of this process of increased
growth will still be limited. However, if there is a large
potential to multiply, a prolonged, chronic course is
likely.
In the future c-kit research will provide knowledge
to improve the treatment of adult-onset mastocytosis.
The treatment of childhood-onset mastocytosis will
probably benefit less from these developments, and
symptomatic treatment is likely to remain the method
of choice.
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Definition
The term   mastocytosis   denotes a heterogeneous group of disorders, char-
acterized by local or diffuse increased non-malignant proliferation and accu-
mulation of mast cells (MC) in the skin and/or in internal organs. The clinical
signs and symptoms are caused by the functional effects of mast cell media-
tors that are produced and released at various anatomical sites. The skin is
most frequently involved, but other organs may also be involved. Mastocy-
tosis can be classified according to prognosis, or according to organ systems
and symptoms. 1
Classification
A basic classification scheme dividing mastocytosis into four prognostic
categories was developed by Metcalfe as follows:2
1 An indolent variant with either skin disease or specific organ involvement
and an excellent prognosis.
2 A variant, associated with hematological disorders.
3 A rare group of patients with an aggressive form of mastocytosis with
rapid development of prominent lymphadenopathy and eosinophilia; the
survival time of these patients after diagnosis without chemotherapy is 2 
4 years.
4 A very rare and fatal form: mast cell leukemia.
Recently the classification was modified several times by the European
Network on Mastocytosis.3 In that concept, the diagnosis of cutaneous mas-
tocytosis (CM) is based on clinical and histological findings in the skin in the
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absence of criteria that would allow the diagnosis of systemic mastocytosis.
Systemic mastocytosis is a clonal disorder of the mast cell and its progenitor.
The symptoms of systemic mastocytosis are due to the pathologic accumula-
tion and activation of mast cells in various tissues such as bone marrow, skin,
gastrointestinal tract, liver, and spleen.4
Systemic mastocytosis (SM) criteria are divided into major criteria and
minor criteria. Major criteria relate to major histological and immunohisto-
chemical (Tryptase staining of tissue sections) findings. The most important
aspect here is the dense focal infiltrate of MC that consists of a considerable
number of MC (> 15) and is detectable at more than one site in the tissue(s)
(multifocal pattern). Minor criteria relate to typical cytomorphological aspects
of MC (in tissue sections and/or bone marrow smears) as well as to novel
biochemical markers that indicate some degree of specificity for SM. It is
proposed that the diagnosis is   systemic mastocytosis   if one major and one
minor or three minor criteria for SM are fulfilled (Table1). Likewise, if dense
multifocal infiltrates in the bone marrow consist of > 15 MC that appear to
be spindle-shaped (> 25% MC are spindle-shaped), the diagnosis of SM can
be established on histology without further investigation (and irrespective of
the stain used). If MC are round, one should ask for additional criteria of SM
(morphology of MC in bone marrow smears; CD2/CD25-expression on MC;
serum tryptase, c-kit mutation) to establish the diagnosis of SM, because focal
accumulations of round MC have also been observed in reactive MC hyper-
plasia.
Four major variants of SM have been defined by the working group: in-
dolent systemic mastocytosis (ISM), systemic mastocytosis with an associ-
ated clonal hematologic non-mast cell lineage disease (SM-AHNMD), ag-
gressive systemic mastocytosis (ASM), and mast cell leukemia (MCL). This
classification is more useful in adult mastocytosis.55
Epidemiology
The exact prevalence of mastocytosis in the general population is unknown.
Children without skin lesions or with indolent cutaneous mastocytosis may remain
undiagnosed or unreported. The incidence figures vary widely from 1 in every 1000
to 1 in 8000 new patients at various dermatological units. Mastocytosis may oc-
cur at any age, but in approximately half of the cases, the onset is between birth
and the age of 2 years; the disease is congenital in 15%, a further 30% of patients
develop mastocytosis before the age of 6 months, another 10% by the age of 2 years,
and about 10% between 2 and 15 years of age. There is no clear-cut sex predomi-
nance, and children of all races are affected. Although some 50 cases of familial
mastocytosis have been reported the overall occurrence is sporadic. It has not been
possible to discover the pattern of inheritance in the few cases in which more than
one generation was involved.
Pathogenesis
The Stem cell factor (SCF) receptor is encoded by the protooncogene c-kit
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and belongs to the type III transmembrane receptor tyrosine kinase subfamily.
Apart from MC and their progenitors, c-kit is also expressed on other
hematopoietic and nonhematopoietic (progenitor) cells. Binding of SCF by c-
kit induces receptor dimerization followed by transphosphorylation of tyro-
sine residues becoming docking sites for the recruitment and activation of
various cellular substrates.1 The activated substrates then induce multiple
intracellular signaling pathways responsible for MC differentiation, prolifera-
tion, survival and activation. Somatic c-kit mutations leading to ligand-inde-
pendent (constitutive) activation of the receptor have been detected in several
MC-related and non-MC neoplasms. In typical pediatric cases of CM, most
studies failed to report recurrent abnormalities in the sequence of c-kit. Nev-
ertheless, a point mutation of codon 839 with substitution of lysine for glutamic
acid (c-kitE839K) was found in a case of CM. In the rare familial cases, no
Table 1. Proposed criteria to diagnose mastocytosis (adapted from Valent et al, 2001)
 
Cutaneous mastocytosis: 
 
Typical skin lesions (urticaria pigmentosa, diffuse cutaneous mastocytosis, 
mastocytoma) and  
positive histology with typical infiltrates of MC (diagnostic infiltrate-pattern: 
multi/focal or diffuse) 
 
Systemic mast cell disease:  
 
'Systemic Mastocytosis (SM) criteria' 
Major : Multifocal dense infiltrates of MC (> 15 MC aggregating) detected in 
sections of bone marrow and/or of other extracutaneous organ(s) by tryptase-
inununohistochemistry or other stains 
Minor: a. In MC infiltrates detected in sections of bone marrow or other 
extracutaneous organs, >25% of MC are spindle-shaped or:     in bone marrow 
smears, atypical MC (type I plus type II) comprise >25% of all MC 
b. Detection of a c-kit point mutation at codon 816 in bone marrow or 
blood or other extracutaneous organ(s) 
c. Kit+ mast cells in bone marrow or blood or other extracutaneous 
organ(s) co-express CD2 or/and CD25 
d. Serum total tryptase concentration persistently > 20 ng/ml (in case of 
an associated clonal hematologic non-mast cell lineage disease (AHNMO), 
d. is not valid) a 
 
If one major and one minor, or three minor criteria are fulfilled 
then the diagnosis is systemic mastocytosis (SM) 
------------------------------------------------------------------------------------------ 
a In acute myeloid leukemia or myelodysplastic syndrome or myeloproliferative 
syndrome, elevated serum tryptase levels have been detected without increase 
in mast cell numbers or signs of mastocytosis. 
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  classical   c-kit mutations were found. Yanagihori et al. (2005) compared
adults with mastocytosis with childhood-onset and adult-onset. They con-
firmed a high incidence of two distinct c-kit mutations, Asp-816-Val and
Asp-816-Phe, in patients with childhood-onset cutaneous mastocytosis. These
results underlined the importance of c-kit mutation analysis in children with
mastocytosis for prognostic reasons.6 The heterogeneity of c-kit mutations
contribute to difficulties in characterizing genotype-phenotype correlation in
the disease.
Clinical features
The clinical expressions of cutaneous mastocytosis (CM) are solitary
mastocytoma, urticaria pigmentosa, diffuse cutaneous mastocytosis and Tel-
angiectasia macularis eruptive perstans (TMEP).
The most frequent clinical form of mastocytosis was urticaria pigmentosa
followed by mastocytoma and diffuse cutaneous mastocytosis. Darier  s sign
was present in 94% of cases. A negative Darier  s sign does not rule out
mastocytosis.7
In CM the visible cutaneous abnormalities are frequently of major concern
to the patients and their family. However, in some patients the signs and
symptoms produced by the functional effects of mast cell mediators may
dominate the clinical picture, pruritus being the most frequent symptom. Pruritus
tends to be paroxysmal, is most frequently mild to moderate, being only
rarely severe, and frequently remains confined to the sites of mast cell infil-
Table 2. Diagnostic work-up scheme
Inspection of cutaneous lesions, clinical examination 
 
Darier’s sign (eliciting urtication by rubbing the lesion) 
 
Skin biopsy (pathology diagnosis and C-kit mutation) 
 
Measurement of mast cell mediators and/or their metabolites in serum and/or 
urine, preferably serum tryptase. 
 
Further investigations (if systemic mastocytosis is suspected): full blood count  
and peripheral blood smear; bone marrow aspirate and biopsy;  skeletal survey,  
bone scan and bone densitometry; gastrointestinal investigations (contrast  
studies or endoscopy, abdominal ultrasound scan) 
 
Immunophenotyping of blood cells and bone marrow aspirate 
C-kit mutation analysis (if available) 
 
 
Note: In children often a blood sample and skin biopsy for routine histology are  
enough. 
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On the rare occasion when systemic involvement is
highly suspected, a multidisciplinary approach in which
carefulmonitoring ofmediator-related symptoms, organ
function, growth as well as hematologic and bone mar-
row analysis are performed is imperative.
Preventive measures with respect to wasp stings and
anesthesia are only necessary in cases with (subjective)
symptoms and clearly elevated serum tryptase levels.We
developed the SCORMA index which has proved useful
in cases in which obtaining repeated blood samples such
Brief Reports 499
Figure	1.	Mastocytosis	SCORMA	index.
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tration. Systemic mastocytosis may occur with or without skin lesions. Symp-
toms appear to be derived primarily from the systemic and local effects of
mast cell mediators and only secondarily from the space-occupying nature of
the mast cell infiltrate.
In about the half of the children the manifestations disappear before, dur-
ing or in late puberty. 5 Most cases of pediatric mastocytosis are sporadic and
appear during the first 2 years of
life, especially on the trunk. Urticaria pigmentosa is the most frequent
variant. The prognosis of pediatric mastocytosis, is generally good.8
Severity of mastocytosis can be scored by using the by us described SCORMA.
(Figure 1)
A diagnostic work scheme is documented in Table 2.
Treatment of mastocytosis in childhood is usually unnecessary. Only when
there are complications, treatment will be indicated to complications. When
flushing or pruritus is prominent, antihistamines are used. In case of chronic
diarrhea sodium cromoglycate is indicated.
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ABSTRACT
Objective To compare the incidence, symptomatology and course of mastocytosis with onset in childhood
and in adults.
Design Retrospective study of 101 patients with mastocytosis who were referred from 1980 to 1998.
Patients Medical records of 65 cases of mastocytosis with onset in childhood and 36 in adulthood were
analysed. The clinical course was assessed in a subgroup consisting of 33 subjects with childhood onset who
were followed up until at least adolescence and 12 subjects with adult onset who were followed up for at least
10 years.
Results The onset of the disease occurred before the age of 2 years in 50% and between the ages of 2 and
15 years in 14% of cases (childhood onset). In 36% of patients onset occurred at the age of 16 years and older
(adult onset). An incidence peak of 60% was noted in the first year of life. Mast cell-mediated symptoms
were not experienced by 21 of 36 adult onset mastocytosis patients nor by 27 of 65 childhood onset masto-
cytosis patients. Complete resolution was observed in five of 33 children. The majority of childhood onset
cases (21 of 33) showed some improvement. Complete resolution was achieved in three of 12 adults. The
majority of the remaining adults (eight of 12) showed no improvement.
Conclusions We confirm the incidence of onset of mastocytosis previously reported in the literature. We
conclude that childhood onset mastocytosis is much less transitory than generally is assumed, although
improvement occurs in the majority of cases. Symptomatology and clinical course of adult onset masto-
cytosis is less severe than suggested in the literature.
Key words: adults, children, follow-up studies, mastocytosis
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Introduction
Mastocytosis is a heterogeneous disease that is character-
ized by an increased number of tissue mast cells.1 Mast cell
proliferation is located mainly in the skin, but can also be found
in internal organs, such as the liver, spleen, lymph nodes, bone
marrow, lungs and gastrointestinal system. The clinical
symptoms are caused by the release of mast cell mediators.
Mastocytosis can be classified according to prognosis as
reported by Travis et al.2 and modified by Metcalfe.3 In daily
practice we prefer to use the dermatological classification that
divides the disease into four cutaneous forms.4 Urticaria
pigmentosa (UP) is the most common type and represents
about 65% of all paediatric cases.5 The typical lesions consist of
red–brown to yellowish macules, papules or nodules that may
vary in size from several millimetres to centimetres in diameter.
Erythema, swelling and blister formation as well as itching
of the lesions may occur spontaneously or after stroking or
rubbing. The blistering heals without permanent scarring. The
lesions are generalized and randomly disseminated. The palms,
soles, scalp and sunlight exposed areas of the body are often less
affected.
Solitary mastocytoma (SM) is the second most common
cutaneous presentation of childhood onset mastocytosis. SM is
defined by the presence of one to several lesions (commonly five
separate lesions or less) that have characteristics similar to those
of UP. It is encountered in 10–35% of cases of childhood onset
mastocytosis.6,7 However, this figure may be an underestimate
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as an asymptomatic solitary lesion may be overlooked or mis-
taken for a mole or juvenile xanthogranuloma. Of all clinical
subtypes of childhood onset mastocytosis, SM invariably fol-
lows a mild course with complete resolution generally before
adulthood.
Diffuse cutaneous mastocytosis (DCM) is rare and most
patients have been described in case reports. By definition, the
entire skin is involved, although the central region and the
scalp are primarily affected. The clinical features become
prominent at birth or in early infancy.7–9 These consist of
widespread spontaneous blistering with erosions and crusts,
various degrees of erythroderma, strong dermographism and
itching. The diagnosis of mastocytosis must be ruled out in
new-borns with blistering and bullae. The blisters may be
haemorrhagic in diffuse cutaneous mastocytosis. The aspect of
the skin may be leather-like and thickened, especially in the
flexural regions. In toddlers, the skin becomes less reactive, but
diffuse hyperpigmentation and positive dermographism may
persist into adulthood.
Telangiectasia macularis eruptiva perstans (TMEP) is the
least common cutaneous manifestation of mastocytosis.
The lesions consist of persistent red or light brown macules
with visible telangiectases. The lesions are poorly demarcated
and sometimes difficult to recognize. Darier’s sign (swelling
and redness induced by rubbing of the lesion) is generally
positive.8 As an entity, it is said to occur only in adults. The
clinical features overlap with those of UP. Thus, underestima-
tion of the incidence of this form is plausible, especially in
children.
Based on the clinical picture and course, mastocytosis may
also be divided into childhood onset mastocytosis (≤ 15 years)
and adult onset mastocytosis (> 16 years). The age of the sub-
ject at onset is one of the main prognostic factors for the
course of the disease.10,11 Approximately 50–80% of children
with UP is expected to undergo resolution of lesions and
symptoms by adolescence, whereas the remainder exhibits
a marked reduction of cutaneous lesions.12 Children with SM
typically exhibit complete involution of their lesions during
childhood.10 Childhood onset DCM is also known to resolve
spontaneously. Adult forms of mastocytosis tend to be
chronically progressive.13
Lately there has been much discussion on the differences in
the aetiology of mastocytosis in children and adults. Evidence-
based studies indicate that a somatic mutation in c-Kit receptor,
of which stem cell factor is the ligand, may be responsible for a
chronic progressive course in adults and sporadically in chil-
dren.14,15 However, no satisfactory explanation has been found
for the majority of childhood onset cases. In the current study
we analysed the medical records of 101 patients with masto-
cytosis examined in our dermatology department during the
period 1980–98. The aim of the study was to investigate
whether clinical types of mastocytosis clearly separate the chil-
dren from the adults, as is generally accepted in the literature.
Patients and methods
Patients
Our series comprised 65 cases of childhood onset mastocytosis
and 36 cases of adult onset mastocytosis who had undergone
dermatological evaluation between the period 1980–98 at the
outpatient clinic of the Department of Dermato-Venereology at
the University Hospital Rotterdam, The Netherlands. Male to
female ratio was 1.7 : 1 (63 : 38). Skin lesions were the first
manifestation of the disease in all cases. In 44 cases (44%) the
diagnosis was based only on clinical examination, including
a positive Darier’s sign. In 57 cases (56%) the diagnosis
was confirmed by histopathological examination. Skin biopsy
was omitted in uncomplicated cases with evident UP or
mastocytoma. The distribution of the cutaneous forms is
shown in Table 1. The follow-up period for the whole group,
defined as the period between initial symptoms and the last day
of consultation, ranged from 0 years up to 61 years (mean:
8 years). Thus, for cases of childhood onset mastocytosis the
maximum period reviewed was 61 years (mean: 9 years) and for
cases of adult onset mastocytosis up to 21 years (mean: 6 years).
In 45 of the 101 cases the medical records were sufficient for
long-term assessment of the clinical course. All subjects under-
went a standard routine work up on a yearly basis, which
included physical examination, blood counts, blood chemistry
and urine analysis; additional investigations were decided on an
individual basis. From 1994 onward measurement of urine N-
methyl histamine was added to the work up. In well established
uncomplicated cases of mastocytosis, diagnosed in the skin,
bone marrow biopsy was excluded from routine investigations,
because it is irrelevant in the management of the disease.
This subgroup of 45 patients consisted of 33 cases with
childhood onset and 12 cases with adult onset mastocytosis, all
chosen based on one of the following three criteria:
1 Childhood onset patients followed until at least the age of
15 years.
2 Adult onset patients followed for at least 10 years.
3 Childhood and/or adult onset patients reporting marked
improvement of lesions and/or mast cell-mediated symptoms.
Table 1 Distribution of the cutaneous forms of mastocytosis in the study 
population (n = 101) for childhood onset mastocytosis and adult onset 
mastocytosis
Cutaneous 
form
Childhood 
onset
Adult 
onset Total
UP 44 (44%) 27 (27%) 71 (70%)
SM 18 (18%) 2 (2%) 20 (20%)
DCM 2 (2%) 3 (3%) 5 (5%)
TMEP 1 (1%) 4 (4%) 5 (5%)
Total 65 (64%) 36 (36%) 101 (100%)
UP, urticaria pigmentosa; SM, solitary mastocytomas; DCM, diffuse 
cutaneous mastocytosis; TMEP, telangiectasia macularis eruptiva perstans.
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Methods
All medical records were analysed retrospectively. We developed
a standardized form on which several items were recorded,
including: the cutaneous form, mast cell-mediated symptoms,
Darier’s sign and factors provoking or aggravating the
symptoms. Neither additional investigation used for diagnosis
or follow-up purposes nor given therapy was recorded due to
incomplete or sporadic mention in the medical records. Care
was taken to record the items in chronological order to obtain
insight into the course of the disease.
Statistical analysis
The items were recorded on a spreadsheet and were translated
to the statistical package SPSS for Windows to enable statistical
analysis. The first part of the evaluation consisted of analysing
the items listed, whereas the second part consisted of statistical
calculations of quantified items. Differences in prevalence rates
between two groups were compared using Fisher’s exact test.
Two-sided P < 0.05 was considered to be statistically significant.
Results
Age of onset
An overview of the age of onset is shown in fig. 1(a,b). In the
majority of patients with childhood onset mastocytosis the
disease started before the age of 5 years, with an incidence peak
in the first year of life. The incidence of adult onset mastocytosis
was stable over the years. In this series only three new cases were
diagnosed in subjects after the fourth decade of life.
Familial involvement
One female with childhood onset UP also had a twin sister with
childhood onset UP, although the disease was less severe in the
sister. In contrast, we also encountered a female with adult onset
UP whose twin sister had no evident mastocytosis. One male
with childhood onset DCM reported that several male relatives
in different generations on his paternal side also had similar
complaints.
Symptomatology
The distribution of the different cutaneous forms in our
population is listed in Table 1. The most frequently cited mast
cell-mediated symptoms in childhood and adult onset masto-
cytosis are listed in Table 2. Half of the patients with adult onset
mastocytosis had never experienced any mast cell-mediated
symptoms, but 25 of the 65 childhood onset mastocytosis
Table 2 An overview of symptoms per cutaneous form in childhood and adult onset mastocytosis
Symptoms UP SM DCM TMEP Total
P-valueCh Ad Ch Ad Ch Ad Ch Ad Ch Ad
No symptoms 18 14 7 2 – – – 2 25 18 0.145
Symptoms (at least once) 26 13 11 – 2 3 1 2 38 15
Pruritus 22 10 5 – 2 3 1 2 30 15
Flushing 10 – 8 – 0 2 1 1 19 3
Abdominal pain 8 1 6 – 2 – 1 – 17 1
Diarrhoea 7 – 3 – 1 1 1 – 12 1
Headache 3 1 2 – 2 1 – – 7 2
Ch, childhood onset mastocytosis; Ad, adult onset mastocytosis; UP, urticaria pigmentosa; SM, solitary mastocytomas; DCM, diffuse cutaneous mastocytosis; 
TMEP, telangiectasia macularis eruptiva perstans.
fig. 1 (a) Number of patients with childhood onset mastocytosis per age of onset;
(b) Number of patients with adult onset mastocytosis per age of onset.
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patients had. However, the difference was not statistically
significant (P = 0.145). Mast cell-mediated symptoms, such
as those involving the skin (pruritus and urticaria) or the
gastrointestinal system (abdominal pain, nausea, vomiting and
diarrhoea), and constitutional symptoms (including flushing,
headaches, dizziness, malaise and collapse) were reported.
Subjects with childhood onset mastocytosis had statistically
significant (P = 0.004) more gastrointestinal symptoms than
those with adult onset mastocytosis.
Provoking factors
A total 64 subjects reported provocation or worsening of
the symptoms under certain circumstances. Heat or cold was
by far the most frequently cited provoking factor, followed
by friction, psychological stress, physical effort, alcohol, food,
certain medications, flu, fever and insect bites. The number of
provoking factors mentioned per patient ranged from 0 to 5.
The majority of subjects reported only one provoking factor.
Clinical course
The clinical course could only be assessed in a subgroup con-
sisting of 33 childhood onset and 12 adult onset mastocytosis
patients as shown in Table 3. The clinical course was divided
into improvement vs. no improvement. Improvement was
defined as complete or partial resolution of skin lesions and/or
symptoms. Compared with adult onset patients, patients with
childhood onset mastocytosis experienced more often statis-
tically significant improvement in the clinical picture (Fisher’s
Exact Test; P = 0.010). Progression of the disease resulting in
haematological disease was not found in the study group.
Discussion
The aim of this retrospective study was to establish whether
there are differences between the clinical symptoms and the
course in childhood onset and adult onset mastocytosis. As it is
postulated that childhood and adult onset mastocytosis might
have two different aetiological mechanisms, an insight into
their course may increase the understanding of the aetiology
of the disease, in the hope that such subjects will be followed
up and treated more effectively. In this analysis of 101 med-
ical records we focused exclusively on the clinical forms of
mastocytosis and the course followed by the disease. It is evident
that the results reflect those cases of mastocytosis in which skin
symptoms are the main manifestation of the disease.
In our population, 64% of the cases of mastocytosis started in
childhood. One-half (50%) of the subjects developed the first
lesions before age 2 and 14% between the ages of 2 and 15 years.
The remaining 36% developed the first lesions after the age of
15 years (adult onset mastocytosis). These incidence figures
closely resemble and confirm those reported in the literature.11
Although we confirmed that there is a clear peak of incidence
(60%) in the first year of life (fig. 1a), we did not observe a sec-
ond peak of incidence in adult onset mastocytosis (fig. 1b).10
The incidence from the age of 16 years onward was fairly regular
over the years with a decrease in incidence as the age increased.
The distribution of the cutaneous forms within our popula-
tion is consistent with that reported in the literature16 and is
shown in Table 1. We noticed that lesions of adulthood onset
UP more often tended to be small in diameter, whereas those in
childhood onset UP were more often large and widespread.
We also observed some exceptional cases in our population. For
DCM, a form considered mainly to be of childhood onset, the
number of adult onset DCM patients was one more (three)
than the number (two) of patients with childhood onset DCM.
There were five patients with TMEP, one with childhood onset,
which is noteworthy considering the rarity of this form and the
fact that TMEP is very rarely observed in childhood.8 These
findings point out that all the cutaneous forms of mastocytosis
may occur at any age.
Familial cases of mastocytosis are rare.17–19 Two of our
patients reported familial involvement. The first patient was a
female with childhood onset UP, whose twin sister also had UP.
However, this sister had a less severe form, as the skin lesions
were less pigmented and lower in number and she had no mast
cell-mediated symptoms. In contrast, another patient in our
Table 3 Course of lesions and/or mast cell-related symptoms in childhood and adult onset mastocytosis
UP SM DCM TMEP Total
P–valueCh Ad Ch Ad Ch Ad Ch Ad Ch Ad
Change 18 3 8 1 – 0 0 0 26 4
Complete resolution 2 (10) 2 (37) 3 (18) 1 (31) – 0 0 0 5 3
Improvement 16 (10) 1 (28) 5 (6) 0 – 0 0 0 21 1
No change 6 (28) 5 (44) 0 0 – 1 (44) 1 (52) 2 (68) 7 8 0.010
Total 24 8 8 1 – 1 1 2 33 12
Numbers in brackets represent the mean age at which changes took place or the mean age at the end of the review period. ; Ch, childhood onset mastocytosis; 
Ad, adult onset mastocytosis; UP, urticaria pigmentosa; SM, solitary mastocytomas; DCM, diffuse cutaneous mastocytosis; TMEP, telangiectasia macularis 
eruptiva perstans.
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population, a female with adult onset UP, had a twin sister who
did not have mastocytosis. An autosomal dominant inheritance
with incomplete penetrance has been suggested as an explana-
tion for the differences in the occurrence of mastocytosis in
twins.20 We cannot draw any conclusions about the mode of
inheritance from such small numbers. The second patient
reporting familial involvement was a male with childhood onset
DCM, who had several male relatives in different generations
on his paternal side with similar complaints.
The typical symptomatology of mastocytosis is caused by the
release of mast cell mediators. The five most frequent symptoms
in our population (Table 2), can all be attributed to the action
of mast cell mediators, especially histamine.1 The number of
patients reporting gastrointestinal symptoms was significantly
higher in the childhood onset than in the adult onset mastocy-
tosis group. However, the possibility of bias cannot be ruled out,
as children are known to be more susceptible to gastrointestinal
afflictions. Although headache, the fifth most frequent symp-
tom, is known to be a symptom of mastocytosis,16 its cause was
difficult to establish.
It is worth of note that 43 (43%) of the 101 patients had not
experienced any mast cell-mediated symptoms. In the adult
onset group this was the case for 18 of the 36 subjects. This
observation is important because of the assumed chronic pro-
gressive nature of cutaneous mastocytosis in adults.
The course of mastocytosis in the adult onset group, for
which there was adequate follow-up, was more favourable than
expected; this was in contrast to the childhood onset group, also
for which there was adequate follow-up. For the childhood
onset group adequate follow-up was defined as follow-up until
adolescence (age 15 years), as this is the age at which the disease
is expected to resolve.11 For the adult onset group this follow-up
had to be at least 10 years. Subjects with either childhood or
adult onset mastocytosis reporting improvement of lesions
and/or symptoms automatically fell into this subgroup. Inter-
estingly, only two of 24 childhood onset UP patients showed
complete resolution of lesions and/or symptoms, compared
with the prognosis of 50–80% experiencing complete resolu-
tion reported by Caplan.12 The majority of patients with child-
hood onset mastocytosis, namely 21 of the 33 showed only
partial improvement in their lesions and/or symptoms, but the
remaining seven subjects showed no changes in the clinical pic-
ture at all. The same trend was observed in the SM group. Con-
sidering the fact that SM is the form of mastocytosis that has the
best prognosis,20 only three of the eight children were com-
pletely cured. Again, the majority of childhood onset SM
patients, namely five of the eight patients had partial improve-
ment of lesions and/or mast cell-mediated symptoms during
the follow-up period. These findings provide a different view on
the prognosis of childhood onset and adult onset mastocytosis.
Childhood onset mastocytosis is not as transitory as suggested
in the literature, where a higher number of complete resolutions
is reported.12
Although five of the eight adult onset UP subjects did not
show any changes in the clinical picture, as expected, two sub-
jects achieved complete resolution and one partial resolution.
The only adult with SM also experienced complete resolution of
the lesion. No changes in the disease were noted in adults with
DCM and TMEP. The favourable course of adult onset masto-
cytosis in our group indicated that this type of mastocytosis
located in the skin had a better prognosis than expected based
on the literature.
While analysing the patient records, we noted the absence of
an objective standardized method of evaluating mastocytosis.
The clinical findings were always classified subjectively in the
physician’s own words. This introduced numerous interper-
sonal and intrapersonal variations. Variations in the description
as well as in the assessment of severity and the course of the dis-
ease were common. A uniform and reproducible standardized
questionnaire for scoring mastocytosis would eliminate this
problem. It would also facilitate an objective comparison of
cases and reduce confusion in communication between physi-
cians. Therefore, we are developing such a questionnaire for scoring
mastocytosis and will not discuss the problem further here.
From the results of this retrospective study, we can conclude
that the incidence for the four cutaneous forms of mastocytosis
generally corroborate those reported in the literature.11 We
could not confirm that a second peak of incidence occurs in
adults, as the incidence was evenly distributed over the years. It
was noteworthy that we observed marked differences in com-
parison of findings reported in the literature,12 with respect to
the clinical course for cutaneous mastocytosis, both in the
childhood onset and adult onset group. A considerable number
of both groups had never experienced any mast cell-mediated
symptoms. In contrast to what is reported in the literature, in
our series childhood onset mastocytosis was not a transitory
disease as it rarely showed complete resolution, although there
was some improvement in the majority of cases. In our study,
the prognosis of adult onset mastocytosis with respect to
symptomatology and course of the disease was noted to be
much better than that reported in the literature.
These observations shed new light on the discussion that
childhood onset and adult onset mastocytosis are two different
clinical entities. Molecular biological research focused on iden-
tifying changes within the mast cell itself, especially on growth
regulation, may further clarify the observations reported here.
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Objective: This paper describes  the different forms 
of  diffuse cutaneous mastocytosis (DCM), based on 
the largest series published to date. 
 
Design: We undertook a case controlled analysis of 
eight children with DCM. Results of laboratory testing 
including mast cell mediator levels and clinical 
symptoms on presentation and during follow up were 
analyzed.  
 
Setting: Department of Dermatology and Venereology 
(Pediatric Dermatology), Erasmus MC, University 
Medical Center – Sophia Children’s Hospital , 
Rotterdam. The Netherlands Department of 
Pediatrics, Onze Lieve Vrouweziekenhuis, Aalst, 
Belgium. Department of Dermatology, Radboud 
University Nijmegen Medical Centre, Nijmegen. The 
Netherlands.  Department of Dermatology and 
Allergology, University Medical Center Utrecht. The 
Netherlands.  1st Pediatric Department, Athens 
University, Aghia Sophia Children’s Hospital, Athens. 
Greece  
Results: The levels of urinary N-methylhistamine and 
serum Tryptase were initially high in all cases, but 
declined sharply later on. Two of seven cases in which 
mast cell mediator decline could be calculated showed 
a reduction of 20%, while the remaining five showed a 
reduction of 80%. Clinical improvement showed the 
same pattern. 
 
Conclusions:  Diffuse cutaneous mastocytosis (DCM) 
is a rare variant of cutaneous childhood onset 
mastocytosis. Various forms show the same or 
overlapping features at various times. It appears to 
follow a course similar to that in other types of 
childhood onset mastocytosis taking into account the 
decreased symptoms and the levels of mast cell 
mediators during the follow up. The markedly 
elevated levels of N-methylhistamine and serum 
Tryptase are not the only factors that should be 
considered in deciding whether to obtain a bone 
marrow biopsy for diagnosis according to the recent 
consensus on mastocytosis.   
 
 
Author affiliations are listed at the end of this article 
 
lassification of mastocytosis is structured since the publication of WHO guidelines. The WHO classification 
divides cutaneous mastocytosis (CM) from systemic mastocytosis, the latter being subdivided into four 
categories of  increasing severity1,2. Thorough and broad based further recommendations in the 
standardization and work up of the recognized subtypes of mastocytosis have been published by Valent et 
al 3. To date systemic mastocytosis is regarded as a clonal myeloproliferative disease based on the presence 
of a somatic mutation predominantly in codon D816V encountered in many patients with systemic mastocytosis. Over 
50 other c-kit mutations  of varying clinical relevance are known4. However, it is debated whether pediatric 
mastocytosis should be regarded as clonal5. In contrast to adult onset mastocytosis this clinical variant of 
mastocytosis may regress in time. Of all cases of mastocytosis, the majority are pediatric cases with cutaneous 
abnormalities and lack sufficient criteria for classification as systemic cases. The clinical expressions of CM in adults 
and children recognized by the WHO are maculopapular; diffuse cutaneous mastocytosis and solitary mastocytoma. 
From a dermatologist’s perspective the WHO sub-classification may be an over-simplification of cutaneous 
mastocytosis. This issue was raised by Hartmann and Henz6. They argued based on course and prognosis that 
maculopapular mastocytosis in fact consists  of different entities of cutaneous mastocytosis; maculopapular cutaneous 
mastocytosis with small lesions that occurs in children and in adults rarely resolves spontaneously and will often 
eventually be categorized as indolent systemic mastocytosis. In contrast to this they point out that the plaque type 
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cutaneous mastocytosis with lesions of several centimeters in diameter and solitary mastocytomas do not evolve but 
tend to disappear6.  Pediatric mastocytosis is predominantly encountered in patients during the first 2 years of life. 
Maculopapular mastocytosis is the commonest variant, but this may depend on the setting of the institution. The 
prognosis of pediatric mastocytosis is mostly good 5,7,8. The visible cutaneous abnormalities in CM are frequently of 
major concern to the patients and their family. In about the half of the children the manifestations disappear before, 
during or in late puberty.  As a subtype of pediatric mastocytosis diffuse cutaneous mastocytosis (DCM) remains a 
rarity9,10. The clinical picture may be impressive and treatment options for severe cases include oral steroids and 
PUVA, mild cases may benefit form anti-histamine agents. Eight patients with DCM are reported in this 
communication.  
 
       ….. r  ….PATIENTS AND METHODS……  ..S      
 
The combined group of patients with predominantly cutaneous mastocytosis presently under surveillance of the 
authors consists of 8 patients with DCM.  Consent for publication of data and clinical photographs were obtained 
either from the patients or their parents and approval of the medical ethical committee was obtained. 
Four patients were seen at the Pediatric Dermatology Unit of the department of dermatology Erasmus Medical Center, 
Rotterdam. The remaining 4 patients were seen at the dermatology outpatient clinic of University Medical Center, 
Utrecht, at the outpatient clinic of Radboud University Medical Center, Nijmegen, at the department of pediatrics, 
Onze Lieve Vrouweziekenhuis in Aalst, Belgium, and at the 1st Pediatric Department, Athens University, Aghia Sophia 
Children’s Hospital in Athens. Greece. The follow up ranged from 2 to 19 years, with a mean follow up of 9 years. The 
characteristics of all 8 patients are shown in Tables 1a and 1b.  
The diagnostics included history, physical examination, skin biopsy, serum Tryptase and urinary N-methylhistamine 
levels and abdominal ultrasound11,12. In the cases with a follow up of over 5 years, initial mast cell mediator analysis 
included urinary N-methylhistamine which was later replaced with serum Tryptase as the preferred indicator of mast 
cell activity. The average decline in the level of serum Tryptase was 65% over a period of 4.5 years in seven patients. 
One patient had serum Tryptase level of higher than 200 ng/l which exceeded the range of laboratory test. In this case 
no changes in the level of serum Tryptase were observed. 
 Two cases (Patients no.1 and 8) are described in details. Patient no. 1 represents a typical case starting in the first 
months of life. Bone marrow biopsy was not obtained from this patient. Patient no. 8 represents an impressive case of 
the same disease manifestation illustrating the diversity of DCM. In this case neither bone marrow analysis nor c-kit 
mutation analysis showed significant changes. 
HISTOPATHOLOGY 
Histopathological examination of the skin biopsy in all cases showed the same pattern of a diffuse infiltration of mast 
cells as a broad band under the epidermis, which was accompanied by either a large or a small blister formation. The 
clinically involved skin was somewhat more infiltrated than the not involved skin, but the general histopathological 
picture was the same. 
 
 
Figure 1a and 1b 

 

 
Histopathology of Diffuse Cutaneous Mastocytosis 
(1a H&E staining 100X, 1b Tryptase staining – inset- 400X)
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CASE REPORT PATIENT NO. 1 
A boy aged 2-3 months with progressive blistering and red skin, but without fever or pruritus was examined at the 
Pediatric Dermatology Unit of the department of dermatology Erasmus Medical Center, Rotterdam. There was no 
history of skeletal pain, diarrhea, vomiting or other complaints. The initial diagnosis was impetigo bullosa, but 
treatment was not successful. Dermatological examination showed vesiculo-bullous areas on the left shoulder and on 
the trunk. Some lesions appeared to be infiltrated. Some were more yellow. Dermography and Darier’s sign (lesional 
dermographism) were present. Diagnosis of DCM was based on clinical examination, histological examination of 
lesional and apparently non-lesional skin, indicating that the entire skin was involved. Histopathological examination 
of a skin biopsy showed dense infiltrates of Tryptase positive mast cells. 
Treatment was started with oral anti-histamines (ketotifen) and topical sulphur 5% in Zinc linament. As the effect was 
minimal, the oral medication was changed into dimetindene (and later into oxatomide), both with minimal or no 
effect. The symptoms became less prominent during the follow up of 8 years. 
 
CASE REPORT PATIENT NO. 8. 
A boy aged 33 months with slowly progressive diffusely distributed firm infiltrative subcutaneous nodules and severe 
accumulation of nodules in the head and neck area was under treatment at the 1th Paediatric Department, Athens 
University, Aghia Sophia Children’s Hospital in  Athens  Greece  since the age of 3 months. The Medical history 
revealed diffuse erythema and blistering at birth, evolving into a maculopapular – nodular appearance at 3 months, 
and further evolving into the nodular infiltrative lesions at the present age. The blistering diminished in time, but 
flushing and pruritus persisted. Diarrhoea from the third month onwards caused retardation of growth. Disodium 
chromoglycate treatment form the fifth month onwards stopped the diarrhoea. 
The diagnosis of diffuse cutaneous mastocytosis was based on clinical examination, histological examination of 
lesional skin. Serum Tryptase levels were measured at  the age of 3, 12, 18 and 21 months and showed values 
exceeding 200μg/l. The level of serum Tryptase had decreased to 160μg/l  at the age of 32 months. Other blood 
chemistry and blood cell count and white blood cell count were normal.  The bone marrow analysis showed diffuse 
infiltration of mast cells. C-kit analysis did not show any mutations. Currently the patient is treated orally with 
disodium chromoglycate, cetirizine, ranitidine and L- Thyroxine. Additional therapy with topical corticosteroids the 
last two months showed improvement of the nodular lesions and the pruritus.  
 
SERIES OF PATIENTS 
The initial symptoms were noticed in all patients during the first months of life, before the age of 6 months. The 
disease began with blistering in all the cases. Two variations in the initial presentation were recognized –  starting 
with red skin and extensive blistering (cases 1, 2, 4-6) and directly starting with yellow-orange infiltrates with only 
limited blistering (cases 3,4,8) Blistering disappeared before the age of 2 years, but was most prominent in the first 
year of life. 
Table 1a 
 
Presenting clinical characteristics of eight DCM  cases  
Patient 
number blistering redness 
Dariers 
sign 
dermo- 
graphy infiltrates 
diffuse 
infiltrates 
Yellow 
Skin flushing urticaria 
liver 
enlarged prutitus fever 
1* yes yes yes yes         
2** yes yes yes yes         
3 yes    yes  yes yes  yes   
4 yes    yes  yes yes yes   yes 
5  yes yes yes       yes  
6 yes     yes yes      
7      yes yes   yes   
8 yes yes   yes        
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Table 1b 
 
Patient 
number 
follow up 
(yrs) 
mediator 
levels# 
Period 
(yrs) c-Kit mutation analysis 
1 9 Nmh -93% 3 n.a. 
2 19 Nmh -28% 5 asp816val 
3 13 Nmh -72% 6 n.a. 
4 4 Tryptase  -58% 3 n.a. 
5 6 Tryptase -22% 1 n.a. 
6 3 Tryptase -83% 3 n.a. 
7 15 Nmh/Tryptase -85% 10 n.a. 
8 2 Tryptase change not esthablished ## 2 negative 
n.a. = information is not available 
Clinical characteristics of eight DCM  cases 
 
Published cases  
* Kuijken I, Bergman W, Oranje AP. Diffuse cutaneous mastocytosis. Ned Tijdschr Geneeskd 2001;145:1527. Dutch. 
** Oranje AP, Soekanto W, Sukardi A, Vuzevski VD, van der Willigen A, Afiani 
HM. Diffuse cutaneous mastocytosis mimicking staphylococcal scalded-skin  syndrome: report of three cases. Pediatr Dermatol 
1991;8:147-51. 
# Note: 
The mast cell mediators urinary N-methylhistamine and serum Tryptase are both valid parameters of mast cell activity in mastocytosis. 
As the markers were not available in all patients at all times, therefore the changes in time of the measured parameters are mentioned. 
## Note: 
The laboratory report did not specify values in excess of 200 µl/l. The initial Tryptase level present in this patient  exceeded of 200 µl/l. 
 
Figure 2 
 
 
 
Red large blister type (in patient no 5.) 
 
Figure 3 
 
 
 
Red large blister type (patient no 1.) 
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Figure 4 
 
 
 
Yellow infiltrated small blister type 
(patient no 7.) 
 
Figure 5 
 
 
 
Yellow infiltrated small blister type 
(patient no 4.) 
 
 
Figure 6 
 
 
 
Yellow infiltrated small blister type extreme presentation (patient no 8.) 
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The levels of urinary N-methylhistamine and serum Tryptase were initially high, but decreased slowly during the 
course of time, except in case 4, where there was a temporary and unexplained increase in the serum Tryptase level 
lasting for 3 months. Bone marrow biopsy was refused by the parents of this child. The child continued to improve 
and the serum Tryptase levels did decrease later on. 
 
In Table 1b it can be seen that there was a decrease of approximately 20% in the levels of mast cell mediators in two 
cases (cases 2, 5), whereas there was a decrease of 80% in the levels of mast cell mediators in five cases (cases 1, 3, 4, 
6, 7). 
At the time of writing of this paper, one of the cases with a limited decline in the levels of mast cell mediators has been 
diagnosed with indolent systemic mastocytosis, with a positive asp816val mutation. The patient is doing fine and 
receives no specific treatment. The other patient is now six years old and a bone marrow biopsy is likely to be 
obtained if elevated levels of serum Tryptase continue to persist. 
 
     ….. r     …….DISCUSSION……       ..S      
 
Diffuse cutaneous mastocytosis (DCM) is very rare as can be concluded from the small number of studies on pediatric 
patients that have been reported. Inamadar and Palit reported 6 cases of cutaneous mastocytosis of which 3 patients 
suffered from diffuse cutaneous mastocytosis 13. Kiszewski described 71 children with mastocytosis of whom 6 (8%) 
had diffuse cutaneous mastocytosis 14. In most series of patients with pediatric mastocytosis, the number of cases with 
DCM was low. Ben-Amitai et al, described 180 children with cutaneous mastocytosis but none of the patients had DCM 
9. Hannaford reported 3 cases with DCM among 173 pediatric patients with mastocytosis10. We reported 2 cases of 
DCM among 65 cases of childhood onset mastocytosis in 2002 7. To our knowledge this case study is the largest series 
of DCM reported. 
 
 On the one hand, clinical presentation begins with a variable degree of generalized blistering early in life. The 
blistering may be extensive and even life-threatening. The bullous type of DCM has widespread bullae and redness as 
the main cutaneous feature. These patients often show widespread erythema. It mimics other diseases such as 
Staphylococcal Scalded Skin Syndrome (SSSS) and bullous erythema multiforme15-18. On the other hand, the disease 
shows yellow-orange infiltrations (xanthogranuloma like abnormalities) and slight blistering. This presentation has 
been reported in a very limited number of cases 19,20. Walker reported a rare case of diffuse cutaneous bullous 
mastocytosis with pachydermia and unusually extensive skin folding in a 3-week-old girl who fits in the subgroup of 
the yellow-orange variant21. Whether the two variants are indeed different or are manifestations of the same disease 
presenting with different clinical features during the course has no influence on the management of the patients. 
There is limited information on the prognosis of DCM, but it seems to be similar to that in other forms of CM in 
childhood. None of the patients reported here experienced severe life-threatening events and treatment was 
restricted to anti-histamine agents and disodium cromoglycate. Oral steroid treatment and photo-chemo therapy with 
UV-A light are also other suitable strategies in severe persistent cases 24, 25 The authors are not in favor of using the 
latter two therapies as first line treatment in infancy. 
  
Bone marrow biopsies were not taken as a routine from any of our patients because of reluctance of the parents due 
to clinical improvement, decrease in the levels of serum Tryptase or urinary N-methylhistamine. Arguably, bone 
marrow analysis is important for the choice of therapy, especially in the case of persistent rising serum Tryptase 
levels, c-Kit abnormalities, and suspicion of myeloproliferative disease. Diffuse cutaneous mastocytosis was shown to 
be a part of systemic cases of mastocytosis 22, 23. Furthermore, in SM there is substantial risk of osteoporosis, a 
condition which must be treated. 
The clinical features of red large blistering and orange-yellow small blistering in DCM raises the question of whether 
there is a single clinical description that fits all presentations. The very low incidence of DCM makes the initial 
diagnosis difficult as demonstrated in our series in 4 out of the 8 cases where a faulty initial diagnosis was made. 
Diffuse cutaneous mastocytosis in all the cases presented as a cutaneous disease with a benign course. The levels of 
serum Tryptase or urinary N-methylhistamine were highly elevated similar to that in other forms of mastocytosis 
classified as systemic. However, in DCM the number of the cutaneous mast cells alone may be sufficient to cause the 
elevated levels of the mediators. This is supported by the observed simultaneous decrease in the cutaneous symptoms 
and the levels of the mediators.  If one would apply the consensus standard algorithm as published by Valent et al in 
2007, then almost all the patients would be candidates for a bone marrow biopsy, especially the youngest patients.  In 
this series, one patient showed a temporary increase in serum Tryptase level instead of the expected decrease. The 
significance of this still remains unknown. At the present the patient is doing fine and has no sign of hematological 
disease, but would have qualified for bone marrow analysis. Two of seven cases in whom the percentage of decline in 
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the level of mediators was calculated showed a reduction of approximately 20%. This is a fourfold difference 
compared with five other cases in whom there was a reduction of 80%. The less drastic improvement could be 
explained in one patient who is now twenty years old and in whom indolent systemic mastocytosis (asp816val 
positive) has been diagnosed. The other patient is now six years old and in whom bone marrow investigations are 
awaited. 
Given the rarity of DCM, one is unable to clearly recommend when to pursue bone marrow analysis in infants 
suspected of this disease.  One must realize that the severity of the disease dictates whether one should do this, 
considering the effects of such an intervention for the patients and their parents.  Determining the levels of mast cell 
mediators alone may not be the best tool to decide the most appropriate therapeutical approach because both serum 
Tryptase and urinary N-methylhistamine levels tend to be very high, but decrease in time. Whether newly reported 
plasma IL-6 levels may be of use in such cases is uncertain since there are correlations between plasma IL-6 levels and  
total serum Tryptase levels, severity of bone marrow pathology, organomegaly, and the extent of skin involvement26.    
Therapeutic recommendations in cases of DCM are tailored and dosage schemes of H1 and H2 antagonists and mast 
cell stabilizing drug may exceed the recommended dosage. Special care is needed when anesthesia and radiography 
with contrast medium is undertaken. A protocol on the treatment of mastocytosis in childhood by our group has 
recently been published 27.  
The cases of DCM (in infancy) reported in the literature and from our own experience tend to improve in time. 
Therefore, we recommend to include the clinical presentation of symptoms, progress of disease and elevated levels of 
serum Tryptase before deciding whether to obtain bone marrow biopsies and choosing the most effective therapy. An 
algorithm for the work up of patients suspected of DCM is presented in the appendix. 
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 Appendix.   
 
An algorithm of work up for patients suspected of suffering from diffuse cutaneous mastocytosis (DCM) 
 
1) A newborn or an infant with an extensive or a generalized urticating, blistering or maculopapular 
erythematous eruption without any apparent cause and cases with anaphylactic episodes. 
2) Consider the diagnosis of DCM 
3) Establish any provoking factors 
4) Provoke Darier’s sign or dermatography 
5) Determine serum Tryptase levels  (persistently raised serum Tryptase levels  makes the diagnosis of 
mastocytosis likely but does not confirm it) 
6) Obtain skin biopsies from lesional and non-lesional skin and also  stain for CD25 and  undertake Kit 
mutation analysis 
7) Repeat measurements every 3 – 6 months  in case of inconclusive results 
8) Team up with a pediatrician in case of positive findings :  
9) Abdominal ultrasound and hematological work up is recommended   
10)  Treatment and follow up is tailored according to the laboratory findings, imaging and severity of 
symptoms 
11) Lack of improvement of symptoms over a 12-month period  in established DCM,  hematological 
aberrations, established mutation in Kit are indications for bone marrow investigations 
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Aims: To investigate mast cell distribution in normal adult skin to provide a reference range for comparison
with mastocytosis.
Methods: Mast cells (MCs) were counted in uninvolved skin adjacent to basal cell carcinomas and other
dermatological disorders in adults.
Results: There was an uneven distribution of MCs in different body sites using the anti-tryptase monoclonal
antibody technique. Numbers of MCs on the trunk, upper arm, and upper leg were similar, but were
significantly different from those found on the lower leg and forearm. Two distinct groups were formed—
proximal and distal. There were 77.0 MCs/mm2 at proximal body sites and 108.2 MCs/mm2 at distal
sites. Adjusted for the adjacent diagnosis and age, this difference was consistent. The numbers of MCs in
uninvolved skin adjacent to basal cell carcinomas and other dermatological disorders were not different
from those in the control group. Differences in the numbers of MCs between the distal and the proximal
body sites must be considered when MCs are counted for a reliable diagnosis of mastocytosis. A pilot
study in patients with mastocytosis underlined the variation in the numbers of MCs in mastocytosis and
normal skin, but showed a considerable overlap. The observed numbers of MCs in adults cannot be
extrapolated to children.
Conclusions: MC numbers varied significantly between proximal and distal body sites and these
differences must be considered when MCs are counted for a reliable diagnosis of mastocytosis. There was
a considerable overlap between the numbers of MCs in mastocytosis and normal skin.
M
ast cells (MCs) are multifunctional cells that play an
important role in inflammatory and allergic reactions.
They attract other key players of the immune system
by releasing cytokines. Skin MCs are easily recognised by
their metachromatic granules, which release their contents
after activation by surface antigen or cytokine dependent
events. The number of skin MCs can increase under certain
conditions. In mastocytosis, the increase in the number of
MCs is considered a primary event with an unknown
pathogenesis.1 Cutaneous mastocytosis presents with mildly
to severely pruritic macules and papules that host an
increased number of MCs.2 Systemic mastocytosis affects
several internal organs and presents with a wide range of
symptoms, such as hypotension, seizures, skeletal pain,
abdominal pain, and changes in defaecation.2 3 These
symptoms may occur in various diseases and in the absence
of dermatological signs, making the diagnosis of mastocytosis
very difficult, so that it may even be missed by the clinician.
Several criteria should be met for the diagnosis of masto-
cytosis. An increased serum tryptase concentration (. 13.5 ng/
ml), dense infiltrates of mast cells in the cutaneous lesions
or in the bone marrow, the expression of CD2 and CD25 on
bone marrow mast cells, or the presence of a c-kit mutation
may assist in the diagnosis.2 4 When systemic mastocytosis is
suspected, a skin biopsy from lesional skin, or even from non-
lesional skin, may be helpful in determining the number of
MCs in the skin. In some cases, a slight increase in the
number of MCs is seen, and in the absence of reliable
reference values for the numbers of MCs in healthy skin, it
remains unclear whether there is a pathological increase in
the number of MCs or whether the values are within the
normal range. Therefore, a reference value for the normal
numbers of MCs in healthy skin may provide a valuable tool
for improving the accuracy of diagnosis.
‘‘Tryptase is considered to be an immunohistochemical
marker for mast cells’’
In previous studies, different numbers of MCs in normal
skin were reported, but they could not serve as reference
values because the methods that were used for counting MCs
in skin biopsies were not uniform.5–10 Furthermore, research-
ers used different staining techniques and often the studied
groups were very small.11 Staining with anti-tryptase mono-
clonal antibody (ATA) is now considered to be the gold
standard for identifying MCs.12 The enzyme tryptase is also
present in basophilic granulocytes, but its concentration is so
low that they are stained very weakly with ATA. Therefore,
tryptase is considered to be an immunohistochemical marker
for MCs.12 The aim of our present study was to determine a
reliable reference value for the numbers of MCs in healthy
skin that could be used to establish the diagnosis of
mastocytosis with certainty.
MATERIALS AND METHODS
Biopsies
Paraffin wax embedded blocks of skin biopsies, collected
between 1996 and 2001 at the department of pathology of the
Erasmus MC, Rotterdam, the Netherlands, were used. The
biopsy blocks were divided into three groups. The first group
consisted of perilesional skin from 25 basal cell carcinoma
(BCC) biopsies. The mean age of the patients in this group
was 66.8 years (range, 47–81). The second group consisted of
perilesional skin from 95 biopsies taken from patients with
various dermatological disorders (compound naevi, Spitz
naevi, scars, dermatofibromas, and others). All biopsies were
from the trunk, upper arm, forearm, upper leg, or lower leg.
Exclusion criteria were inflammatory changes in the skin,
massive degranulation of MCs, or other abnormalities. The
mean age of the patients in this group was 49.7 years (range,
15–87). The third group consisted of skin biopsies of 21
healthy women (mean age, 37.7 years; range, 18–63) who
Abbreviations: ATA, anti-tryptase monoclonal antibody; BCC, basal
cell carcinoma; MC, mast cell; PBS, phosphate buffered saline
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underwent elective mamma reduction or abdominoplasty at
the department of plastic and reconstructive surgery. None of
these women had dermatological disorders and there was no
report of systemic use of immunosuppressives or glucocorti-
coids. These biopsies were collected directly after the surgical
intervention and were obtained and included after informed
consent. This group served as the control group.
Staining procedure
Formalin fixed, paraffin wax embedded sections (4 mm) were
used. Staining was performed using mouse ATA clone AA1
(Dako, Glostrup, Denmark) as the primary antibody, as
described previously.12 Briefly, 141 skin slides were dewaxed
in xylene three times for five minutes, washed in ethanol
three times for five minutes, and then washed in phosphate
buffered saline (PBS; pH 7.4) three times for five minutes.
Endogenous peroxidase activity was blocked with 3%
hydrogen peroxide for 10 minutes. To block non-specific
antibody binding, the slides were preincubated with protein
blocking reagent (Immunologic/Labvision, Klinipath, Duiven,
the Netherlands) for five minutes. The slides were incubated
with primary antibody AA1, diluted 1/ 200 in PBS/5% bovine
serum albumin for 30 minutes, rinsed in PBS/0.1% Tween
twice for five minutes, and incubated with polyvalent
biotinylated antibody (Immunologic/Labvision) for 10 min-
utes. After washing with PBS three times for five minutes,
the slides were incubated with streptavidin–peroxidase
(Immunologic/Labvision) for 10 minutes. The reaction
was visualised using 3,39 diaminobenzidine (Fluka Sigma-
Aldrich, Zoetermeer, the Netherlands) and 30% hydrogen
peroxide (Merck, Darmstadt, Germany) in PBS for seven
minutes, then rinsed with tap water for two minutes. All
sections were counterstained with Mayer’s haematoxylin
(Fluka AG, Buchs, Germany) for 10 seconds and rinsed in
running tap water for 10 minutes. Slides were immersed
three times in ethanol for three minutes after incubation in
PBS for five minutes. The sections were mounted in Pertex
(Histolab, Goteborg, Sweden). The negative controls con-
sisted of omitting the staining with the primary antibody.
MC quantification
The numbers of mast cells were determined at a magnifica-
tion of6400 using a Zeiss Axioplan microscope (Carl Zeiss,
Weesp, the Netherlands). Each section was photographed
using a Sony colour video camera 3 CCD connected to the
microscope. For accuracy of counting, a graticule with 100
fields measuring 0.226 0.22 mm (0.0484 mm2) under6400
magnification was projected over each photograph. This
counting method was based on the morphometric point
counting technique, and the size of overlaying fields was
fitted to the size of one mast cell.13 14 Ten photographs in
different dermal layers were analysed for each section. To
provide an overview of the dermal MCs, four photographs
were taken from the stratum papillaris, three from the mid
stratum reticularis, and three from the bottom stratum
reticularis. Every square overlaying an MC scored one point
and the sum of MCs in 10 photographs was calculated for
each section. Capillaries, skin appendages, and the whole
epidermis were scored in the same way. In addition to true
MCs with a nucleus, clustered positively stained granules
were counted as MCs and scored one point for each cluster.
The numbers of MCs in each section were expressed as
MCs/mm2.
MCs in all the three different biopsy groups were counted.
The numbers of MCs in perilesional skin around BCCs and
other skin lesions were counted and compared with those in
the skin from healthy women (control group).
MC numbers, sample characteristics, and patient assess-
ments were recorded in SPSS for Windows. Both paired and
unpaired Student’s t tests were used to compare the means. A
p value of , 0.05 was considered significant.
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Figure 1 (A) The numbers of mast cells (MCs) were determined in three
different biopsy groups, using anti-tryptase antibody staining and
expressed as MC/mm2. No differences were found between perilesional
skin biopsies around basal cell carcinomas (BCCs), perilesional skin
around various dermatological disorders, and control skin (p = 0.560).
(B) From these three biopsy groups, the numbers of MCs were
determined in five different body sites; p values for differences in MC
numbers in the trunk, upper arm, and upper leg were not significant
(0.929), and neither were p values for differences between the forearm
and lower leg (p = 0.240). (C) Body sites with similar MC numbers
were placed into two groups. The ‘‘proximal’’ group was formed by the
trunk, upper arm, and upper leg, whereas the ‘‘distal’’ group was
formed by the forearm and lower leg (unpaired Student’s t test,
p , 0.001).
Table 1 Mean mast cell (MC) numbers in the 3 biopsy
groups
Group Mean (SD) MC numbers p Value*
Group 1: BCC (n = 25) 91.3 (36.0) 0.560
Group 2: other dermatological
disorders (n = 95)
87.8 (41.8) 0.560
Group 3: controls (n = 21) 79.5 (31.8) 0.560
Group 1, mean number of MCs/mm2 in biopsies from perilesional skin
around basal cell carcinomas (BCCs); group 2, mean number of MCs/
mm2 in biopsies from perilesional skin around other dermatological
disorders; group 3, mean number of MCs/mm2 in skin biopsies from
healthy women.
*p Value for differences in MCs/mm2 between the three groups; Student’s
t test.
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RESULTS
Numbers of MCs in healthy non-lesional and
perilesional skin
In sections stained with ATA, the numbers of MCs in the
sections of skin from healthy women who underwent
mamma reduction or abdominoplasty (control group) were
compared with those in the other two biopsy groups using an
unpaired parametric Student’s t test (table 1; fig 1A). The
numbers of MCs in perilesional skin in BCCs (n = 25),
perilesional skin from various dermatological disorders
(n = 95), and skin from the healthy group (n = 21) were
not significantly different from each other. The 25 BCC
biopsies and 95 other dermatological disorder biopsies were
obtained from five different body sites and not exclusively
from the trunk. To determine the possible influence of the
body site and of the adjacent diagnosis of perilesional skin on
the numbers of MCs, a multiple linear regression analysis
was performed. When adjusted for the body site from which
the biopsies were obtained, the numbers of MCs did not
depend on the adjacent original diagnosis (p = 0.992).
MCs in various body sites
Perilesional skin samples stained with ATA were used for
counting MCs in biopsies from different body sites. Adjusted
for the diagnosis, the numbers of MCs were significantly
dependent on the body site from which the skin samples
were obtained (p = 0.001) (figs 2, 3A, B).
Table 2 and fig 1B and C show the numbers of MCs at
different body sites. The highest numbers of tryptase positive
MCs were found in the lower leg and the forearm. These were
significantly higher (p , 0.001) than was seen on the trunk,
upper leg, and upper arm. As shown in table 2 and fig 2, two
body site groups were formed according to this finding. The
proximal group comprised biopsies obtained from the trunk,
upper leg, and upper arm. The mean number of MCs in this
group was 77.0 MCs/mm2 (SD, 33.6). The distal group
comprised biopsies obtained from the lower leg and forearm.
The mean number of MCs in this group was 108.2 MCs/mm2
(SD, 41.4). Adjusted for the diagnosis around which the MCs
were counted (BCC or other skin lesions), a similar difference
was found in the numbers of MCs at proximal and distal
body sites.
The number of capillaries in a biopsy does not affect
MC counts
The numbers of MCs were calculated by dividing the total
number of MCs by the total area of the biopsy. When the
numbers of capillaries and skin appendages were subtracted
from the total area of one skin biopsy, the numbers of
MCs/mm2 were computed. It appeared that the numbers of
capillaries and skin appendages subtracted from the total
surface area had no significant influence on the accuracy of
the numbers of MCs/mm2. However, the number and surface
area of capillaries appeared to correlate (p , 0.001) with the
number of MCs (B coefficient, 1.198). When adjusted for age,
there was a significant effect of the number of capillaries on
the number of MCs in proximal body sites (B coefficient, 1.5;
p , 0.001). The number of capillaries had no effect on the
number of MCs at distal body sites (B coefficient, 20.4;
p = 0.639).
Pilot study in patients with mastocytosis (comparison)
Numerous MCs are present in mastocytosis and occur as oval
to spindle shaped cells with a centrally located round to oval
nucleus. They are concentrated in the upper dermis and
around the blood vessels (fig 3C, D).
The numbers of MCs in a pilot study group of 14 patients
with mastocytosis ranged from 78 to 2409 MC/mm2 (mean,
821; SD, 582). The ages of these patients ranged from 4 to 49
years, with six patients younger than 16 years. The numbers
of MCs in mastocytosis were increased nearly 10 fold
compared with those seen in normal skin. Figure 3E and F
shows immunohistochemical staining for CD117, and an
example of c-kit analysis, which is only possible in digested
tissue, is shown in fig 4.
Table 2 Mast cell (MC) numbers according to the
different body sites
Body area N Mean (SD) MC/mm2
Trunk 17 78.6* (31.5)
Upper arm 44 76.5* (32.7)
Upper leg 29 74.9* (38.8)
Proximal 90 77.0** (33.6)
Forearm 27 101.2*** (32.6)
Lower leg 24 113.1*** (46.7)
Distal 51 108.2** (41.4)
Perilesional skin around basal cell carcinomas, various dermatological
disorders, and the control group.
*Difference in MCs/mm2 between trunk, upper arm, and upper leg:
p = 0.929; **difference of MCs/mm2 between proximal and distal body
areas: p = 0.000; ***difference of MCs/mm2 between forearm and lower
leg: p = 0.240 (all Student’s t test).
Proximal: trunk, upper arm, and upper leg; distal: forearm and lower leg.
Figure 2 Mast cell distribution in
human adult skin. Darker areas,
highest numbers of mast cells in
human skin (distal areas); lighter
areas with the lowest numbers of
mast cells in human skin (proximal
areas). Mast cells in the facial
area were not determined so that
this area is left white.
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DISCUSSION
In our present study, the numbers of MCs in adults were
determined in biopsies obtained from five different body
sites. Higher numbers of MCs were found in the forearm and
lower leg (distal extremities) compared with those in the
trunk, upper leg, and upper arm (centre and proximal
extremities). Mast cells on the face were not counted in our
study because diagnostic biopsies for mastocytosis are
preferentially not taken from the face. From a pilot study
in 14 patients with mastocytosis, we concluded that the lower
limit for the number of MCs in mastocytosis may be as low as
78 MCs/mm2, which is also lower than the mean number of
MCs in healthy skin (87.8 MCs/mm2). Thus, there was an
overlap in the range of numbers of MCs in mastocytosis and
normal skin.
The first reports on the measurement of MC numbers in
different body sites date to 1950.15 In those early studies,5 6 10
different counting and staining techniques were used and no
differences in the numbers of MCs in relation to the site of
origin of the biopsy were noted. The numbers of MCs were
found to be between 44 and 50 MCs/mm2. The uneven
distribution in the numbers of MCs in different body
sites may be the result of differences in their functional,
environmental, and haemodynamic properties. Although still
controversial, the numbers of MCs do not appear to be related
to variations in the exposure of different body sites to
ultraviolet light.16–20
We confirm the results obtained by Weber et al, who
reported increased numbers of MCs on the face compared with
other body sites and variations in numbers of MCs at different
body sites similar to those reported here.21 The main difference
between their study and ours is that they used the toluidine
blue staining technique. It may be the case that more granules
were stained in our study than that of Weber et al because the
ATA technique is more sensitive than the toluidine blue stain
used in their study. We also used a high magnification (6400)
for analysing stained MCs from a picture on the computer
screen. This may have magnified groups of granules that
would have otherwise remained undetected.
‘‘There was an overlap in the range of numbers of mast
cells in mastocytosis and normal skin’’
Collecting a large number of skin samples, using perile-
sional skin biopsies from BCCs or various dermatological
disorders was useful, making biopsies from healthy indivi-
duals (controls) unnecessary. Cohen and Rogers emphasised
the increased numbers of MCs around BCCs.22 They reported
significant differences between the numbers of MCs in skin
directly adjacent to a BCC compared with the surrounding
skin, independent of the overall inflammatory cell response
in the area. An increase in the numbers of MCs was described
above and around multiple and single dermatofibromas and
other benign epithelial tumours.23 24 In contrast, in other
Figure 3 (A) Normal skin near basal cell carcinoma (original magnification,6100). Mast cells occur in the normal dermis in small numbers as oval to
spindle shaped cells. They are concentrated around the blood vessels. (B) Normal skin of mamma reduction tissue (original magnification,6100). Mast
cells occur in the normal dermis in small numbers as oval to spindle shaped cells. They are concentrated around the blood vessels. (C) Haematoxylin
and eosin staining of mastocytosis (urticaria pigmentosa) (original magnification,6100). Mast cells in the normal skin are indistinguishable from other
perivascular cells. A small amount of granular cytoplasm is seen. (D) Urticaria pigmentosa, dense infiltrate of mast cells in the upper dermis located
directly under the basal membrane. The infiltrate is also more concentrated around the blood vessels (original magnification,6300). (E) Urticaria
pigmentosa: positive staining of the mast cell infiltrate with CD117 (original magnification,6300). (F) Urticaria pigmentosa: positive staining of the
mast cell infiltrate with CD117 (original magnification,6700).
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studies there was no difference in the numbers of perilesional
MCs between benign and malignant skin lesions.11 By using
perilesional skin biopsies without obvious signs of inflam-
mation and determining the numbers of MCs as far away
from the original lesion as possible, we avoided possible
influences of inflammation on MC numbers.
Although MCs are mostly seen around dermal capillaries,6
in our study we found that adjusting for the number of
capillaries does not contribute to a more precise quantifica-
tion of MCs/mm2. In other studies on MC quantitation, an
attempt was made to define the numbers of MCs in different
dermal layers.5 7 In our study, the dermis was not divided into
different dermal layers because the border between the
papillary dermis and reticular dermis was not always clearly
visible, which would make counting in relation to different
dermal layers less accurate.
Based on our results, it is impossible to draw a strict
distinguishing line between the upper limit of MC numbers
in normal skin and the lower limit of MC numbers in
mastocytosis. We suggest that a figure of up to 75 MCs/mm2
should be considered as normal and more than 250 MCs/
mm2 as abnormal. Between 75 and 250 MCs/mm2 is the
borderline area in which a diagnosis of mastocytosis should
certainly be considered. These figures are crude and an
individual approach still remains essential. Further studies in
a large number of patients with mastocytosis are necessary to
clarify the lower limit of the numbers of MCs in these
patients.
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Figure 4 Digestion fragments from polymerase chain reaction (PCR)
products obtained from genomic DNA of one patient, analysed on a 4%
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Schdik.
Take home messages
N There was a significant difference between the numbers
of mast cells (MCs) on the trunk, upper arm, and upper
leg (distal location) and those found on the lower leg
and forearm (proximal location)
N These differences between distal and proximal loca-
tions must be considered when MCs are counted for a
reliable diagnosis of mastocytosis
N A pilot study in patients with mastocytosis underlined
the variation in the numbers of MCs in mastocytosis
and normal skin, but showed a considerable overlap,
and further studies are needed to clarify the lower limit
of the numbers of MCs in patients with mastocytosis
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Urinary N-methylhistamine as an indicator of bone marrow
involvement in mastocytosis
A. P. Oranje, P. Riezebos, A. W. van Toorenenbergen,* P. G. H. Mulder,† R. Heide
and B. Tank
Departments of Dermatology, *Clinical Chemistry and †Epidemiology & Biostatistics, University Hospital Rotterdam, Dijkzigt and Erasmus University,
Rotterdam, the Netherlands
Summary Thirty-seven patients with mastocytosis and unexplained elevated levels of urinary
N-methylhistamine who were undergoing bone marrow biopsy were studied with
respect to the diagnosis of mastocytosis and the manifestations of the disease. These
patients were from a group of 66 patients from whom a bone marrow biopsy was
obtained and urinary N-methylhistamine levels were measured in the period
1990–1998. In seven (19%) of the 37 patients, mastocytosis was limited to the
skin. Five (14%) of the 37 patients showed accumulation of mast cells in the bone
marrow without characteristic skin lesions, whereas seven (19%) of the 37 patients
showed increased numbers of mast cells both in the skin and the bone marrow.
Eighteen (49%) of the 37 patients with elevated N-methylhistamine did not have mast
cell accumulation in either the skin or the bone marrow biopsy. The median level of
N-methylhistamine in the urine of patients with mastocytosis limited to the skin was
245 lmol ⁄mol creatinine. The average level of N-methylhistamine was
509 lmol ⁄mol creatinine in patients with mast cell accumulation in the bone
marrow and cutaneous mastocytosis. There was a significant difference in the levels of
N-methylhistamine in patients with mast cell accumulation in the bone marrow biopsy
compared with those without. The likelihood of mastocytosis with mast cell
accumulation in the bone marrow biopsy at a given level of N-methylhistamine was
calculated. It was established that an N-methylhistamine level of 297 lmol ⁄mol
creatinine or higher may be considered as a threshold indicator for obtaining a bone
marrow biopsy in patients suspected of mastocytosis with mast cell accumulation in
the bone marrow. For practical purposes, we propose to consider the cut-off level of
�300 lmol ⁄mol N-methylhistamine creatinine for this assay.
Introduction
The diagnosis of mastocytosis is based on the clinical
symptoms and the pathology.1–3 Extracutaneous mast-
ocytosis is difficult to diagnose. Measuring the levels of
mast cell mediator metabolites may be helpful in
obtaining clues for this disease. However, biopsy of the
bone marrow or other organs is necessary for estab-
lishing the diagnosis. Mastocytosis may be classified
as indolent, associated with haematological disorders,
aggressive or malignant.3 Information on prognostic
factors for the disease is limited.
Mastocytosis in children is more often transient than
in adults in whom there is a stable or progressive
disease.4–6 Thorough monitoring of the patients is
necessary, given the likelihood of mast cell accumula-
tion in the bone marrow in patients with persistent
childhood and adult onset disease.7–10 Various types of
skeletal and bone marrow lesions have been described in
mastocytosis of the bone marrow, the most common
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type being nodular or granuloma-like mast cell accu-
mulation. The risk of osteoporosis in patients with mast
cell accumulation in the bone marrow is considerable
and estimated at up to 85%.11,12 The risk of early
skeletal decalcification appears to be proportional to the
amount and the activity of the mast cells in the bone
marrow. Heparin and prostaglandins are believed to
have a role in the induction of osteoporosis, whereas
sclerotic lesions are induced by histamine.13 A subgroup
of the patients with mast cells in the bone marrow
develops complications such as haematological disor-
ders or progression to aggressive or malignant masto-
cytosis. Later onset of symptoms, absence of cutaneous
mastocytosis, thrombocytopenia, elevated lactatic dehy-
drogenase level, anaemia, bone marrow hypercellular-
ity, qualitative peripheral blood smear abnormalities,
elevated alkaline phosphatase level and hepatospleno-
megaly are all associated with decreased survival.14 The
identification of somatic mutations in the C-kit coding
genome in mast cells of adults may prove useful as a
predictor of bone marrow involvement and possibly of
myelodysplastic or other complications.15–17 The treat-
ment of mastocytosis is largely symptomatic. However,
some potential complications of mastocytosis may be
detected before clinical symptoms occur. Osteoporosis
especially, may be successfully treated with bisphospho-
nates and interferon alpha.18–20 Myelodysplastic and
other haematological complications require co-opera-
tion with haematologists. Bone marrow biopsy is the
most reliable method to identify the patients at risk for
these complications. Elevated levels of mast cell medi-
ator metabolites in the urine have been associated with
the presence of extracutaneous mast cell accumula-
tion.21–27 The aim of our study was to assess the
diagnostic value of N-methylhistamine levels in identi-
fying patients with the (tentative) diagnosis of masto-
cytosis who are likely to have mast cell accumulation in
the bone marrow.
Materials and methods
Routine measurements of N-methylhistamine in urine
samples performed during 1990–1998 were reviewed
with respect to the levels, concurrent bone marrow
biopsy and the diagnosis of mastocytosis.
N-methylhistamine in the urine samples was deter-
mined in duplicate using a competitive radioimmuno-
assay according to the manufacturer’s instructions
(Pharmacia & Upjohn, Woerden, the Netherlands), as
described previously.28 The levels of N-methylhista-
mine in all samples were expressed as micromoles
N-methylhistamine per mole creatinine. Reference
values of urinary N-methylhistamine for adults using
this method ranged between 50 and 155 lmol ⁄mol
creatinine. An elevated level of N-methylhistamine was
defined as 156 lmol ⁄mol creatinine or higher.
N-methylhistamine levels were measured and bone
marrow biopsy was obtained from 66 patients for
various reasons. Levels of the N-methylhistamine,
outcome of the bone marrow biopsy and clinical
observations were analysed statistically using SPSS.
The significance of differences in N-methylhistamine
levels between a group of patients with accumulated
mast cells in the bone marrow biopsy and a group of
patients without was determined using the Mann–
Whitney test. If there is a significant difference, the
relevance of N-methylhistamine as a diagnostic test for
predicting bone marrow involvement may be investi-
gated further. The Mann–Whitney test is particularly
relevant here, because the value of the test statistic is
essentially equal to the area under the ROC-curve.27 A
ROC-curve is the relationship between sensitivity and
100 ) specificity obtained from varying the cut-off level
of the diagnostic test parameter (here N-methylhista-
mine). A significant Mann–Whitney test coincides with
an area under the ROC-curve that is significantly larger
than 50% and hence with sums of sensitivity and
specificity that are larger than 100%. A measure for the
validity of a diagnostic test is the sum of its sensitivity
and specificity. The criterion used in this paper for
choosing a cut-off level for N-methylhistamine is the
maximum of the sum of sensitivity and specificity.
The likelihood of mastocytosis with mast cell accu-
mulation in the bone marrow at a given N-methylhis-
tamine cut-off level was calculated using a 2 · 2 table.
The validity of the test is expressed here as the sum of
sensitivity and specificity. Sensitivity is defined as the
chance that the test result is positive in a patient
with the disease. In the 37 patients with elevated levels
of N-methylhistamine an optimal cut-off value for
detecting mast cell accumulation in bone marrow
biopsy was 297 lmol ⁄mol creatinine. At this cut-off
level the sum of specificity and sensitivity was maxi-
mum: the specificity was 84% and the sensitivity was
67% as shown in Table 1.
Results
Thirty-seven (56%) of the 66 patients from whom a
bone marrow biopsy had been obtained also had
elevated levels of N-methylhistamine. Nineteen (51%)
of these 37 patients had biopsy proven mastocytosis.
Of 29 patients without elevated N-methylhistamine
levels and from whom a bone marrow biopsy had been
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obtained, only three had mastocytosis, which was
limited to the skin.
Of the 19 patients with biopsy-proven mastocytosis
and elevated urinary N-methylhistamine levels seven
(37%) had mastocytosis of the skin. Five patients (26%)
showed bone marrow mast cell accumulation without
characteristic skin lesions and seven (37%) showed
increased numbers of mast cells in both skin and bone
marrow. The other 18 (49%) of the 37 patients with
elevated levels of N-methylhistamine did not have mast
cell accumulation in the skin or bone marrow.
In patients with mast cell accumulation in the bone
marrow, but without the typical skin lesions, the
average level of N-methylhistamine was 795.8 lmol ⁄ -
mol creatinine. The average level of N-methylhistamine
in patients with mastocytosis in the skin and mast cell
accumulation in the bone marrow, was 781.7 lmol ⁄ -
mol creatinine.
There was a significant difference in the levels of
N-methylhistamine in patients with accumulated mast
cells in the bone marrow biopsy compared with those
without as shown in Fig. 1. In the 37 patients with
elevated levels of N-methylhistamine, the optimal pre-
dictive value for detecting mast cell accumulation in
bone marrow biopsy was observed at an N-methylhis-
tamine level of 297 lmol ⁄mol creatinine at which the
specificity was 84% and the sensitivity was 67%
(Table 1 and Figure 2).
Discussion
The aetiology of mastocytosis has not yet been
elucidated. A minority of the patients with mastocyto-
sis develops complications that require extensive mon-
itoring and treatment. These complications may be
subdivided into those related primarily to the large
number of mast cells, excessive amounts of mast cell
mediators and complications related to changes in the
myeloid cell lineage. Both types of complications are
Table 1 Sensitivity and specificity at an N-methylhistamine cut-off level of 300 lmol ⁄mol creatinine in relation to mast cell numbers in
bone marrow (borderline significance range, 250–350 lmol ⁄mol creatinine).
Urine N-methyl histamine level
> 250–350 lmol ⁄mol creatinine
Mast cell number in bone
marrow not increased (n ¼ 25)
Mast cell number in bone
marrow increased (n ¼ 12) Total number of patients (n ¼ 37)
Test result negative 14 (56%) 3 (25%) 17 (47%)
Test result doubtful* 7 (28%) 1 (8%) 8 (21%)
Test result positive 4 (16%) 8 (67%) 12 (32%)
*In cases where the test result is doubtful we advise to repeat the N-methylhistamine test.
Figure 1 Urinary N-methylhistamine levels in patients with
mastocytosis with (positive) and without (negative) involvement
of the bone marrow. Data are median and SD. y-axis: values in
lmol ⁄mol creatinine.
Figure 2 ROC-curve of the sensitivity in relation to 1 ) specificity
for various cut-off levels of urinary N-methylhistamine. (area
under the ROC-curve equals 0.79 with 95% CI of 0.64–0.94).
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likely to occur in patients with mastocytosis who
develop significant mast cell accumulation in the bone
marrow. Bone marrow biopsy is the method of choice
to identify patients who may be at risk of such
complications. Bone marrow biopsy is an invasive
procedure with potential morbidity. Care must be
taken to identify patients who may benefit from bone
marrow biopsy.
The current method of staging mastocytosis depends
on repeated evaluations of the clinical condition of the
patient, blood- and urine chemistry, haematological
screening as well as bone marrow biopsy and bone
density measurement. N-methylhistamine in the urine
indicates mast cell activity and mast cell density. In the
reported group of patients, N-methylhistamine levels
were determined in order to stagemastocytosis in patients
suspected of having mastocytosis without skin involve-
ment and those with established mastocytosis. Levels of
N-methylhistamine >156 lmol ⁄mol creatinine always
indicated that a bone marrow biopsy was essential.
The likelihood of mast cell accumulation in the bone
marrow could be predicted on the basis of eleva-
ted N-methylhistamine levels. In the given group of
patients, an N-methylhistamine level of 297 lmol ⁄mol
creatinine was the cut-off point of choice for obtaining a
bone marrow biopsy. We propose to handle in practise
as follows: Below 250 lmol ⁄mol no bone marrow
examination indicated; from 250 to 350lmol ⁄mol
creatinine doubtful, repeat test; and ‡350lmol ⁄mol
creatinine bone marrow examination indicated.
The level of N-methylhistamine as a diagnostic aid for
levels of mastocytosis has limited value. There are
several conditions that lead to elevated levels of
N-methylhistamine. The most important of these are
allergic reactions,29 histamine-rich diets,30 and intersti-
tial cystitis.31 Persistent levels of N-methylhistamine
exceeding 297 lmol ⁄mol creatinine may indicate mast
cell accumulation in the bone marrow.
Based on the results of this study it is recommended to
restrict bone marrow biopsy to patients with established
or suspected mastocytosis and unexplained osteoporosis,
osteosclerosis or haematological aberrations and in
cases in which the diagnosis cannot be confirmed by a
skin biopsy.
Long-standing mastocytosis with elevated levels of
N-methylhistamine, but without signs of osteoporosis or
osteosclerosis on densitometry are not primary candi-
dates for bone marrow biopsy unless there are haema-
tological disturbances. The process of diagnosing
mastocytosis may be difficult in some patients, especially
in patients without the classical skin lesions. In patients
suspected of having mastocytosis, persistent levels of
N-methylhistamine >300 lmol ⁄mol creatinine may
indicate accumulation of mast cells in the bone marrow.
In patients suspected of having mastocytosis, but with-
out elevated levels of N-methylhistamine a �wait and see�
approach is justified. Where there is doubt about
whether or not to obtain a bone marrow biopsy it may
be helpful to determine the level of N-methylhistamine.
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mast cells are normally present. The organ most fre-
quently affected is the skin, but the gastrointestinal tract, 
bone marrow, bones, liver, spleen and lymph nodes can 
also be involved  [1–3] . 
 Mastocytosis can be divided into a classification sys-
tem based on consensus  [1] . There are two main variants, 
cutaneous and systemic forms  [3, 4] . Based on the clinical 
presentation, six subtypes can be distinguished: masto-
cytoma, urticaria pigmentosa, diffuse cutaneous masto-
cytosis, telangiectasia macularis eruptiva perstans 
(TMEP), systemic mastocytosis and mast cell leukemia 
( table 1 ). This classification has been preferred in chil-
dren  [3, 4] . Mastocytosis in adults frequently is a persist-
ing or progressive disorder, whereas in many children the 
disorder resolves with age  [4, 5] . Although generally mas-
tocytosis is a rare disorder, families have been described 
in which more than one member is affected  [6] . In pa-
tients with mastocytosis, symptoms are primarily caused 
by the release of mast cell mediators, although they may 
also be due to local accumulation of mast cells. Recent 
studies have shown that mutations in c-kit may cause 
some forms of mastocytosis  [7] . C-kit is a proto-oncogene 
encoding for a tyrosine kinase receptor (fig. 1). Apart 
from the presence of the receptor on mast cells, c-kit is 
also expressed on various other cells, including hemato-
poietic stem cells and melanocytes. Mutations in c-kit 
may lead to SCF-independent activation of the receptor, 
preventing proliferation and apoptosis of mast cells  [7, 8] . 
In familial forms of mastocytosis, the Asp-816-Val muta-
tion has never been demonstrated  [6, 7] .
 Key Words 
 Mastocytosis  � C-kit Asp-816-Val mutation  � Mast cells 
 Abstract 
 Background:  Mastocytosis is a heterogeneous group of dis-
orders characterized by abnormal accumulation of mast 
cells.  Objective: Skin biopsies from 24 patients (23 with 
proven mastocytosis) were screened for the presence of the 
c-kit Asp-816-Val mutation.  Methods: In frozen biopsies, 
RNA was isolated, cDNA synthesis and PCR, the expected 
PCR product of 346 bp was obtained from 23 patients.  Re-
sults:  In patients with urticaria pigmentosa, the mutation 
was detected in 38% of the adults and 25% of the children. 
With regard to the clinical presentation of the disease, no 
difference was found between adult patients with and with-
out the mutation, as detected with our assay. One out of the 
2 children with the mutation had an atypical presentation of 
the disease.  Conclusion: the mutation could not be detect-
ed in all the patients, probably due to lack of sensitivity of 
the methods.  Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Mastocytosis is a heterogeneous group of disorders 
characterized by proliferation and accumulation of mast 
cells in one or more organ systems  [1, 2] . In mastocytosis, 
the disorder becomes clinically manifest at sites where 
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 Besides the Asp-816-Val mutation, a number of other 
mutations in c-kit have been found in patients with mas-
tocytosis ( table 2 )  [2, 9, 10] . Because the presence of cer-
tain mutations may be relevant to the prognosis (masto-
cytosis in children with the Asp-816-Val mutation may 
be chronic) and the sensitivity to therapy, it is important 
to demonstrate such mutations  [11, 12] . Because of the 
possible clinical implications, skin biopsies from 24 pa-
tients with mastocytosis were screened for the presence 
of the Asp-816-Val mutation, and in this patient group 
the prevalence of the mutation was determined. A pos-
sible relation between the presence of the mutation and 
the clinical presentation of the patients was also investi-
gated. 
 Material and Methods 
 Patients and Biopsies 
 At the time the study was performed, 72 patients with masto-
cytosis of the skin were recorded at the Dermatology outpatient 
clinic of the Academic Hospital Rotterdam. Frozen biopsies from 
24 patients (n = 24), 12 adult and 12 children ( table 3 ) were used. 
Among these patients, 9 adults suffered from sporadic urticaria 
pigmentosa (patients 1–5 and 7–10), and in 3 of those 9 patients 
multiorgan involvement was demonstrated (patients 3, 5 and 10), 
1 adult had sporadic TMEP (patient 6), a father and son were di-
agnosed with familial urticaria pigmentosa (patients 12 and 13), 
and 8 children with sporadic urticaria pigmentosa (patients 14–16 
Table 1. Subtypes of mastocytosis with common average age of onset and clinical characteristics [4]
Subtype Age Characteristics
Mastocytoma 0–6 months 1–5 reddish brown hyperpigmented/skin colored noduli/nodi
Urticaria pigmentosa 3–9 months; if onset after the age of
10 years, average age at onset 26.5 years 
Multiple reddish brown hyperpigmented maculae and papules
Diffuse cutaneous
mastocytosis 
In general before the age of 3 years, 
 frequently at birth 
Thickened lichenified skin with papules, rarely without skin 
abnormalities, formation of bullae following minor trauma 
TMEP Almost exclusively at adult age Hyperpigmented telangiectatic maculae
Systemic mastocytosis Adult age, rarely childhood Mast cell infiltrates in skin and internal organs
Mast cell leukemia (rare) Adult age Mast cells in peripheral blood
Table 2. Mutations in c-kit in patients with mastocytosis
C-kit mutation Demonstrated in
Asp-816-Val Systemic mastocytosis
Mastocytosis with associated hematologic disorder
Adults with cutaneous mastocytosis
Children with atypical mastocytosis
Asp-816-Tyr Children with atypical mastocytosis
Asp-816-Phe Children with atypical mastocytosis
Asp-816-His Mastocytosis associated with acute myeloid leukemia
Asp-820-Gly Aggressive mastocytosis
Val-560-Gly Adults with indolent cutaneous mastocytosis
Gln-839-Lys Children with typical mastocytosis
From references [2, 7, 9, 11].
 Fig. 1. Schematic representation of the structure of the c-kit recep-
tor. Adapted from reference [3] . 
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and 19–23), of which 1 also showed juvenile xanthogranuloma 
(patient 16), and 3 children suffered from sporadic diffuse cutane-
ous mastocytosis (patients 17, 18 and 24). Moreover, a skin biopsy 
of the twin sister of patient 10 was screened. In this adult, masto-
cytosis could not be diagnosed, despite the fact that some com-
plaints were possibly consistent with mastocytosis (patient 11).
 From the skin biopsies from patients 2–24, 3–5 sections of 
about 20  � m were cut. Due to the small tissue biopsy taken from 
patient 1, no additional sections could be made for use in further 
analysis. 
 Mutation Analysis 
 RNA Extraction 
 Cells were lysed in Trizol (Life Technologies) and total RNA 
was extracted according to the manufacturer’s protocol (method 
based upon the acid guanidinium/phenol/chloroform extraction 
 [13] ). RNA was dissolved in 25  � l RNAse-free water.
 Synthesis of cDNA and Polymerase Chain Reaction 
 From 6  � l of isolated total RNA, cDNA was synthesized using 
2  � l AMV reverse transcriptase (9 U/ � l, Promega), 2  � l random 
hexamers (500  � g/ml, Roche), 5  � l dNTPs (4 m M , Roche), 4  � l 
RT buffer (Promega) and 1  � l RNAsin (40 u/ � l, Promega). This 
cDNA was used as a template in a polymerase chain reaction 
(PCR) (45 cycles: 1 min 94  °  C, 1 min 55  °  C, 1 min 72  °  C) using the 
primers 5 � -ACATAGAAAGAGATGTGACTCCCG-3 � (P187, nu-
cleotide 2261-2284) and 5 � -AGCTCCCAAAGAAAAATCCCAT
AGG-3 � (P188, nucleotide 2606-2582) (GenBank No. 1:X06182), 
resulting in a PCR product of 346 bp.
 Digestion of the PCR Product 
 Two digests were performed on the PCR product: 5  � l PCR 
product was cleaved with restriction enzyme  Hin f I and 5  � l PCR 
product was cleaved with restriction enzymes  Hin f I and  Hae III, 
the latter for a better resolution on a gel  [13] . If an A ] T substitu-
tion occurs at nucleotide 2468, an extra cleavage site for  Hin f I will 
be formed, and the expected fragments will be 188, 127, 17 and 
 14 bp ( Hin f I) and 157, 127, 31, 17, 14 bp ( Hin f I and  Hae III). If the 
mutation is not present, the fragments will have a length of 202, 127 
and 17 bp ( Hin f I) and 171, 127, 31 and 17 bp ( Hin f I and  Hae III). 
 In the  Hin f I digest, the presence of a 188-bp product is indic-
ative of the presence of the Asp-816-Val mutation; in the  Hin f I 
and  Hae III digest, the presence of a 157-bp product is indicative 
of the mutation.
Patient Gender Type Age at onset Age at biopsy Clinical diagnosis
1 m sporadic 34 years 38 years UP
2 f sporadic 70 years 71 years UP
3 f sporadic 29 years 47 years UP+Sysa
4 f sporadic 24 years 24 years UP
5 m sporadic 31 years 40 years UP+Sysa
6 f sporadic 49 years 50 years TMEP
7 f sporadic 29 years 41 years UP
8 f sporadic 30 years 40 years UP
9 m sporadic 38 years 49 years UP
10 f sporadic 20 years 28 years UP+Sysb
11 f – – 29 years –
12 m familial childhood 49 years UP
13 m familial 3 months 14 years UP
14 m sporadic 6 months 4 years UP
15 m sporadic 3 months 8 years UP
16 m sporadic birth 7 months UP/Juv Xanth
17 m sporadic birth 7 years DCM
18 m sporadic early infancy 9 months DCM
19 f sporadic 2 years 7 years UP
20 f sporadic 4 months 6 years UP
21 f sporadic 6 months 5 years UP
22 m sporadic at birth 2 years UP
23 m sporadic 10 days 12 years UP
24 m sporadic neonatal 11 years DCM
UP = Urticaria pigmentosa; DCM = diffuse cutaneous mastocytosis; Sys = systemic 
extension demonstrated; Juv Xanth = juvenile xanthogranuloma. 
a Infiltration of mast cells demonstrated in bone marrow; in other patients systemic 
extension not tested. 
b Infiltration of mast cells demonstrated in intestine; in other patients systemic exten-
sion not tested.
Table 3. Patient characteristics
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 Gel Electrophoresis 
 The cleaved PCR products were mixed with loading buffer, 
and separated on a 2% agarose gel (product cleaved with  Hin f I) 
and 4% agarose gel (product cleaved with  Hin f I and  Hae III), and 
stained with ethidium bromide. 
 Results 
 Following RNA isolation, cDNA synthesis and PCR, 
the expected PCR product of 346 bp was obtained from 
patients 2–24. No PCR product from patient 1 was 
found; this patient was subsequently excluded from the 
study. Following cleavage of the PCR product with 
 Hin f I and analysis on a 2% agarose gel, fragments of 202 
and 127 bp were found for all patients, but no fragments 
of 188 bp.
 For better separation of fragments, the PCR product 
was cleaved with  Hin f I and  Hae III and applied to a 4% 
agarose gel. In 5 patients (patients 7, 9, 10, 16 and 23), an-
other extra fragment of 157 bp was found in addition to 
fragments of 171 and 127 bp. This is in accordance with 
the c-kit Asp-816-Val mutation ( fig. 2 ). 
 Therefore, the c-kit Asp-816-Val mutation could be 
demonstrated in 3 out of 10 adult patients (30%) and in 2 
out of 12 children with mastocytosis (17%;  table 4 ). 
 In the adult patients, the mutation was found in 3 pa-
tients with sporadic urticaria pigmentosa (patients 7, 9 
and 10). In one of the patients with sporadic urticaria 
 Fig. 2.  Hin f I/ Hae III digestion fragments 
from PCR products obtained from genom-
ic DNA of 24 patients, analyzed on a 4% 
agarose gel. Left and right: 50-bp DNA 
ladder. The 171-bp and 127-bp digestion 
products are visible in all samples except 
patient 1. The 157-bp fragment, indicating 
the presence of the mutation encoding the 
Asp-816-Val change, is present in patients 
7, 9, 10, 16 and 23. a Patients 1–12. b Pa-
tients 13–24; in patient 13 the PCR was 
negative.
Table 4. Results of the c-kit Asp-816-Val mutation analysis
Clinical diagnosis Patients Patients without
Asp-816-Val mutation
Patients with
Asp-816-Val mutation
Adults (n = 11) total 10 7/10 (70%) 3/10 (30%)
Sp UP/Sp UP+Sys 8 5/8 (63%) 3/8 (38%)
Fam UP 1 1/1 (100%) 0/1 (0%)
Sp TMEP 1 1/1 (100%) 0/1 (0%)
No mastocytosis 1 1/1 (100%) 0/1 (0%)
Children (n = 12) total 12 10/12 (83%) 2/12 (17%)
Sp UP 8 6/8 (75%) 2/8 (25%)
Fam UP 1 1/1 (100%) 0/1 (0%)
Sp DCM 3 3/3 (100%) 0/3 (0%)
Sp UP = Sporadic urticaria pigmentosa; Sp TMEP = sporadic TMEP; Sys = systemic extension; Sp DCM = 
sporadic diffuse cutaneous mastocytosis;  Fam UP = familial urticaria pigmentosa.
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pigmentosa with the mutation, involvement of the intes-
tine had been established (patient 10). Adult patients with 
the mutation do not differ clinically from patients with 
sporadic urticaria pigmentosa that do not carry the mu-
tation. The mutation was demonstrated neither in the pa-
tient with familial urticaria pigmentosa (patient 6), nor 
in the patient with TMEP (patient 12). In patient 11 (no 
mastocytosis diagnosed) no Asp-816-Val mutation was 
found, in contrast to her twin sister with mastocytosis 
(patient 10).
 With regard to the children, the mutation was dem-
onstrated in 2 patients with sporadic urticaria pigmen-
tosa (patients 16 and 23). Besides urticaria pigmentosa, 
patient 16 also showed juvenile xanthogranuloma, con-
sistent with an abnormal clinical presentation. Patient 
23 showed no abnormal clinical presentation. The mu-
tation was not found in the child with familial urticaria 
pigmentosa (patient 13) and in the children with spo-
radic diffuse cutaneous mastocytosis (patients 17, 18 
and 24). 
 Discussion and Conclusion 
 Because of the potential prognostic significance of the 
Asp-816-Val mutation and the possible relationship be-
tween certain mutations and the sensitivity to therapy, a 
PCR was carried out for c-kit Asp-816-Val mutation anal-
ysis in skin biopsy sections  [11, 12] . In 23 out of 24 pa-
tients a PCR product was found. The absence of PCR 
product for one patient might be due to the fact that in 
this patient the whole biopsy was used instead of sections: 
because of the thickness of the material, this may have 
warmed up before the buffer was able to inhibit RNAse 
activity, resulting in insufficient amounts of intact RNA. 
The best analysis results were obtained using the double 
digest  Hin f I and  Hae III, followed by electrophoresis on 
a 4% agarose gel. 
 The prevalence of the c-kit Asp-816-Val mutation in 
the total patient group examined by us was 30 and 17% 
for adults and children, respectively. Within the groups 
with sporadic urticaria pigmentosa the prevalence was 
38% (adults) and 25% (children). In contrast to earlier 
publications by Longley et al.  [7] and Büttner et al.  [9] , 
the mutation was not demonstrated in all adults with 
sporadic cutaneous mastocytosis. No distinction was 
made between the patient groups with or without dem-
onstrated systemic extension, because recent investiga-
tions have shown that on bone marrow testing in patients 
with cutaneous mastocytosis, in virtually all patients 
bone marrow involvement, and therefore systemic ex-
tension, will be found  [14] . The Asp-816-Val mutation 
could not be demonstrated in familial urticaria pigmen-
tosa. This is consistent with earlier publications, al-
though we only studied 2 cases  [6, 7] . The suggested
absence of Asp-816-Val mutation in familial cases of 
mastocytosis must be further evaluated in such popu-
lations. 
 Mastocytosis is very heterogeneous and the manifes-
tations differ from one to other cases in several ways. Teb-
be et al. [15] illustrated it in an observational study in 14 
adults with cutaneous mastocytosis. Bone marrow in-
volvement was observed in only 7 of 13 patients investi-
gated  [15] .
 The prevalence of the Asp-816-Val mutation was found 
in 2 children with mastocytosis (17%). One child with the 
mutation showed an atypical clinical presentation of ur-
ticaria pigmentosa and juvenile xanthogranuloma. Ac-
cording to Longley et al. [7] , children in whom the Asp-
816-Val mutation is found will be characterized by an 
atypical presentation. Up to now, the second child in 
which the mutation was demonstrated did not show an 
atypical clinical presentation. In patient 11 (no diagnosed 
mastocytosis), the Asp-816-Val mutation was not found. 
Detection of the mutation in her (monozygotic) twin sis-
ter confirms that this mutation did not occur in early 
embryonic development (germ cell mutation). In this 
case, it is an acquired somatic mutation associated with 
the disease. An illustration that atypical manifestations 
not always are Asp-816-Val positive was demonstrated by 
Walker et al. [16] , who described a child with neonatal 
mastocytosis with pachydermic bullous skin without the 
Asp-816-Val mutation.
 The discrepancy between our c-kit mutation findings 
and those from earlier publications may be due to insuf-
ficient sensitivity of our assay. As for sensitivity, however, 
the method used by us (PCR + restriction analysis) is at 
least comparable to the methods used by Longley et al.  [7] 
(sequencing) and Büttner et al.  [9] (sequencing and PCR 
+ restriction analysis). A discrepancy introduced by sam-
pling is very unlikely because the material was obtained 
in an identical way. A possibility that cannot be ruled out 
is that the patient populations from studies mentioned be-
fore are different from the population examined by us.
 Summarizing, we conclude that  Hin f  I/ Hae III double 
digests of c-kit PCR fragments separated on a 4% agarose 
gel can be used for detection of the c-kit Asp-816-Val mu-
tation in skin biopsies. In contrast to the literature, we 
find the Asp-816-Val mutation only in 38% of the adults 
with sporadic urticaria pigmentosa. Careful follow-up of 
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patients will give a decisive answer on the question wheth-
er patients with the mutation are more severely affected 
and/or whether the disease runs a more progressive 
course in patients with the mutation.
 Acknowledgement 
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Clinical Scoring of Cutaneous Mastocytosis
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behalf of the MASTOCYTOSIS STUDY GROUP ROTTERDAM
Departments of 1Dermato-Venereology and 2Epidemiology & Biostatistics, University Hospital Rotterdam and Erasmus University Rotterdam,
Rotterdam, The Netherlands
represents 1% skin involvement. In the case of diVuse cutaneousThere are still many controversies in dening and evaluating
mastocytosis, by denition the skin is completely involved (100%).mastocytosis. One of the aspects that is missing is a system for
clinical evaluation of mastocytosis of the skin. A calculation Part B. The pattern of the local reactivity of the skin lesions is limited
based on a semi-quantitative analysis of three aspects of masto- to erythema, swelling and blistering of varying degrees. This may
cytosis was designed. The method is called the scoring index of occur spontaneously or be caused intentionally by rubbing the skin
lesion (Darier’s sign).mastocytosis (SCORMA). The clinical use of SCORMA is
In assessing mastocytosis, the activity of the individual mast cell isadvocated. Key words: mast cell disease; skin; SCORMA. probably reected by the activity of the skin lesions. This is exemplied
by the observation that, in resolving mastocytosis, reactivity to various(Accepted April 18, 2001.)
stimuli decreases a long time before resolution of the associated
hyperpigmentation. Subsequently, it is our opinion that assessing theActa Derm Venereol 2001; 81: 273–276.
activity of the lesions provides a close impression of the actual local
Arnold P. Oranje, MD, PhD, Department of Dermato- state of the disease activity. Reduction of mediator-induced symptoms
owing to a decrease of degranulation is always established in treatmentVenereology, University Hospital Rotterdam, Dr.
that is considered successful. The relevance of looking at the lesionalMolewaterplein 40, NL-3015 GD Rotterdam, The Nether-
activity is therefore evident.lands. E-mail: aoranje@inter.nl.net The activity of the disease is measured by one elected lesion. The
chosen lesion should be typical in shape, size and colour for the
majority of the skin lesions. A lesion on the back of the trunk may
be chosen because of the limited exposure to UV radiation fromMastocytosis is a rare and heterogeneous disease, which is
sunlight. Secondly, non-lesional skin will be present close to the lesion.characterized by an abnormal accumulation of non-malignant This is used to assess dermographism due to rubbing of unaVected skin.
mast cells (1–3). Usually symptomatic skin involvement is Four items of the chosen lesion are scored semi-quantitatively:
present and is either localized or diVuse (2). Dermatologists pigmentation/erythema, vesiculation, elevation and Darier’s sign
(Fig. 1). The score for each item is 0–3. In total, the range of themay encounter new cases of mastocytosis at a ratio of one in
score is 1 to a maximum of 12.every 1,000–8,000 new patients (3). Bone marrow involvement
can be observed in most of the adult patients (4, 5). Despite Part C. In mastocytosis, many patients lack symptoms such as itchingrapidly growing knowledge, there are still many controversies or ushing, but they complain about the adverse cosmetic aspects of
in dening and evaluating mastocytosis(6–11). Because there their disease. Occasionally, patients are restricted in their daily activi-
ties because of severe constitutional symptoms caused by mediatorsis no system for clinical evaluation of mastocytosis of the skin,
released upon mast cell degranulation. Scoring subjective complaintswe designed a method for quantifying and scoring masto-
involves a certain degree of inaccuracy caused by the patient’s mentalcytosis. The method is called the scoring index of mastocytosis state. Subjective complaints were included in the SCORMA index,
(SCORMA). Details of SCORMA and an evaluation of its but have only a limited inuence on the nal score.
The subjective symptoms prior to consultation were evaluated. Aapplication by a panel of dermatologists are presented in
period of 3 weeks was chosen in order to gain an impression of thethis report.
persistent nature of a given complaint. A shorter period of observation
would increase the risk of including non-specic complaints or symp-
toms of a transient nature, while a longer period of observation wouldMATERIALS AND METHODS
exclude the possibility of evaluation of the eVect of therapy on a
shorter interval. However, until data are available on the duration ofSCORMA
symptoms in mastocytosis, these cannot be included as complaints
A semi-quantitative analysis of three aspects of skin mastocytosis that are likely to be caused by mastocytosis. Five questions were put
was made using the same principles of the ‘‘SCORAD’’ for atopic to the patient. Question 1 dealt with the daily inconvenience caused
dermatitis (12–15). by this disease. The remaining questions dealt with specic symptoms
The analysis was divided into 3 parts. In the rst part (A) the caused by mediator release or mast cell accumulation. The severity of
extent of the skin involvement was assessed. In the second part (B), the symptoms was scored from 0 to 10. A visual analogue scale was
the activity of the lesions was estimated, and in the third part (C), used in children older than 4 years of age. The score ranged from 0
the subjective symptoms were recorded. Each part was rated separately to a maximum of 50.
on a semi-quantitative scale. The combined scores of A, B and C
formed the SCORMA index.
Formula for calculating SCORMA index
Part A. There is a substantial variety in skin lesions in the cutaneous
manifestation of mastocytosis. Using a pencil, the extent of the disease It was our intention to develop a semi-quantitative clinical index to
monitor the eVect of therapy on skin mastocytosis. We have assumedis estimated by roughly marking the contours of the skin abnormalities
in the picture printed on the SCORMA form (Fig. 1). Thereby, the that the lesional activity was a reection of the potential degranulating
activity of all the mast cells. Consequently, during the course of thediVerence in morphology of the variation in presentations of skin
mastocytosis is minimized. The percentage of skin involvement is disease and treatment, increase or decrease in the lesional activity is
probably the rst objectively measurable item to change. Therepresented by the marked surface. In the SCORMA setting there are
two assumptions. In the case of solitary mastocytomas, each lesion SCORMA index was intended to be sensitive for monitoring changes
© 2001 Taylor & Francis. ISSN 0001-5555 Acta Derm Venereol 81
83
274 R. Heide et al.
during the course of the disease. Emphasis was therefore put on the SCORMA index was compared with the dermatologists’ assess-
ment on severity. The assessment of the severity was documented onlesional activity by multiplying it by a factor of three as compared
with extent of complaints and subjective complaints. The multiplica- a 0–100 scale for each patient separately prior to revealing the
SCORMA index calculation.tion factor 3 for lesional activity was chosen in analogy with the
SCORAD (12–15) used in atopic dermatitis. In 1998, 9 dermatologists were invited to participate in a course to
evaluate 9 patients (6 boys and 3 girls) with mastocytosis using theThe resulting scores of each item are incorporated in the SCORMA
index formula: A+ 3B+C. SCORMA index (Fig. 1). The SCORMA index of all the patients is
shown in Table I.In order to use the SCORMA index formula: A+ 3B+C, the ranges
of the scores of A, B and C were equalized to 20. This was done by All relevant clinical information was provided by a slide presentation
of an overview of the skin as well as close-ups of the lesional skin.dividing A by 5 (maximum outcome: 100/5= 20), multiplying B by
5/3 (maximum outcome: 12 ´ 5/3= 20) and multiplying C by 2/5 None of the dermatologists had information on the SCORMA
index formula prior to the course. The data were processed and(maximum outcome: 50 ´ 2/5= 20). Finally, the score of B is multiplied
by 3. The SCORMA index formula in practice is A/5+ 5B+ 2C/5, calculated using SSPS. For all patients and all parts, statistical analysis
was made including the inter-investigator variations expressed as inter-and ranges from 5.2 to 100.
We assessed whether the SCORMA index also has practical value rater agreement for each patient (16, 17). The degree of agreement is
expressed as the proportion of the possible scope of doing better thanfor dermatologists not involved in basic research programmes on
mastocytosis. The reliability of the SCORMA index was determined by chance. A value between 0.41 and 0.60 is considered moderate,
between 0.61 and 0.80 as good and between 0.81 and 1.00 as veryby measuring the inter-rater agreement on all the items of the
SCORMA index. Secondly, the severity of the disease calculated as good (16, 17).
Fig. 1. The scoring index of mastocytosis (SCORMA).
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Table I. Assessment of the severity of mastocytosis by 9 dermatologists in each patient (mean ± SD)
Patient Diagnosis Extent score Intensity score SCORMA index Dermatologist’s global evaluation (scale 0–100)*
1 UP 21 ± 14.2 2.4 ± 0.8 19.8 ± 5.4 21.1 ± 12.2
2 SM 1 ± 0 3.6 ± 0.7 20.6 ± 3.5 10.4 ± 7.9
3 UP 17.2 ± 3.8 3.6 ± 0.5 21.4 ± 2.8 19.2 ± 5.9
4 UP 44.1 ± 10.7 2.8 ± 1.0 29.6 ± 6.8 47.8 ± 17.2
5 UP 31.4 ± 7.2 3.4 ± 0.8 30.5 ± 4.7 44.4 ± 17.2
6 UP 52.4 ± 10.9 3.8 ± 0.9 30.7 ± 5.0 51.7 ± 16.4
7 UP 70 ± 9.7 4.6 ± 0.5 37 ± 2.8 69.4 ± 9.2
8 DCM 100 ± 0 3.6 ± 1.2 42 ± 12.3 74.9 ± 12.3
9 DCM 100 ± 0 10.6 ± 1.3 78.6 ± 6.3 92 ± 8.3
UP=Urticaria pigmentosa; SM= solitary mastocytoma; DCM=diVuse cutaneous mastocytosis.
*Impression prior to SCORMA.
RESULTS because it quickly provides a point of reference for the doctor
and the patient.The means and standard deviations for the extent of skin The SCORMA index calculation contains a factor three-involvement for all the 9 patients are listed in Table I. Note weight advantage for lesional activity over extent of the diseasethat for patients 2, 8 and 9 there is a unanimous assessment. and subjective complaints. Consequently, emphasis has beenThese patients had a dened percentage of skin involvement; put on the items of mastocytosis of the skin that are likely to1% for solitary mastocytoma (1 pat.) and 100% for diVuse be the rst features that undergo change in progressive diseasecutaneous mastocytosis (2 pats.).The mean results show less as well as in subsiding disease. It serves the goal of monitoringvariety for activity than for extent. This can be explained by changes in mast cell activity and, to a lesser degree, to monitorthe limited width in range for part B. changes in subjective aspects of the disease and pigmentation.There was a high degree of inter-rater agreement for all the At our clinic, many of the mastocytosis patients are enrolledinvestigated items, for parts A and B and the outcome of the in therapeutic trails for which we use the SCORMA index asSCORMA index. The lowest value, 0.43, was noted in sub- well as measurements of several mast cell mediator metabolites.section B1 (erythema). Correlation studies between reduction of the SCORMA indexThe results of the SCORMA index compared with the and mediator metabolites are being pursued.results of the global evaluation of dermatologists before dis- In order to gain insight into the reproducibility of theclosing the SCORMA formula are also presented in Table I. SCORMA system, it was put to the test by 9 practisingThe two assessments diVer in the degree of severity in 7 of the dermatologists at regional hospitals. Based on the results of9 patients. In 4 of those patients the severity was assessed as the assessment of 9 patients, a very high degree of agreementmore than 50% higher by the dermatologists than by the was achieved when the SCORMA index was used, evenSCORMA index. without prior familiarity with the method. Therefore, it also
has practical value when used incidentally. The results of the
SCORMA index compared with the dermatologists’ opinionDISCUSSION
on the severity of the disease diVer with respect to the extentMastocytosis is characterized by an indolent or progressive of the disease. In general, patients with a relatively highdisease. In the majority of cases, mastocytosis is manifested percentage of involved body surface were considered to beby skin symptoms. In patients with a high suspicion of more severely aVected than those who had a lower percentagemastocytosis, histopathological examination of the bone of involvement, the latter, regardless of the activity of skinmarrow or other organs may be necessary to establish the lesions. This indicates further that standardized observationdiagnosis in cases in which histopathological examination of using the SCORMA index of the skin in mastocytosis couldthe skin showed no abnormalities. Measurement of mast cell provide a more accurate clinical description of the activity ofmediator metabolites, such as N-methyl histamine and protryp- the disease.tase, is valuable in staging mastocytosis. However, these
measurements have no diagnostic signicance, because
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Summary Background. Skin lesions are the predominant clinical feature of the commonest
form of mastocytosis. Mastocytosis is classified according to World Health Organization
criteria. Determination of the levels of mast-cell mediators or their metabolites reflects
the mast-cell burden. The extent of cutaneous mastocytosis can be assessed clinically
using a scoring system (SCORing MAstocytosis; SCORMA Index) that we have
developed.
Objective. Serum tryptase levels were compared with the SCORMA Index in a large
group of paediatric and adult patients to investigate whether there was any correlation
between the two.
Methods. The SCORMA Index in 64 patients (31 children and 33 adults) was
compared with serum tryptase levels. The results of the first visit at which SCORMA
and tryptase were evaluated were analysed.
Results. There was a positive correlation between the SCORMA Index and serum
tryptase levels, indicating the value of the SCORMA Index in the assessment of
mastocytosis with skin involvement.
Conclusion. The results of this study showed that the SCORMA Index is a useful tool
for evaluating the severity of cutaneous mastocytosis. The correlation between the
SCORMA Index and serum tryptase levels underlines the benefit of the SCORMA Index
as a clinical tool. Repeated SCORMA Index measurements can provide a rapid
impression of changes in the clinical state of mastocytosis. This is particularly relevant
in children, because taking blood samples from this group is much more difficult. The
well-established methods for evaluation of disease severity may be expanded by the
rapid SCORMA Index method.
Introduction
Mastocytosis is a heterogeneous group of mostly clonal
myeloproliferative diseases characterized by aberrant
proliferation and accumulation of mast cells in one or
more organ systems.1–3 In the 2001 World Health
Organization (WHO) classification, systemic mastocyto-
sis is differentiated from cutaneous mastocytosis (CM)
based on clinical, biochemical and pathological criteria,
especially bone-marrow smears.2 Childhood mastocytosis
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accounts for most of the cases of mastocytosis seen.4
Unlike adult-onset mastocytosis, childhood cases of
mastocytosis are primarily cutaneous, and complete
remission will develop in a considerable number of
patients during puberty.5,6 The affected skin shows
localized or diffuse accumulations of mast cells, resulting
in pigmented macules and plaques.7
In 2001, we developed a system for scoring the
clinical extent of mastocytosis, which was evaluated in
nine patients by a group of nine dermatologists.8 The
system is known as the SCORMA (SCORing MAstocy-
tosis) Index. The SCORMA Index consists of three parts
and is based on the principles of the SCORAD
(SCORing Atopic Dermatitis Index).9 In the SCORMA
Index, the extent of the skin abnormality is evaluated
in the first part (A) using the relevant form (Fig. 1).
The marked area represents the percentage of exposed
skin. By definition, the lesion is 1% of the affected skin
in solitary mastocytoma and almost the whole (100%)
of the skin in diffuse CM. (R Heide, E Zuidema, AP
Oranje, submitted) The intensity of the disorder is dealt
with in part B, for which a lesion of a typical form, size
and colour representing the majority of the lesions is
examined. A lesion that is not affected by sunlight,
such as one located on the back, is preferred. This
lesion is then judged on its pigmentation ⁄ erythema,
vesiculation, elevation and Darier’s sign. Each item is
scored from 0 to 3 (0 = absent, 3 = most severe). Five
subjective symptoms (triggering factors, flushing, diar-
rhoea, itch and local bone pain) that may occur in
mastocytosis are dealt with in part C, which is scored
by the patient on a 10 point visual analogue scale
(VAS), where 0 = absent and 10 = continuously pres-
ent. The formula: A ⁄ 5 + 5B + 2C ⁄ 5 is used to calcu-
late the final SCORMA Index. The value of the
SCORMA Index then lies between 5.2 and 100.8
In the study reported below, a group of adult and
paediatric patients with cutaneous features of masto-
cytosis were evaluated using the SCORMA. In total, 15
of these patients were classified as having indolent
systemic mastocytosis (ISM) and their SCORMA Index
was compared with their serum tryptase level to
examine whether there was any correlation between
the two.
Methods
All patients approved the use of their data for
scientific purposes, but written informed consent was
omitted, as no additional procedures or investigations
took place. The study was approved by the local
ethics committee.
Patients
Patients with mastocytosis and evident cutaneous
lesions were selected for this study. The medical records
of the patients with proven or suspected mastocytosis
were drawn from the hospital registry. In total, 67
patients were found in the database up to 5 years before
the study, of which 64 (31 children aged 0–18 years
and 33 adults aged > 18 years) were evaluated at least
once, and these were entered into the final analysis. The
inclusion and exclusion criteria for this study are shown
in Table 1. In children the peak incidence was between
0 and 5 years.
The diagnoses are listed in Table 2. Most of the
patients (n = 40) had maculopapular, plaque-type
mastocytosis (urticaria pigmentosa) or telangiectatic
CM. A minority of the patients (n = 6) had solitary
mastocytoma. Other diagnoses were diffuse CM (n = 3)
and ISM (n = 15).
In addition to the SCORMA Index and serum tryptase
level, the patients underwent full clinical examination
and skin biopsy was obtained (if not obtained before or
obtained elsewhere). C-kit mutation analysis was either
not performed or unavailable in all cases.
Classification based on clinical signs and conform
the WHO guidelines was used to subdivide the
patients.2 Many of the patients reported in this paper
were diagnosed and underwent complete investigation
before 2001 when the WHO guidelines were pub-
lished. The diagnosis of SM in this group was made on
the basis of the presence of mast-cell accumulation in
the skin and in ‡ 1 extracutaneous site. Immuno-
staining of bone-marrow sections, which is advocated
by Working Conference on Mastocytosis, was not
performed as a routine staining procedure [2]. The
pre-2001 cases were reviewed to confirm their estab-
lished diagnosis based on the available data during the
preparation of this manuscript.
Tryptase levels
Serum tryptase level was determined on the same day
as the SCORMA Index during routine checkups for
each patient, and not while the patient was experienc-
ing a worsening of the disease. Serum tryptase levels
were determined using a commercial fluorescent
enzyme immunoassay (UniCAP assay and UniCAP
100 instrument; Phadia, Nieuwegein, the Netherlands)
according to the manufacturer’s instructions. The
‘Directions for Use’ of this tryptase assay gives
11.4 lg ⁄ L as the 95% upper percentile value for
healthy children and adults.
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Figure 1 SCORing MAstocytosis Index.
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SCORMA Index
Clinical evaluation of the patients using the SCORMA
system was performed by one or both of two investiga-
tors (RH or APO) according to the previously published
method. As the interobserver variation in the SCORMA
is low, this had no substantial effect on the outcome.8
Statistical analysis
The particulars of all patients were entered in a database
and analysed using SPSS software (SPSS Inc., Chicago,
IL, USA). Pearson’s correlation coefficient and the
partial correlation coefficient were used for evaluating
the relationship between SCORMA Index and serum
tryptase. Serum tryptase was logarithmically trans-
formed before analysis as its distribution was strongly
skewed to the right. For the partial correlation coeffi-
cient, adjustment was made for the age of the patient.
Values were also corrected for age because normal
values of serum tryptase are influenced by age.
P < 0.05 was considered significant.
Results
All cases of SM had skin involvement and serum
tryptase levels > 20 lg ⁄ L. It was noted that patients 15,
27, 39 and 62 with bone-marrow findings showing
increased mast-cell numbers had serum tryptase levels
< 20 lg ⁄ L. Likewise, in patients 10, 12, 17, 32 and 55,
who had raised levels of serum tryptase, apparently
normal bone-marrow results were found.
The paired serum tryptase levels and SCORMA Index
of all 64 patients classified by disease category are
shown in Table 3. A scatter plot diagram showing the
relationship between the SCORMA Index and serum
tryptase level (after natural logarithmic transformation)
of the same 64 patients is shown in Fig. 2. The Pearson
correlation coefficient was 0.35 (P = 0.004). When
solitary mastocytoma (n = 6) was excluded, making the
population n = 58, the Pearson correlation coefficient
was even higher (0.41, P = 0.002). After adjusting for
the age of the patient, the partial correlation coefficient
was 0.47 (P < 0.0005).
Discussion
Mastocytosis is rare, complex and sometimes diagnosed
late. However, diagnostic methods are now more readily
available and increasingly sensitive.10 The following
clinically distinct variations are recognized in the WHO
classification; CM, ISM, SM with an associated clonal
haematological non-mast-cell lineage disease, aggres-
sive SM, MC leukaemia (leukaemic SM variant), MC
sarcoma and extracutaneous mastocytoma.2 From a
dermatologist’s perspective, the WHO subclassification
of CM into three categories namely maculopapular CM
(also known as urticaria pigmentosa), diffuse CM and
solitary mastocytoma of the skin) may be debatable, as
reported by Hartmann and Henz.11 These authors
suggested, based on the course and prognosis, that
maculopapular mastocytosis in fact consists of different
variations of CM. Maculopapular CM has small lesions,
occurs in children and in adults, rarely resolves spon-
taneously and will often eventually be categorized as
Table 1 Inclusion and exclusion criteria for the study.
Inclusion criteria Exclusion criteria
Description
of patient
population
Diagnosis of mastocytosis
according to WHO criteria
WHO criteria for any
type of mastocytosis
not met
Comparison
SCORMA
and tryptase
Diagnosis of mastocytosis
SCORMA and tryptase with
corroborating data
Uncertain diagnosis,
no SCORMA and ⁄ or
tryptase
SCORMA, SCORing Mastocytosis; WHO, World Health Organiza-
tion.
Table 2 Types of mastocytosis in the
patients in this study.
Diagnosis according to WHO recommendation
Investigated
population
(n = 64)
Children
(n = 31)
Adults
(n = 33)
% n % n % n
Nodular cutaneous mastocytosis 9.4 6 19.4 6 0 0
Maculopapular cutaneous mastocytosis* 62.6 40 64.5 20 60.6 20
Diffuse cutaneous mastocytosis 4.7 3 9.7 3 0 0
Indolent systemic mastocytosis
(with cutaneous features as the
dominant symptom)
23.4 15 6.5 2 39.4 13
*Includes plaque-type cutaneous mastocytosis, maculopapular cutaneous mastocytosis,
telangiectatic cutaneous mastocytosis.
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ISM. In contrast, plaque-type CM has lesions of several
centimetres in diameter and the solitary mastocytomas
do not evolve but tend to disappear. However, in this
paper we analysed the results according to the WHO
subclassification and included mastocytosis of the skin
as a part of an established (indolent) SM. The diagnosis
of SM was reconsidered because many of the reported
cases were diagnosed before the WHO subclassification,
and we were unable to revise the diagnosis on the basis
of the available data at the time of collection.
An important aspect in terms of prognosis is to
distinguish mastocytosis that has developed in the first
5 years of life from that arising in adulthood.12,13
Several mediators or their metabolites have been used to
evaluate the severity of mastocytosis, which is impor-
tant for the prognosis. Tryptase and histamine are
prominent indicators of mast-cell activation. Urinary
Table 3 Paired serum tryptase levels and SCORMA Index.
Patient
no.
Age,
years
Tryptase
level, ng ⁄ L SCORMA
Nodular cutaneous mastocytosis (n = 6)
5 0 3.9 36
7 0 3.9 16
38 0 20.3 21
41 0 9.8 21
54 0 5.1 21
64 0 5.8 29
Maculopapular cutaneous mastocytosis (n = 40)
1 40 9.9 12
3 40 10.3 21
4 1 3.4 24
10 51 24.5 24
11 0 6.4 14
12 39 29.3 37
16 56 25.6 12
17 20 130 40
20 – 7.2 45
22 32 8.4 27
23 20 10.5 12
24 0 5.4 12
25 49 5.2 25
26 1 9.8 15
28 2 6.5 18
29 1 17.2 18
30 65 13.7 22
32 – 25.7 42
33 20 21.3 22
34 0 9.8 30
36 38 13.4 30
43 13 15.1 27
44 0 2.7 27
45 2 8.2 18
46 1 18.2 22
47 23 18.2 40
48 33 4.2 21
52 0 5.1 28
53 1 13.7 26
55 0 69.1 31
56 0 12.3 44
58 14 4.6 34
63 17 7.7 22
60 0 14.7 21
61 0 4.3 31
65 0 3.9 19
14 40 6.8 4
18 49 5.9 11
37 41 10.3 13
59 6 4.3 10
Diffuse cutaneous mastocytosis (n = 3)
9 0 15.2 23
21 0 32.6 35
40 9 9.5 33
Indolent systemic mastocytosis (n = 15)
2 53 35.4 23
6 38 28.1 32
8 1 20 47
13 34 182 43
Table 3 Continued.
Patient
no.
Age,
years
Tryptase
level, ng ⁄ L SCORMA
15 30 12.4 22
19 42 28.8 19
27 38 17.5 34
31 20 25.8 42
39 18 14.7 30
42 39 483 30
49 35 22.8 15
50 25 22.5 41
51 57 34.5 11
57 23 221 46
62 2 10.4 27
SCORMA, SCORing MAstocytosis.
Ln(tryptase)
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Figure 2 The relationship between the SCORMA index and the
natural logarithm (Ln) of serum tryptase levels (lg ⁄mL).
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N-methylhistamine (NMH) levels correlate with the
extent and the activity of the mastocytosis. In a previous
study, a significant correlation between serum tryptase
levels and urinary NMH levels was found in 138
patients.14 Serum tryptase levels are a much better tool
than NMH levels to distinguish patients with mastocy-
tosis at an extracutaneous location, thereby making
these patients potential candidates for mast-cell target-
ing therapy.15 Serum tryptase levels in mastocytosis are
normal in most cases of uncomplicated CM and masto-
cytoma, but are > 20 lg ⁄ L in SM.16 The correlation
between exclusive CM and serum tryptase levels may
therefore be weak. In adults with SM, however, a
positive correlation between density of the skin lesions,
duration of the disease and constitutional symptoms,
organomegaly and raised serum tryptase levels has been
shown, whereas in children such a relationship has not
been observed.16 Our findings show an unexpected high
number of cases in which raised serum tryptase levels
could not be shown in combination with bone-marrow
involvement. Possible explanations for these findings
are that bone-marrow lesions in ISM may be difficult to
find and require immunostaining instead of Giemsa ⁄ Le-
der or toluidine, which are the commonly used stains.
Thus, bone-marrow involvement may be underappreci-
ated in these cases.3 Normal serum tryptase levels was
noted in five of our patients with SM. This has been
reported previously, and on its own is not a reason to
doubt the diagnosis.2 In our study we used a previously
validated clinical evaluation system for mastocytosis
and compared this with serum tryptase levels. Our
system for mastocytosis is called SCORMA and may be
used to take a clinical snapshot of a patient with
mastocytosis. Its clinical applications have been pub-
lished previously.8 The SCORMA system is comparable
with that used for atopic dermatitis (modified-objective
SCORAD, Eczema Area and Severity Index, and Six Area
Six Sign Atopic Dermatitis) and psoriasis (Psoriasis and
Severity Index). Such a system is particularly beneficial
in paediatric and adult patients with maculopapular
mastocytosis (urticaria pigmentosa), because the clini-
cal features of the disease may vary during the course of
the disease and because of therapeutic interventions.17
However, there are several limitations to this obser-
vational technique. In patients with an associated
haematological disorder such as myelodysplasia, regres-
sion of skin lesions may be accompanied by disease
progression.18 In contrast with this, regression of CM in
patients with the indolent course parallels with a
decrease in disease severity, although abnormal bone-
marrow findings are still present.18 Furthermore, the
SCORMA Index requires the input of subjective factors.
The degree of discomfort is often difficult to express not
only by children but also by adults. In our study, the
SCORMA Index in 64 patients (31 children and 33
adults) was compared with serum tryptase levels. The
results of the first visit, at which both SCORMA Index
and serum tryptase levels were determined were anal-
ysed. The SCORMA Index and serum tryptase levels
showed a moderate correlation indicating that both are
valuable for assessing CM or SM in cases where the skin
is involved. The results of this study in children and in
adults with mastocytosis show that SCORMA is of
practical value for evaluating the severity of the disease.
It is plausible that comparing sequential SCORMA
values in an individual patient may be a useful tool to
monitor disease progression and treatment efficacy.
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Mastocytosis is an abnormal accumulation of mast 
cells in the absence of an apparent cause  [1, 2] . The skin is 
the most frequent site of involvement. Mastocytosis
is associated with a broad range of local and systemic 
symptoms primarily caused by the release of mast cell me-
diators  [3] . Rare manifestations of mastocytosis have con-
stantly been reported  [4] . Available therapies are symp-
tomatic  [5] . These include H1- and H2-receptor antago-
nists and disodium cromoglycate. PUVA or UVA1 
therapy may reduce mast cell numbers and alleviate symp-
toms for several months  [6] . Topical application of highly 
potent corticosteroids under occlusion has been used suc-
cessfully in adult patients with urticaria pigmentosa and 
in solitary mastocytoma in children. UV light therapy or 
highly potent corticosteroids under occlusion are unsuit-
able for treating children with urticaria pigmentosa be-
cause of potential side effects. Dilutions of 0.5–50% fluti-
casone propionate 0.05% cream or other topical steroids 
under wet-wrap occlusion have been safely used in chil-
dren and adults with atopic eczema covering large surface 
area  [7, 8] . In this open case-controlled pilot study, we in-
vestigated the efficacy of topical fluticasone propionate 
0.05% cream under wet-wrap occlusion in 5 adults (4 with 
urticaria pigmentosa, 1 with teleangiectasia macularis 
eruptiva perstans) and 6 children (4 with urticaria pig-
mentosa, 2 with diffuse cutaneous mastocytosis). 
 The extent of lesions in each patient was assessed using 
a semiquantative scoring system called SCORMA that we 
 Key Words 
 Mastocytosis  � Fluticasone propionate 25% diluted  � 
Wet-wrap 
 Abstract 
 Background: Mastocytosis is a disorder that can be subdi-
vided into two forms: cutaneous and systemic. Patients with 
cutaneous mastocytosis only may suffer from cosmetic 
problems. Topical steroid application has been shown to be 
effective in cases of limited skin lesions. Methods: A case-
controlled pilot study was conducted during a 6-weeks 
treatment using diluted 25% fluticasone propionate 0.05% 
cream under wet-wrap occlusion in 5 adults and 6 children. 
Improvement was measured up to the 24th week after treat-
ment using the SCORMA Index. Results: The results of this 
pilot study showed a partial but clear cosmetic improve-
ment in 9 of the 11 patients. The mean SCORMA Index de-
creased after treatment from 38 to 26. Conclusion: 25% dilu-
tion of fluticasone propionate 0.05% cream under wet-wrap 
occlusion is an alternative treatment modality for alleviating 
the symptoms of cutaneous mastocytosis, but the improve-
ment may be moderate and fall short of the patient’s expec-
tations.  Copyright © 2007 S. Karger AG, Basel 
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had previously developed and described in details else-
where  [9] . The SCORMA Index in the 5 adults ranged 
from 35 to 47 (mean 40), whereas it ranged from 28 to 41 
(mean 35) in the 6 children before wet-wrap treatment. 
The most common subjective symptoms before and after 
treatment are summarized in  table 1 . 
 Prior to this pilot study, wet-wrap treatment with di-
luted corticosteroids was approved by the Medical Ethi-
cal Committee of our institution. After informed con-
sent had been obtained, each patient was treated with 
25% dilution of fluticasone propionate cream 0.05% ap-
plied daily under a wet-wrap occlusion dressing for 6 
weeks. The amount of cream used for the 5 adults ranged 
from 4 to 12 g (average 8 g) daily and for the 6 children 
ranged from 3 to 5 g (average 4 g daily) and were per-
formed according to the finger tip method. The therapy 
compliance was monitored by regularly weighing the 
amount of cream. The patients were evaluated at 3, 6, 12 
and 24 weeks after the start of the treatment. Biochemi-
cal parameters such as routine blood and urine examina-
tion including the levels of urinary N-methylhistamine 
and fasting serum cortisol were monitored at each evalu-
ation. Skin infiltrates were stained using the Leder tech-
nique  [10] . The number of mast cells was also counted in 
lesional skin biopsies from all patients before and 6 weeks 
after treatment. Clinical improvement was assessed 
 using SCORMA. The SCORMA Index in the 5 adults 
ranged from 7 to 41 (mean 27), whereas it ranged from 
15 to 46 (mean 26) in the 6 children after wet-wrap treat-
ment.
 Fig. 1.  a Mastocytosis lesions in a patient 
before treatment with 25% diluted flutica-
sone propionate 0.05% cream under occlu-
sion.  b A partial but clear cosmetic im-
provement in the same patient 24 weeks 
after treatment. 
 Fig. 2.  a A large number of mast cell in a 
histological section of lesional skin biopsy 
before treatment. Leder staining.  ! 160.
 b A decreased number of mast cells in the 
histological section of lesional skin biopsy 
after 6 weeks of treatment. Leder staining. 
 ! 100. 
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 The results of this pilot study showed that diluted 25% 
fluticasone propionate 0.05% cream under wet-wrap oc-
clusion led to a partial but clear cosmetic improvement in 
9 of the 11 patients ( fig. 1 a, b). An overall summary of the 
clinical results 24 weeks after treatment is shown in  ta-
ble 2 .
 The mean SCORMA Index decreased from 38 before 
treatment to 26 after treatment. The number of mast cells 
counted in skin biopsies from all patients taken before the 
treatment and after completion at week 6 showed a de-
crease of between 10–60% ( fig. 2 a, b). The levels of uri-
nary N-methylhistamine remained unchanged during 
the course of the treatment in all patients, but serum 
tryptase levels were not determined. Both of these param-
eters can be used to establish the intensity of mastocytosis 
 [11] . The treatment was noted to be safe on the basis of 
fasting serum cortisol levels, which remained unchanged 
during the course of the treatment in all patients.
 From the results, it can be concluded that 25% dilution 
of fluticasone propionate 0.05% cream under wet-wrap 
occlusion is an alternative treatment modality for allevi-
ating the symptoms of cutaneous mastocytosis affecting 
large skin areas. The treatment had no side effects in this 
series of patients. However, fasting cortisol levels should 
be monitored. Safety of this therapy in atopic dermatitis 
has also been reported  [12, 13] . Nonetheless, the clinical 
and cosmetic improvement achieved may fall short of pa-
tient’s expectation and all patients should be made aware 
of this aspect of the treatment. Further prospective ran-
domized studies involving a large number of patients are 
necessary to optimize the effect of this therapy.
 
Table 2. Clinical improvement 24 weeks after start of the treat-
ment
Clinical assessment Before treatment After treatment
mean range mean range
Extent 58% 100–17 40% 100–6
Intensity
Pigmentation/erythema 1.8 3–1 1.3 2–1
Vesiculation 0 0
Elevation 0.4 1–0 0.1 1–0
Darier‘s sign 1.8 2–0 0.9 2–0
SCORMA index 38 47–24 26 46–9
Cosmetic Heat 
intolerance
Pruritus Flushing Abdomi-
nal pain
Before treatment 11/11 10/11 9/11 6/11 5/11
After treatment 9/11 5/11 5/11 4/11 5/11
Table 1. Symptoms before and after 
treatment
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MASTOCYTOSIS IN CHILDREN:
A PROTOCOL FOR MANAGEMENT
Abstract: Mastocytosis is characterized by an
increased number of mast cells with an abnormal
growth and accumulation in one or more organs. In
most children mastocytosis is limited to the skin (cuta-
neous mastocytosis) and often transient as compared
with that in adults in whom mastocytosis is usually
progressive and systemic. Generally, we recognize
three more common forms of cutaneous mastocytosis:
maculopapulous mastocytosis (formerly urticaria pig-
mentosa), mastocytoma of skin, and diffuse cutaneous
mastocytosis. Childhood mastocytosis can further be
divided into cutaneous mastocytosis (nonpersisting
and persisting) and systemic mastocytosis (extremely
rare). An approach to management using a set protocol
is described in table form. In most cases of masto-
cytosis, only yearly checkups are necessary and no
treatment is required; preventive recommendations are
warranted in those individuals with systemic disease
and constitutional symptoms. Symptomatic therapy is
advised in only a minority of cases. This article is meant
as a guideline for physicians involved in the care of
children with mastocytosis and their parents.
Mastocytosis is defined as a heterogenous group of
disorders with an abnormal accumulation of mast
cells (MCs) anywhere in the body. All forms of
mastocytosis are rare. Mastocytosis has many vari-
ants, which share several clinical features (1–3). The
course of mastocytosis is varied and depends on the
subtype and on the age of onset (4–6). In children,
mastocytosis is commonly cutaneous (CM) and often
transient when compared with that in adults, in
whom the disease usually is progressive and systemic
(2,6). However, all variants of mastocytosis may be
diagnosed in children. A considerable body of evi-
dence that many forms of mastocytosis are caused by
point mutations in the genes coding for growth factor
receptor c-kit (2,7–9). Genetic findings also indicate
several different pathogenetic forms of mastocytosis.
Adult patients and minor subsets of pediatric
mastocytosis express activating mutations of the c-kit
receptor, whereas in most cases of childhood-onset
mastocytosis such mutations were not reported (10).
The heterogeneity of c-kit mutations may have con-
tributed to difficulties in characterizing genotype–
phenotype correlations of the disease (11).
Traditionally, mastocytosis has been classified on the
basis of clinical presentation. In 2001 a consensus clas-
sification based on the behavior ⁄course of the disease
rather than its clinical description was proposed and
approved by the World Health Organization (12). In
this consensus, classification mastocytosis is divided
into three major groups consisting of CM, systemic
mastocytosis (SM), and the extremely rare localized
extracutaneousMC neoplasms not described in children
(13). In children, mastocytosis is mostly cutaneous and
transient. Therefore, for childhood mastocytosis we
prefer a classification of five subgroups of increasing
severity andmorbidity as shown in Table 1. First, CM is
distinguished from SM on the basis of criteria shown in
Table 2. Second, the severity of the systemic subtype is
definedon the basis of investigations of skin lesions, bone
marrow, peripheral blood, and serum tryptase levels, as
well as the functions of the liver, the spleen, the lymph
nodes, and other organs. The skin lesions may be
clinically classified as shown in Table 3. In February
2007 additional broad-based thorough recommenda-
tions for the standardization of the recognized subtypes
and workup of mastocytosis were reported by Valent
et al (8). In that article, mastocytosis in adults is con-
sidered systemic until proved otherwise. In children
this is not the case unless persistently high (or rising)
serum tryptase levels and other signs of SM are
encountered.
Generally, we recognize threemore common forms of
childhood CM: maculopapular mastocytosis (urticaria
pigmentosa), mastocytoma of skin, and diffuse cutane-
ous mastocytosis (DCM). Telangiectasia macularis
eruptive perstans has not been recognized by the
WHO. SM is usually indolent and is extremely rare in
children (5).
This protocol forms a practical guideline for the
diagnosis, the evaluation, and the treatment of masto-
cytosis in children. It is primarily intended for derma-
tologists, allergists, and pediatricians.
RECOMMENDATIONS ON HISTORY,
EXAMINATION, DIAGNOSTICS, THERAPY,
AND FOLLOW-UP
History
History should include the following topics:
• Duration of the disease. Is there an increase ⁄decrease
in the number of lesions?;
• Factors provoking mediator release;
• Increase ⁄decrease in the activity of the lesions in time;
• Itch (attacks ⁄periodic ⁄chronic);
• Mastocytosis in family;
• Heat;
• Exertion;
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• Showers;
• Stress; and
• Certain foods.
Physical Examination
Physical examination should include:
• Inspection of whole skin;
• Examine Darier sign in suspected lesions;
• Classify skin profile using; and
• SCORMA (see Appendix ‘‘SCORMA’’).
Diagnostics
Diagnostics are limited to the following:
• Skin biopsy from the lesion; and
• Skin biopsy from nonlesional skin only on indication
(high clinical suspicion of DCM).
Interpretation of Skin Biopsies
(1) Histologic findings and MC counts confirm clinical
diagnosis of CM; absence of the characteristic findings
TABLE 1. Mastocytosis Classification (12)
Category Diagnostics Characteristic findings
Cutaneous mastocytosis SM criteria* Not present
Skin lesions Present (mast cell infiltrates in biopsy)
Bone marrow (not required in most cases) No mast cell infiltrates
Peripheral blood profile Normal
Serum tryptase <20 lg ⁄L
Indolent systemic mastocytosis SM criteria* Fulfilled
Skin lesions Generally present
Bone marrow Multifocal mast cell infiltrates;
<20% mast cells in smears
Peripheral blood profile Normal or slightly deviating
Serum tryptase >20 lg ⁄L
Liver ⁄ spleen ⁄ lymph nodes Sometimes enlarged
Systemic mastocytosis with a AHNMD� SM criteria* Fulfilled
Bone marrow and peripheral
blood profile
Besides multifocal mast cell
infiltrates MDS, MPS, AML
of NHL (WHO ⁄FAB criteria)
Aggressive systemic mastocytosis SM criteria* Fulfilled
Skin lesions Often absent
Bone marrow Multifocal mast cell infiltrates;
<20% mast cells in smear; no AHNMD�
Peripheral blood profile Abnormal (leukocyte count
<1.0 · 109 ⁄L, Hb <6.2 mmol ⁄L, and ⁄
of thrombocyte count <100 · 109 ⁄L)
Liver ⁄ spleen ⁄ lymph nodes Enlarged
Organ function Reduced�
Mast cell leukemia SM criteria* Fulfilled
Skin lesions Absent
Bone marrow Diffuse uncontrolled mast cell growth
‡ 20% mast cells in smear
Peripheral blood profile ‡ 10% mast cells (in aleukemic variants)
<10% mast cells
Organ function Reduced
*SM criteria: criteria for establishing the diagnosis of systemic mastocytosis (see Table 2); �AHNMD: associated clonal hematologic illness of
an origin other than the mast cell line; �reduced organ function: ascites, disturbed liver function and ⁄ or portal hypertension (liver),
hypersplenism (spleen), malabsorption with hypalbuminemia and loss of weight (gastrointestinal tract); osteolytic centers and ⁄ or osteoporosis
with fractures (skeleton). MDS, myelodysplastic syndrome; MPS, myeloproliferative syndrome; AML, acute myeloid leukemia; NHL,
non-Hodgkin lymphoma; SM, systemic mastocytosis; WHO ⁄FAB, World Health Organization ⁄French American British study group.
TABLE 2. Criteria for Establishing the Diagnosis of Systemic Mastocytosis (12)
Major criteria Multifocal infiltrates of mast cells (>15 close to each other) observed in bone marrow
biopsies and ⁄ or mast cells stained for tryptase in biopsies from other extracutaneous organs.
Minor criteria >25% spindle-shaped mast cells in infiltrates in biopsies from bone marrow or other extracutaneous
organs or presence of >25% atypical mast cells in bone marrow aspirates.
Demonstration of the c-kit point mutation on codon 816 in bone marrow, blood or other extracutaneous organs.
CD117 (c-kit receptor) positive cells, which are also positive for CD2 and ⁄ or CD25.
Serum tryptase is >20 lg ⁄L.
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and the number of MCs do not exclude the diagnosis in
dermatologic patient population.
Bone Marrow
(1) Generally not required; and
(2) Bone marrow investigation should only be per-
formed in symptomatic pediatric cases with suspected
hematologic disease or suspected SM. Only serum
tryptase levels that are clearly elevated (>20 lg ⁄L)
are not enough to undertake investigations of bone
marrow.
Therapy
Therapy in isolated CMmay be omitted.
Cutaneous mastocytosis with cosmetic complaints
only:
• Generally no therapy; and
• Topical therapy in children older than 2 years (15).
– Confined to about 10%of the body surface area:
corticosteroid cream with occlusive dressing and
– More than 10% of the body surface area: corti-
costeroid cream (one part vs. three parts) 25%
dilutedunderwet-wrapocclusion (optional) for 3
to 6 weeks.
Cutaneous mastocytosis with complaints of itch,
redness, and swelling:
• Avoid foods, which according to the anamnesis pro-
voke the lesions; and
• Systemic therapy, consisting of combination of H1-
and H2-blocker (and oral sodium cromoglycate).
Follow-Up
Follow-up in isolated CM is recommended:
Checkup once a year, and telephone consultation
once every 6 months. The symptoms in SM may vary
considerably and depend on the extent and the site of
MC accumulations in an organ. Most of the com-
plaints are caused by the mediators (histamine,
leukotrienes, prostaglandins, interleukins, platelet-
activating factors, and tryptase) released from MCs.
The mediator-related symptoms may be fainting,
hypotensive shock, diarrhea with abdominal pain,
heartburn, severe bone pain, flushes, and headache. It
should be noted that extensive skin involvement alone
may also induce these symptoms.
When in doubt on the extent of mastocytosis, the
workup should be broadened.
History should also include the following topics:
• Attacks of flushing;
• Attacks of syncope;
• Attacks of heart palpitations;
• Abdominal cramps or pain (attacks ⁄periodic ⁄
chronic);
• Diarrhea (attacks ⁄periodic ⁄chronic);
• Pyrosis (heartburn);
• Reaction to drugs (aspirin, NSAID, codeine, and
opiates);
• Reaction to narcosis;
• Reaction to i.v. radiograph contrast fluids or MRI-
contrast media;
• Reaction to wasp and bee stings;
• Anaphylactoid ⁄anaphylactic reaction;
• Bone-pain; and
• General symptoms:
– Weight loss,
– Nausea,
– (Severe) headache,
– Fever ⁄ feverish feeling,
– General depression, and
– Fatigue.
• Physical examination (preferably in cooperation with
a pediatrician) should also include:
– Length;
– Weight;
– Organomegaly; and
– Other investigations on indication (e.g., constitu-
tional symptoms).
• Indications for screening for SM in the absence of CM
are:
– Unexplainable abdominal pain with diarrhea;
– Unexplainable bone pain;
– Unexplainable flushes;
– Unexplainable itch;
– Occurrence of an anaphylactic reaction ⁄ shock;
– Organomegaly (liver, spleen, or lymph nodes);
– Unexplainable (pan)thrombocytopenia; and
– Combinations of the above.
Diagnostic procedures should include:
(1) Determination of serum tryptase levels; if clearly
elevated (>20 lg ⁄L) proceed to step 2;
(2) Skin biopsy (see addendum);
(3) Abdomen ultrasound;
(4) Peripheral blood analysis (thrombocytope-
nia, leukocytosis, differential cell count); and
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(5) In cases with organomegaly, lymphadenopathy
or abnormalities in the peripheral blood: crista
biopsy and bone marrow aspirate (16).
In tissue ⁄ smear specimen:
– Morphology of MCs and MC counts;
– Immunologic staining (CD2 and CD25 on
CD117 positive MCs);
– Tryptase staining of the MCs; and
– Determination of proto-oncogene c-kitmutation
(codon 816).
Preventive measures in systemic and extensive CM in
children are strongly recommended:
Prevention of anaphylactic ⁄anaphylactoid reactions
in general
• Eliminate allergen(s) ⁄provoking factor(s), if known
• Avoid alcohol, aspirin, NSAIDs, codeine, opiates,
polymyxin B, and intravenous radiograph contrast
fluids and MRI-contrast media, unless (recently)
known tolerance;
• 2x Epinephrine auto injector; for instructions see
http://www.anafylaxis.net;
• H1 + H2 blockers at maximum dose (on indication:
e.g., high frequency);
• Aspirin or NSAID at high dose (on indication: e.g.,
high frequency and insufficient effect of H1 + H2
blockade; see remark);
• ‘‘Medical alert’’ card or chain (seeAppendix: Example
of text ‘‘medical alert’’ and information letter in
English);
• Information letter inEnglish forvacationsabroad; and
• Hyposensitization for wasp or bee sting allergy is
contraindicated.
Remark:
Aspirin and NSAID should be started only at a very
low dose, gradually increased under strict monitoring of
circulation! [pediatric intensive care (ICP ⁄ ICC)].
Preventionofanaphylactoidreactionswithanesthetics:
• See Appendix ‘‘preventive measures’’
Prevention of anaphylactoid reactions to radiograph
contrast fluids or MRI-contrast media:
• See Appendix ‘‘preventive measures for radiograph
contrast fluids or MRI-contrast media’’
Therapy in SM in children is symptomatic:
– Anti-mediator drugs (H1 blockers) such as anti-
histamines: clemastine, ketotifen, and cromo-
glycic acid;
T
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– H2 receptor blockers such as ranitidine particu-
larly for heartburn;
– Aspirin for flushes, tachycardia, or fainting;
(warning: hypotensive crisis during use of aspi-
rin);
– Adequate intake ⁄ formation of vitamin D;
– Adequate calcium intake; and
– Adrenaline auto injector.
Follow-up in SM should include at least:
• Anamnesis (annually);
• Physical examination (annually);
• Laboratory tryptase (annually);
• Abdomen ultrasound (once annually); and
• Additional diagnostics depending on the complaints.
APPENDIX
Skin Biopsy Procedure Indications
• Suspicion of CM; and
• Demonstrated SM in the absence of suspected
abnormalities for CM.
Procedure
• Local anesthetics with low histamine liberating
potential such as lidocaine or bupivacaine;
• 3 to 4 mm punch biopsy from suspected lesion;
• 3 or 4 mm punch biopsy from inner-side of left lower
arm; and
• Send in biopsies on physiologic saline-drenched gauze.
Processing of Biopsy
• Routine Giemsa staining;
• Tryptase staining (else Tolnidine blue staining, if
possible);
• Immunophenotyping;
• Mast cell counts; and
• Mutation in proto-oncogene c-kit.
Evaluation
• Counts (17):
– Healthy controls: max. 58 MCs ⁄mm2;
– Nonlesional skin from CM: min. 68 MCs ⁄mm2;
– Nonlesional skin from SM: min. 30 MCs ⁄mm2;
– Lesional skin from CM: min. 64 MCs ⁄mm2; and
– Lesional skin from SM: min. 335 MCs ⁄mm2.
Remark
In children, 10· higher values are still normal. The
number of cells probably depends on the age, site of the
biopsy and staining. Therefore, the numbers mentioned
above are with reservation. Preventive measures for
children with CM should be considered when use of
narcotics or anesthesia are planned (18).
Considerations when planning a procedure include:
• Intradermal skin testing with drugs to be used in
anesthesia (19);
• Reducing anxiety, preoperative sedation (oral diaze-
pam);
• Minimize the number of pharmacologic agents; and
• Use a relaxing agent with low potential of histamine
liberation.
Suggested measures in children with large or un-
known disease burden on the day of operation:
• Prednisolone i.v., bolus 2 mg ⁄kg, followed by
1 mg ⁄kg prior to the procedure; and
• Clemastine 3 dd 0.05 mg ⁄kg orally.
Peri-operative period
• Isofluran (or others based on the experience of the
attending anesthetist); and
• Keep adrenaline at hand.
Postoperative period
• Paracetamol ⁄acetaminophen.
Aspirin, NSAIDs, codeine, opiates, atropine, poly-
myxin B, and procaine (warning: mouthwashes,
eardrops, and nose ointments) are contraindicated.
No relevant systematic data are available in the liter-
ature on the pharmacologic pretreatment of patients
with mastocytosis. From a theoretical point of view
combined H1- and H2-blockers may be useful because
these drugs have been reported to reduce unprovoked
attacks (20). Unexpectedly, NSAIDs when given con-
tinuously were also shown to reduce attacks in some
patients (21).However,NSAIDsalsomay induceattacks
when given without careful up dosing and are thus not
considered to be safe as a pretreatment regimen. Anti-
IgE (omalizumab) has been shown to reduce attacks in
mastocytosis patients (22). Pretreatment with anti-IgE
probably will only be effective after several weeks of
treatment and only in situations where IgE-mediated
processes occur.
Two possible schemes are proposed based on these
considerations. Scheme 1 may be used as a default and
scheme2maybeused inpatientswith adelayed intestinal
resorption or preoperatively. If clemastine is not avail-
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Remark
In children, 10× higher values are still normal. The 
number of cells probably depends on the age, site of the 
biopsy and staining. Therefore, the numbers mentioned 
above are with reservation.
Pre ntive measures for children with CM sho ld con-
sidered when use of narcotics or anesth sia ar  planned 
(18).
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able, it may be replaced with another injectable drug.
Obviously, anti histamines may be continued in masto-
cytosis patient already on maintenance treatment.
Pretreatment Scheme 1
T = )13 hours
Prednisolone 0.5 mg ⁄kg orally;
Cetirizine 10 mg orally; and
Ranitidine 150 mg orally.
T = )7 hours
Prednisolone 0.5 mg ⁄kg orally.
T = )3 hours
Prednisolone 0.5 mg ⁄kg orally;
Cetirizine 10 mg orally; and
Ranitidine 150 mg orally.
T = 0 hour
Radio contrast.
Cetirizine: Children older than 6 years 10 mg orally,
children 1 to 5 years 2.5 mg orally.
Ranitidine: Children 2 mg ⁄kg orally.
Pretreatment Scheme 2
T = )13 hours
Prednisolone 0.5 mg ⁄kg orally;
Clemastine 2 mg orally; and
Ranitidine 150 mg orally.
T = )7 hours
Prednisolone 0.5 mg ⁄kg orally.
T = )1 hours
Prednisolone 0.5 mg ⁄kg i.v. and Clemastine 2 mg ⁄
kg i.v. (slow i.v. injection)
Ranitidine 50 mg i.v. (in 20 mL, slow i.v. injection)
T = 0 hour
Radio contrast.
Clemastine: Children older than 12 years 2 mg orally
or i.v., children 6 to 12 years 1 mg orally or i.v.
Ranitidine: Children orally 4 mg ⁄kg; intravenously
1 mg ⁄kg (in 20 mL, slow i.v. injection).
Acute Treatment of an Anaphylactoid ⁄Anaphylactic
Reaction in Children
• Eliminate cause (e.g., stop infusion with a provoking
substance);
• Clemastine 0.05 mg ⁄kg i.v.;
• Adrenaline (1:1000) 0.01 mg ⁄kg i.m. or 0.1 mL in
10 mL NaCl 0.9% slowly i.v. under monitoring of
cardiac rhythm in about 6 minutes; and
• Prednisolone 1 mg ⁄kg i.m. or i.v.
Finally, observation during at least 8 to 10 hours.
SCORMA Index
Weneed an alternatemethod formonitoring the severity
of childhood mastocytosis because obtaining blood
samples from children should be avoided as much as
possible (23,24). That was the main reason why we
developed a scoring system comparable with already
existing methods for monitoring the severity of atopic
dermatitis. We also use this system for monitoring the
severity of the disease in adults.
The extent of the skin abnormality is evaluated in
the first part (A). This is filled in the SCORMA form.
The marked area then represents the percentage of
exposed skin. In multiple mastocytoma of skin, each
lesion is 1% of the affected skin. In DCM, by defini-
tion, almost the whole of the skin is affected, thus
100%. The intensity of the disorder is dealt with in part
B. Hereby, a lesion of a typical form, size, and color
representing the majority of the lesions is examined. A
lesion which is not affected by sunlight such as that on
the back is preferred. This lesion is then judged on
pigmentation ⁄erythema, vesiculation, elevation, and
Darier sign. Each item is scored from 0 to 3, whereby
0 is for an absent item and 3 represents the most
severity. The 5 subjective symptoms such as provoca-
tive factors, flushing, diarrhea, itch, and local bone
pain, which may occur in mastocytosis are dealt with in
part C. The patient may score these symptoms from 0
to 10 (using the visual analog scale), whereby 0 is for
absence and 10 is for continuous presence. The for-
mula: A ⁄5 + 5B + 2C ⁄5 is used to calculate the final
SCORMA score. The value of the SCORMA score
then lies between 5.2 and 100.
Note: this system was validated by a group of
dermatologists practicing in greater Rotterdam, The
Netherlands (23).
DISCUSSION
This article is intended as a guideline for physicians
who are involved in pediatric mastocytosis care. Diffi-
culties may arise in establishing the diagnosis despite
the mild course of the disease in the majority of the
children. In cutaneous forms, especially in the macular
subtypes the number of MCs may be low after the
Giemsa staining, Leder staining, or tryptase staining
(18). When the number of MCs is low, the staining for
c-kit usually results in a higher number of MCs,
whereas the other stains are too insensitive. Anti-c-kit
(CD117) staining has a high specificity and a high
sensitivity for MCs in paraffin sections. This staining is
against c-kit membrane receptor. It stains MCs even
after they have degranulated (25).
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On the rare occasion when systemic involvement is
highly suspected, a multidisciplinary approach in which
carefulmonitoring ofmediator-related symptoms, organ
function, growth as well as hematologic and bone mar-
row analysis are performed is imperative.
Preventive measures with respect to wasp stings and
anesthesia are only necessary in cases with (subjective)
symptoms and clearly elevated serum tryptase levels.We
developed the SCORMA index which has proved useful
in cases in which obtaining repeated blood samples such
Brief Reports 499
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as that in children with mild symptoms is problematic
(23). The SCORMA index scoring system shows a good
correlation with serum tryptase levels (submitted) and
provides information on eventual disease improvement
or aggravation (24).
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CHAPTER 14
Discussion and Summary
in English and Dutch
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Cutaneous symptoms are the main presenting feature of 
mastocytosis in almost all children and in the majority of 
adults. The aim of physicians is to assess the severity of 
mastocytosis in all cases because at present mastocyto-
sis is considered to be a clonal disease originating in the 
myeloid precursor cells in the bone marrow.  Systemic 
mastocytosis that is encountered in the majority of adult 
patients is uncommon in children.
The increasing fundamental knowledge on mastocytosis 
now comes from the hemato-oncological field, with ongo-
ing refinement in the subdivision of systemic mastocyto-
sis. New insights and developments in this area probably 
benefit primarily the most severe cases of mastocytosis. 
The dermatologist’s involvement in such severe cases is 
less relevant, but the involvement in absolute numbers of 
patients with mastocytosis is not. In mastocytosis a multi-
disciplinary approach is demanded.
The aim of the investigations presented in this thesis was 
to provide a global dermatological perspective on masto-
cytosis with focus on clinical, diagnostic and therapeu-
tic aspects of the disease in children and adults.  Current 
insights into advances in mast cell-related skin diseases 
and a structured management of pediatric mastocytosis 
are also presented. For sporadic cases with cosmetic com-
plaints of the disease wet- wrap treatment may be a useful, 
but well designed clinical studies are necessary to confirm 
this. 
The general conclusions of the studies were that masto-
cytosis in children remains a different disease category 
despite the demonstration of clonality in some of those 
cases. In diffuse cutaneous mastocytosis, a severe subtype 
of mastocytosis in children, the course of the disease ap-
pears to be similar to maculopapular mastocytosis. The 
dermatologist’s perspective on mastocytosis must evolve 
in the future towards fully supporting their patients in all 
the aspects of the disease. In this, it is highly imperative 
that systemic mastocytosis should be ruled out in all cases. 
Once the diagnosis of mastocytosis has been established, 
the treatment and the follow-up remain tailored. Progress 
has been made in developing new tools for defining the 
extent of the disease, which is supported by mast cell 
counts in the skin and mast cell mediator measurements 
in relation to clinical scoring of the disease and bone mar-
row involvement. 
Discussion 
Summary
In chapter 1, various clinical and biological aspects of 
mastocytosis are presented that are reflected in the stud-
ies of this thesis. The aims of the studies described in this 
thesis are also presented in this chapter.  In chapter 2, the 
current state of affairs on the role of mast cells (MCs) in 
dermatological diseases including mastocytosis is pre-
sented.  Key issues include the contribution of MCs in ur-
ticaria and mastocytosis and other inflammatory diseases 
with a brief description on angiogenesis.  Mast cells play 
a prominent role in several inflammatory and proliferative 
disorders, particularly of the skin. Their role is undisputed 
in mastocytosis and urticaria. At present, there is no caus-
ative treatment and no complete cure for mastocytosis 
possible. Pediatric mastocytosis in most cases is not treat-
ed, particularly because it is asymptomatic and limited to 
the skin. Treatment is only indicated for alleviating severe 
symptoms. In the majority of cases, chronic urticaria is en-
countered in adults. Chronic urticaria is believed to have 
an underlying autoimmune pathogenesis in almost 50% 
of the cases. The role of MCs in autoimmune diseases has 
not yet been completely elucidated.  In atopic dermatitis 
MCs also play a role; although recently an important role 
of the skin barrier function has also become clear. The 
role of MCs in hemangioma is speculative, but may be 
interesting as a target for future therapeutic options.
In 2002, we provided a clinical review on mastocytosis in 
childhood. In the light of emerging new insights in masto-
cytosis a place for clinical description of skin lesions was 
advocated for practical use. This is described in chapter 3. 
It also became obvious at that time that the classification 
of mastocytosis was in need for and undergoing a major 
restructuring. In 2006, an update on the period 2002-2006 
dealing with the WHO classification scheme and its rel-
evance in pediatric mastocytosis described in chapter 4 
was published. 
In 2002, a retrospective analysis of mastocytosis compar-
ing the clinical aspects of 101 children and adults that 
were diagnosed with mastocytosis in the period of 1980-
1998 was conducted. The results are described in chapter 
5 and provide a different view on the prognosis of child-
hood onset and adult onset mastocytosis. Childhood onset 
mastocytosis is not as transitory as was indicated in the 
literature, where a higher number of complete resolutions 
was reported (15% in our study compared with 50-80% 
reported in the literature). The absence of an objective 
standardized method of evaluating the disease severity in 
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mastocytosis was lacking. This made it difficult to evalu-
ate and establish  the spontaneous cure rate of pediatric 
mastocytosis.
A series of eight children suffering from diffuse cutane-
ous mastocytosis (DCM) is presented in chapter 6. It was 
the largest series of DCM  at the time of this writing. The 
eight cases presented showed impressive symptoms and 
sometimes very high serum Tryptase levels, especially 
in young patients. The disease spectrum varied from red 
blistering to infiltrative yellowish nodular lesions. Since 
the disease follows a favorable course, invasive diagnos-
tics such as obtaining bone marrow biopsies should be 
considered only in case of lack of improvement and other 
systemic or hematological symptoms. 
The aim of the investigations described in chapter 7 was 
to determine a reliable reference value for the numbers of 
MCs in healthy skin.  The study was inspired by the diag-
nostic difficulty in cases with suspicion of mastocytosis 
without clear increase in the number of MCs in the skin. 
The numbers of MCs were determined in skin biopsies 
of healthy individuals and compared with those from a 
group of patients with mastocytosis. There was a signifi-
cant difference between the numbers of MCs on the trunk, 
the upper arm, and the upper leg (proximal location) and 
those found on the lower leg and the forearm (distal loca-
tion). The differences between the distal and the proximal 
locations must be considered when the number of MCs is 
determined to establish a reliable diagnosis of mastocyto-
sis. A pilot study in patients with mastocytosis underlined 
the variation in the numbers of MCs in mastocytosis and 
normal skin, but showed a considerable overlap. Further 
studies are necessary to clarify the lower limit of the num-
bers of MCs in patients with mastocytosis.
The predictive value of urinary N-methylhistamine as an 
indicator of bone marrow involvement in mastocytosis 
was examined in studies described in chapter 8. Elevated 
levels of N-methylhistamine and bone marrow analysis 
were matched with respect to the subtype of mastocyto-
sis and clinical manifestation of the disease in 37 adult 
patients. In the reported group of patients, N-methylhis-
tamine levels were determined in order to stage mastocy-
tosis in patients suspected of suffering from mastocytosis 
without skin involvement and those with established mas-
tocytosis. Levels of N-methylhistamine > 156 µmol ⁄ mol 
creatinine always indicated that a bone marrow biopsy 
was essential. The likelihood of mast cell accumulation 
in the bone marrow could be predicted on the basis of 
elevated N-methylhistamine levels. In patients suffering 
from mastocytosis, persistent high levels (> 300 µmol ⁄ 
mol creatinine) of N-methylhistamine may indicate ac-
cumulation of MCs in the bone marrow. The level of N-
methylhistamine as a diagnostic aid for establishing the 
severity of mastocytosis was of limited value. There are 
several conditions that lead to elevated levels of N-meth-
ylhistamine. The most important of these are allergic reac-
tions, histamine-rich diets, and interstitial cystitis.
Analysis of C-kit Asp-816-val mutation in skin biopsies 
of 24 patients is dealt with in chapter 9. A mutation was 
found in 38% of the adult cases with maculopapular mas-
tocytosis (formerly urticaria pigmentosa) and in 25% of 
the juvenile cases. The percentage of C-kit Asp-816-val 
mutation in adults was lower than that reported in litera-
ture, but a plausible explanation for this discrepancy could 
not be found. Both the children positive for C-kit Asp-
816-val mutation showed some interesting characteristics. 
The first patient was one of the homozygous twin; one 
with mastocytosis the other without. The findings con-
firmed that the mutation did not occur in early embryonic 
development (germ cell mutation). Instead it was an ac-
quired somatic mutation associated with the disease.  The 
second child with the mutation showed an atypical clini-
cal presentation of maculopapular mastocytosis (formerly 
urticaria pigmentosa) and juvenile xanthogranuloma.
In studies described in chapter 10, we developed a clini-
cal scoring system to monitor the cutaneous symptoms of 
patients with confirmed mastocytosis. We felt it as a short-
coming that there was no satisfactory system available for 
accurately determining the extent and the severity of the 
disease, for example, as that in our earlier study (chapter 
4). A calculation based on a semi-quantitative analysis of 
three aspects of mastocytosis was designed. The method 
is called the scoring index of mastocytosis (SCORMA). In 
order to gain insight into the reproducibility of the SCOR-
MA system, it was put to the test by 9 dermatologists at 
regional hospitals. Based on the results of the assessment 
of 9 patients, a very high degree of agreement was noted 
when the SCORMA index was used, even without prior 
familiarity with the method. The clinical use of SCORMA 
was recommended for establishing the severity of the dis-
ease. Such systems were not available at that moment, but 
a comparable system called Grading of Mastocytosis in 
the Skin Is available at present from the European Work-
ing Conference on Mastocytosis (2007).
 A validation study incorporating both serum Tryptase 
levels and the SCORMA-index conducted in 64 patients 
(31 children and 33 adults) is described in chapter 11. The 
results of the first visit on which SCORMA index as well 
as the serum Tryptase levels were determined were ana-
lyzed. The SCORMA index scores and the serum Trypt-
ase levels showed a moderate correlation indicating that 
both were valuable for assessing cutaneous mastocytosis 
or systemic mastocytosis whereby the skin was involved. 
The results of this study in children and in adults with 
mastocytosis demonstrated that SCORMA index was of 
practical value for evaluating the severity of the disease. 
It is plausible that comparing sequential SCORMA index 
values in one patient may provide a useful tool to monitor 
disease progression and therapeutic efficacy.
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In chapter 12, a new therapeutic modality for treating 
mastocytosis in the skin is described.  A case controlled 
pilot study was conducted during a 6-weeks treatment 
using diluted 25% fluticasone propionate 0.05% cream 
under wet-wrap occlusion in 5 adults and 6 children. 
Improvement was measured up to the 24th week after 
treatment using the SCORMA Index.  The results of this 
pilot study showed a partial, but clear cosmetic improve-
ment in 9 of the 11 patients. The mean SCORMA Index 
decreased after treatment from 38 to 26. Treatment with 
25% dilution of fluticasone propionate 0.05% cream un-
der wet-wrap occlusion is an alternative modality for al-
leviating the symptoms of cutaneous mastocytosis, but 
the improvement may be moderate and fall short of the 
patient’s expectations.
The recommendations and a protocol for management 
of mastocytosis in children are described in Chapter 13. 
These were compiled and published in co–operation with 
the Dutch National Mastocytosis Work Group.
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Discussie
Bij bijna alle kinderen en bij een meerderheid van de 
volwassenen die zich met mastocytose presenteren staan 
cutane symptomen op de voorgrond. Het eerste doel van 
de behandelende artsen is om vast te stellen wat de ernst 
van de mastocytose is. Mastocytose wordt op dit moment 
beschouwd als een clonale aandoening die zijn oorsprong 
heeft in de myeloide reeks van hematopoetische stamcel-
len in het beenmerg. Bij bijna alle volwassen patiënten 
met mastocytose kan systemische mastocytose worden 
vastgesteld maar dat is ongebruikelijk bij kinderen. 
De groeiende basale kennis over mastocytose is afkom-
stig uit de hoek van de hemato-oncologie. Deze ontwik-
keling uit zich in een steeds verder gaande verfijning van 
de onderverdeling van systemische mastocytose. Van 
nieuwe inzichten en ontwikkelingen op dit terrein zullen 
de patiënten met ernstige mastocytose waarschijnlijk het 
meest profiteren. De bijdrage van dermatologen voor deze 
beperkte patiëntengroep is minder groot, maar de waarde 
van de dermatoloog bij de gehele groep van mastocytose 
patiënten is dat zeker niet. Mastocytose vereist een multi-
disciplinaire benadering.
Het doel van de onderzoeksprojecten die in dit proefschrift 
worden gepresenteerd is om een algemeen dermatologisch 
perspectief te verschaffen op mastocytose. Hierbij ligt de 
focus op klinische, diagnostische en therapeutische as-
pecten van deze aandoening bij volwassenen en kinderen. 
Actuele ontwikkelingen op het gebied van mestcel gerela-
teerde huidaandoeningen en gestructureerde aanbevelin-
gen voor de aanpak van mastocytose bij kinderen worden 
gepresenteerd. Voor incidentele gevallen met mastocytose 
waarbij cosmetische aspecten een rol van betekenis spe-
len, kan wet wrap behandeling een nuttige therapie zijn, 
maar verdere klinische studies moeten dit bevestigen. 
De algemene conclusie van de onderzoeksprojecten is dat 
mastocytose bij kinderen een aparte ziekte categorie blijft, 
ondanks dat bij kinderen in sommige gevallen clonaliteit 
aantoonbaar blijkt. Bij diffuse cutane mastocytose, een 
ernstige variant van mastocytose bij kinderen lijkt de 
prognose overkomstig met maculopapulaire mastocytose. 
Het perspectief van de dermatoloog op mastocytose moet 
zich ontwikkelen om de patiënten optimaal te kunnen 
bedienen in alle aspecten van de aandoening, waarbij de 
belangrijkste boodschap is dat systemische mastocytose 
altijd dient te worden overwogen en uitgesloten. Wanneer 
de diagnose mastocytose is gesteld, blijven keuzes die 
gemaakt worden ten aanzien van follow up en behande-
ling maatwerk. Er is vooruitgang geboekt in het definiëren 
van uitgebreidheid van de ziekte. Dit werd bereikt door 
het vaststellen van normaalwaarden van mestcelaantallen 
in de huid, door metingen van mestcelmediatoren in sa-
menhang met klinische scoring van mastocytose en door 
meting van mediatoren in samenhang met beenmergloka-
lisatie van de aandoening.
Samenvatting
In hoofdstuk 1 worden diverse klinische en biologische 
aspecten van mastocytose gepresenteerd. De doelstel-
lingen van dit proefschrift worden ook beschreven in dit 
hoofdstuk. In hoofdstuk 2 worden de actuele inzichten 
gepresenteerd met betrekking tot de rol van mestcellen 
bij dermatologische aandoeningen. Belangrijke punten 
hierbij zijn de bijdrage van mestcellen aan urticaria, mas-
tocytose en andere inflammatoire ziekten, evenals aan 
angiogenese. Mestcellen spelen een belangrijke rol in 
ontstekingsprocessen en proliferatieve ziekten, vooral in 
de huid. De rol van mestcellen is onomstreden bij masto-
cytose en urticaria. Op dit moment is er geen oorzakelijke 
behandeling voor mastocytose. Mastocytose bij kinderen 
wordt in de meeste gevallen niet behandeld, omdat het be-
loop in de regel asymptomatisch en beperkt is tot de huid. 
Behandeling is alleen aangewezen voor het verlichten van 
ernstige symptomen. 
Het merendeel van de gevallen met chronische urticaria 
treedt op bij volwassenen. Er wordt aangenomen dat in 
meer dan 50% van de gevallen sprake is van een autoim-
muun pathogenese, hoewel dat omstreden is. De rol van 
mestcellen in autoimmuun ziektes is nog niet volledig be-
kend. Bij atopisch eczeem spelen mestcellen een rol van 
betekenis, hoewel recentelijk een belangrijke rol van de 
huidbarrière functie is komen vast te staan. De rol van 
mestcellen bij hemangiomen is speculatief, maar dit ge-
geven zou een interessante target voor therapie kunnen 
betekenen.
In 2002 hebben wij een klinisch review artikel gepubli-
ceerd over mastocytose bij kinderen. In het licht van de 
nieuwe inzichten in de pathogenese van mastocytose werd 
gepropageerd de klinische beschrijving van huidlesies 
voor de dagelijkse praktijk te behouden. Dit is beschreven 
in hoofdstuk 3. In deze periode werd het duidelijk, dat de 
classificatie van mastocytose een grote verandering zou 
(moeten) ondergaan. Hoofdstuk 4 betreft een update over 
de periode 2002-2006 gepubliceerd in 2006, waarin de 
WHO classificatie van mastocytose en de relevantie daar-
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van voor mastocytose bij kinderen werden behandeld.
In 2002 werd een retrospectieve analyse uitgevoerd waar-
bij de klinische aspecten van mastocytose bij 101 volwas-
senen en kinderen met mastocytose gediagnosticeerd in 
1980-1998 onderling werden vergeleken. De resultaten 
hiervan zijn beschreven in hoofdstuk 5 en geven een an-
dere interpretatie van de prognose van mastocytose ont-
staan op kinderleeftijd en ontstaan bij volwassenen. Mas-
tocytose bij kinderen is niet zo transient als aangegeven 
in de literatuur. Complete genezing werd vastgesteld bij 
15%, afgezet tegen 50-80% gesuggereerd in de litera-
tuur. Een systematische methode om de mastocytose te 
beschrijven ontbrak en klinische scoringssystemen waren 
niet voorhanden. Dit gegeven maakt het moeilijk om defi-
nitieve uitspraken te doen over de spontane genezing van 
mastocytose bij kinderen.
In hoofdstuk 6 wordt een serie van acht kinderen met dif-
fuse cutane mastocytose (DCM) gepresenteerd. Het is de 
grootste gepubliceerde serie van DCM op het moment 
van publicatie en illustreert de variabiliteit in presentatie 
van de aandoening. De acht gevallen toonden indrukwek-
kende symptomen en soms zeer hoge serum Tryptase 
waarden, vooral bij de initiële presentatie. Het spectrum 
van de aandoening was variabel van rode blaarvorming 
tot gelige infiltratieve en nodulaire lesies. Aangezien de 
aandoening een gunstig beloop vertoont moet invasieve 
diagnostiek,  zoals beenmerg biopten, beperkt worden tot 
gevallen waarin geen verbetering wordt vastgesteld en 
wanneer er sprake is van andere systemische verschijnse-
len of hematologische afwijkingen.
Het doel van de studie beschreven in hoofdstuk 7 was 
het vaststellen van betrouwbare referentie waarden voor 
mestcelaantallen in de huid. De studie werd geïnspireerd 
door de diagnostische problemen die kunnen ontstaan 
bij patiënten verdacht van mastocytose bij wie de toe-
name van het aantal mestcellen in de huid gering lijkt. 
Het aantal mestcellen in huidbiopten afkomstig van ge-
zonde individuen werd bepaald en vergeleken met het 
aantal mestcellen in huidbiopten afkomstig van een groep 
van mastocytose patiënten. Het aantal mestcellen in het 
romp- , het bovenarm- en bovenbeengebied (proximale 
locatie) verschilde significant van het aantal gevonden in 
het onderbeen- en onderarmgebied (distale locatie). Deze 
verschillen tussen proximale en distale locatie moeten 
worden overwogen wanneer mestcel aantallen worden 
bepaald bij het stellen van de diagnose mastocytose. Een 
pilotstudy bij mastocytosepatiënten bevestigde de variatie 
in mestcel aantallen zowel in mastocytose als in de nor-
male huid. De studie toonde bovendien een aanzienlijke 
overlap in mestcelaantallen in de huid tussen mastocytose 
en de normale huid, zodat verdere studies nodig zijn om 
de ondergrens vast te stellen voor de diagnose mastocy-
tose in de huid.
De voorspellende waarde van N-methylhistamine in de 
urine, voor beenmerg infiltratie van mastocytose is onder-
zocht in de studie beschreven in hoofdstuk 8. Verhoogde 
waarden van N-methylhistamine in de urine en de gege-
vens van beenmergonderzoek afkomstig van 37 volwas-
sen patiënten werden vergeleken met betrekking tot het 
subtype van mastocytose en de klinische manifestatie van 
de aandoening. In de betrokken patiëntengroep werd de 
waarde van het N-methylhistamine in de urine bepaald 
om de mastocytose te stageren bij patiënten verdacht van 
mastocytose zonder huidlokalisatie en bij patiënten met 
bewezen mastocytose. Een waarde van N-methylhista-
mine in de urine > 156 µmol ⁄ mol creatinine was altijd 
aanleiding tot beenmergbiopsie. De kans op ophoping van 
mestcellen in het beenmerg kon worden voorspeld op ba-
sis van een verhoogde waarde van N-methylhistamine in 
de urine. Een persisterende waarde van > 300 µmol ⁄ mol 
creatinine in de urine bij patiënten verdacht voor of met 
mastocytose was indicatief voor de ophoping van mest-
cellen in het beenmerg. De waarde van de bepaling van N-
methylhistamine in de urine als graadmeter voor de ernst 
van de mastocytose is echter beperkt. Er zijn verschillende 
omstandigheden en aandoeningen die ook leiden tot ver-
hoging van de waarde van N-methylhistamine in de urine. 
De belangrijkste daarvan zijn allergische reacties, inname 
van histaminerijk voedsel en interstitiële cystitis.
De analyse van de C-kit Asp-816-val mutatie in huidbi-
opten van 24 patiënten wordt behandeld in hoofdstuk 9. 
Deze mutatie werd gevonden in 38% van de volwassen 
patiënten met maculopapulaire mastocytose (voorheen ur-
ticaria pigmentosa genoemd) en in 25% van de kinderen 
met deze diagnose. Het percentage van C-kit Asp-816-val 
mutaties bij volwassenen was lager dan gerapporteerd 
wordt in de literatuur, maar een aannemelijke verklaring 
voor deze discrepantie kon niet worden gevonden. De 
twee kinderen met C-kit Asp-816-val mutatie in huidbi-
opten hadden beide opvallende eigenschappen. De eerste 
patiënt was onderdeel van een homozygote tweeling; één 
met en één zonder mastocytose. Deze bevindingen be-
vestigen dat de mutatie niet is opgetreden in de vroege 
embryonale ontwikkeling, maar een somatische mutatie 
betreft. Het tweede kind had een atypische presentatie 
van de maculopapulaire mastocytose met juveniele xan-
thogranulomen.
Bij de studie beschreven in hoofdstuk 10 hebben wij een 
klinisch scoringssysteem ontwikkeld voor het monitoren 
van cutane symptomen van patiënten met bewezen mas-
tocytose. Aanleiding hiervoor was het ontbreken van een 
methode voor systematische evaluatie bij onze studie over 
mastocytose bij kinderen versus volwassen. Het systeem 
betreft een calculatie gebaseerd op een semikwantitatieve 
analyse van drie aspecten van mastocytose. De methode 
heet de scoringsindex van mastocytose (SCORMA). 
Om inzicht te krijgen in de reproduceerbaarheid van het 
SCORMA systeem werd het getest met 9 dermatologen 
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uit ziekenhuizen in de regio Rotterdam. Gebaseerd op de 
beoordeling van 9 patiënten, werd vastgesteld dat er een 
hoge mate van overeenkomst is bij het gebruik van deze 
methode zelfs zonder eerdere bekendheid met deze me-
thode. Het gebruik van de methode voor het vaststellen 
van de ernst van de mastocytose in een klinische setting 
werd aanbevolen. Dergelijke systemen waren op dat mo-
ment niet beschikbaar, maar in 2007 is er een vergelijk-
baar systeem gepubliceerd met de naam “Grading of Mas-
tocytosis In the Skin” afkomst van de European Working 
Conference on Mastocytosis (2007). 
Een validatiestudie is verricht waarbij de waarde van 
het serum tryptase werd vergeleken met de SCORMA 
index waardes bij 64 patiënten (31 kinderen en 33 vol-
wassenen). Deze is beschreven in hoofdstuk 11. De re-
sultaten van het eerste bezoek aan de polikliniek, waarbij 
de SCORMA index werd bepaald en de waarde van het 
serum tryptase werd gemeten zijn geanalyseerd. Hierbij 
werd vastgesteld dat beide metingen een matige correlatie 
vertonen. Op grond hiervan werd geconcludeerd dat beide 
metingen nuttig zijn voor het in kaart brengen van cutane 
mastocytose en bij systemische mastocytose waarbij de 
huid betrokken is. De resultaten van de studie bij zowel 
kinderen als volwassenen met mastocytose toonde aan dat 
de SCORMA index van praktisch nut is voor het evalue-
ren van de ernst van de aandoening. Het is aannemelijk 
dat het verrichten van achtereenvolgende metingen van 
de SCORMA index in één patiënt nuttig kan zijn om pro-
gressie van de aandoening en het effect van therapie te 
monitoren.
In hoofdstuk 12 wordt een nieuwe therapie voor masto-
cytose in de huid beschreven. Een case controlled studie 
werd uitgevoerd gedurende een periode van 6 weken. De 
behandeling bestond uit 25% verdunde fluticason propio-
naat 0,05% creme onder wet wrap occlusie bij 5 volwas-
senen en 6 kinderen. Met behulp van de SCORMA index 
werd verbetering vastgesteld tot 24 weken na de behan-
deling. De resultaten toonden partiële, maar duidelijke 
cosmetische verbetering in 9 van de 11 patiënten. De ge-
middelde SCORMA index daalde na behandeling van 38 
tot 26. Geconcludeerd werd dat 25% verdunde fluticason 
propionaat 0,05% creme onder wet wrap occlusie een al-
ternatief kan betekenen voor bestaande therapie voor het 
verlichten van symptomen van cutane mastocytose maar 
dat de verbetering beperkt kan zijn en minder dan de pa-
tiënt verwacht.
De aanbevelingen en een protocol voor de behandeling 
van mastocytose bij kinderen worden beschreven in 
hoofdstuk 13. De publicatie is geschreven in samenwer-
king met de Nederlandse Mastocytose Werkgroep. 
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Curriculum vitae 
The author was born in 1968 in Rotterdam. He obtained 
his high school diploma (gymnasium) in 1986 and com-
menced medical studies at the Faculty of Medicine, Eras-
mus University Rotterdam in the same year. In 1994 he 
received his medical degree (MD) with honors.
From 1994 to 1995, he worked as a resident not in training 
(ANIOS) at the department of General Surgery, Univer-
sity Medical Center Utrecht. His duties included pre- and 
post surgery care of admitted patients as well as assisting 
in the operating theater. From 1995 to 1996, he worked 
as a resident not in training (ANIOS) at the department 
of Dermatology and Phlebology of the Alkmaar Medical 
Center. His duties included all aspects of dermatological 
patient care including advanced dermato-surgical proce-
dures. From 1996 to 2001, he was a resident in training 
(AIOS) at the department of Dermatology and Venereol-
ogy of the Erasmus MC, University Medical Center in 
Rotterdam and he was registered as a Dermato-Venereol-
ogist in 2001. Investigations into various clinical aspects 
of children and adults with mastocytosis were initiated at 
the department of Dermatology and Venereology during 
his residency and continued later cumulating in the inves-
tigations described in this thesis. From 2001 to present, he 
is a staff member in the department of Dermatology and 
Phlebology of the Alkmaar Medical Center. He was the 
head of this department from 2002 to 2006 during which 
he developed and implemented new strategies to increase 
the level of dermatological care, which resulted in qual-
ity enhancement and an increase of more than 30% in the 
production figures of the department.
Curriculum vitae
De auteur is in 1968 geboren te Rotterdam. Hij behaalde 
zijn gymnasium diploma in 1986 en startte in hetzelfde 
jaar met zijn geneeskunde studie aan de Erasmus Univer-
siteit in Rotterdam. In 1994 behaalde hij zijn artsexamen 
cum laude.
Van 1994-1995 werkte hij als arts niet-in-opleiding (ANI-
OS) op de afdeling Algemene Heelkunde van het Uni-
versitair Medisch Centrum Utrecht. Zijn taken betroffen 
pre- en postoperatieve zorg voor opgenomen patiënten en 
assisteren bij operaties. Van 1995-1996 werkte hij als arts 
niet-in-opleiding (ANIOS) op de afdeling Dermatologie 
en Flebologie van het Medisch Centrum Alkmaar, waar 
hij verantwoordelijk was voor dermatologische zorg in 
breedste zin, inclusief uitgebreide dermatochirurgische 
therapie. Van 1996-2001 was hij werkzaam als arts in 
opleiding (AIOS) op de afdeling Dermatologie and Ve-
nereologie van het Erasmus Medisch Centrum Rotter-
dam. In 2001 behaalde hij zijn registratie als Dermato-
Venereoloog. Gedurende zijn opleiding heeft hij diverse 
onderzoeksprojecten naar diverse klinische aspecten van 
mastocytose bij kinderen en volwassenen geïnitieerd en 
uitgevoerd. Een deel van de resultaten daarvan zijn be-
schreven in dit proefschrift. Van 2001 tot heden is hij 
werkzaam als staflid van de discipline Dermatologie en 
Flebologie van het Medisch Centrum Alkmaar. Van 2002-
2006 is hij voorzitter van de discipline geweest en heeft 
hij nieuwe strategieën ontwikkeld en geïmplementeerd 
om het kwaliteitsniveau van de medisch zorg te verhogen. 
Tegelijkertijd is onder zijn leiding een productiestijging 
van de discipline gerealiseerd van meer dan 30%. 
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Bij het tot stand komen van dit proefschrift hebben veel 
mensen een bijdrage geleverd. Ik ben me ervan bewust dat 
ik hier onmogelijk iedereen kan noemen, maar ook diege-
nen die ik niet expliciet noem ben ik veel dank verschul-
digd.
In de eerst plaats wil ik alle patiënten die betrokken zijn bij 
mijn onderzoek bedanken. Hun welzijn staat voorop. Het 
kan niet vaak genoeg worden benadrukt dat de gezondheid-
zorg om hen gaat. Ik dank hen voor het vertouwen dat ze in 
mij hebben gesteld en voor het ter beschikking stellen van 
hun gegevens.
Prof. dr. A.P. Oranje. Beste Arnold, in de afgelopen 12 jaar 
hebben we vaak bij elkaar gezeten en gelachen om alle 
dingen om ons heen. Ondertussen heb je mij altijd kunnen 
motiveren om door te gaan met onderzoek en te schrijven. 
Vaak heb ik me afgevraagd (soms ook mopperend) hoe je 
dat toch deed met de juiste mix van urgentie, humor en een 
onwrikbaar vertouwen in de afloop. Op een aantal cruci-
ale momenten in het begin van mijn loopbaan heb je me 
gecoacht en ook daarvoor ben ik je erg dankbaar. Ik heb 
respect voor jouw down-to-earth aanpak die voor mij ook 
nu nog als voorbeeld dient. Ik bewonder dat je jezelf ook 
kwetsbaar kunt opstellen en buiten je rol kunt treden…maar 
nog steeds heb ik moeite met je te tutoyeren.
Dr. B. Tank. Beste Bob, wij delen een aanzienlijke periode 
van samenwerking. In de jaren achter ons heb ik je leren 
kennen als een warm en hartelijk mens. Ik weet dat het 
schrijven van onze publicaties met jouw suggesties en cor-
recties veel aan efficiëntie heeft gewonnen. Je was altijd 
paraat en snel met antwoorden op mijn vragen ongeacht 
het tijdstip of de dag waarop ik je belde. Ik heb veel plezier 
beleefd aan onze sessies van “clever writing” als we samen 
weer een reviewer moesten beantwoorden en onze bood-
schap toch over konden brengen. 
Promotiecommissie. De leden van de kleine commissie, 
Prof. dr. R. Gerth van Wijk,  Prof. dr. J. Lindemans, Prof. 
dr. J.G.R. de Monchy, wil ik bedanken voor hun kritische 
en stimulerende beoordeling van het proefschrift. Ook 
naar de leden van de grote commissie, Prof. dr. P.C.M. van 
der Kerkhof, Dr. P.L.A. van Daele en Dr. M.M. van den 
Heuvel-Eibrink gaat mijn dank uit.
De coauteurs en medewerkers. In de periode dat ik met het 
onderzoek en het schrijven van de publicaties ben bezig ge-
weest heb ik met jullie mogen samenwerken. Graag wil ik 
jullie allemaal bedanken voor jullie inzet, kritiek en door-
zettingsvermogen. Apart noem ik hierbij degenen die mij 
ook op de werkvloer veel geholpen hebben; Soe Janssens, 
Annette Verzijl, Patricia Riezebos en Hester Langeveld.
Dr. M.A. Middelkamp Hup. Beste Pina, als eerste onder-
zoeksstudent in het mastocytose project heb je mij gehol-
pen om “de eerste meters te maken”. Je had en hebt een 
onvermoeibare frisse en kritische kijk op de dingen waar 
we mee bezig waren. Je hebt me laten zien dat het delen van 
kennis heel erg leuk kan zijn. Veel plezier heb ik beleefd 
om te zien en te horen hoe je mijn “tips en tricks” in de 
praktijk bracht. Jij bent mij in academische zin gepasseerd 
en gepromoveerd toen ik nog moest beginnen met het sa-
menstellen van dit boekje. Ik had eigenlijk niet anders van 
je verwacht!
Collega’s. Mijn vorming als dermatoloog is ooit begonnen 
als ANIOS in het Medisch Centrum Alkmaar in 1995. In die 
periode heb ik veel van de dingen geleerd die ik nog dage-
lijks in de praktijk breng. Mijn enthousiasme voor het vak 
dank ik aan Frans Rosweide, Henk van den Hoogenband 
en Paul Cirkel. Vooral Frans heeft mij in die tijd onder zijn 
hoede genomen en mij het gevoel gegeven dat ik het in me 
had om (snijdend)dermatoloog te worden. Op mijn laatste 
werkdag in 1996 schreef hij voor mij op een briefje dat ik 
mijn enthousiasme moest bedwingen en niet als een jonge 
hond moest rondspringen, anders zou ik mijn hoofd hard 
kunnen stoten. Tot mijn spijt kreeg hij snel gelijk. Maar ik 
heb hem ook een voorspelling gedaan; ik was ervan over-
tuigd naar het MCA terug te komen en toe te treden als 
maat. Nog voor het beëindigen van mijn opleiding was ik al 
terug en heb de laatste maanden van mijn opleiding op de-
tacheringbasis gewerkt in het MCA om daarna in 2001 toe 
te treden tot de maatschap Dermatologie en Flebologie.
De laatste loodjes zijn net zo zwaar als de eerste en geluk-
kig heb ik ook bij het schrijven van de introductie gebruik 
mogen maken van het kritisch oordeel van dr. Paul van 
Daele. 
Mijn goede vriend Boudewijn van der Gronden wil ik be-
danken voor zijn kritisch oordeel over de Nederlandstalige 
onderdelen. Buiten de directe context van dit proefschrift 
wil ik hem bedanken voor zijn altijd luisterend oor, zijn 
sprankelende humor en zijn vermogen dingen opzettelijk 
anders te zien. Niet zelden heb ik uren met hem aan de te-
lefoon gezeten terwijl ik aan mijn promotie zou werken, 
debaterend over tastbare en ontastbare dingen, over ideale 
gezondheidszorg, over motorfietsen en over ondernemen in 
de zorg. Hij heeft me een andere kant van management in 
de zorg laten zien.
Mijn ouders wil ik danken voor hun steun en het vertrou-
wen dat ze altijd in mij hebben gehad. Lieve Ad en Ada, ik 
ben net zo trots op jullie als jullie op mij. Mijn zus Femke 
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wil ik bedanken voor het feit dat wij op elkaar kunnen re-
kenen, er voor elkaar zijn als dat nodig is en voor haar loy-
aliteit naar mij ook al zien we elkaar minder vaak dan we 
zouden moeten. 
Mijn schoonmoeder Esje Brahim heeft er bijna ongemerkt 
voor gezorgd dat ik tijd vrij kon maken om te werken aan 
mijn proefschrift. Nooit is op de kinderen passen een last 
voor haar, nooit is een inspanning te veel om bij te sprin-
gen in ons gezin. Zij is zo bescheiden in haar aanwezigheid 
maar zo belangrijk voor de routine in het gezin dat zij een 
Cum Laude verdient voor het vak oma zijn.
Mijn zwager Maurice Kartodikromo wil ik bedanken voor 
zijn vriendschap. In hem heb ik al meer dan 10 jaar een 
soul mate.
De drie belangrijkste mensen in leven zijn degenen die de 
grootste offers hebben gebracht. Hoe vaak moest papa weer 
eens “werken aan zijn promotie” in plaats van spelen met 
Morris en Juna, en hoe vaak moest Karin háár agenda weer 
aanpassen als ik weer afspraken had of weer geen tijd.
Morris (2006) jij bent een charmeur en boefje, veel vaker 
dan ik wil lukt het jou om toch je zin te krijgen. Voor deze 
papa is er weinig dat leuker is dan door zijn zoon bij de 
neus te worden genomen.
Juna (2003) jij bent mijn trots en soms moet ik goed kijken 
om te zien dat je pas vijf bent, want vaak lijk je veel groter. 
Je bent voor mij het allermooiste meisje van de wereld en 
Ik vind het heerlijk om gek met je doen …. Je bent mijn 
MEIDER. 
Karin. Niemand kan beter relativeren dan jij. Ik heb in de 
11 jaar dat we elkaar kennen zo veel van je geleerd dat ik 
ervan overtuigd ben een beter mens te zijn door jou. Nog 
steeds ben jij in staat met twee zinnen de angel uit een pro-
bleem te halen waar ik dagen mee rond loop. Jouw intuïtie 
en logische manier van denken dwingen nog dagelijks mijn 
respect af. Maar het is ook gewoon lekker om met je te zijn 
en ons leven samen vorm te geven.
Rogier
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AML Acute Myeloblastic Leukemia 
Asp D, Aspartic acid, (aspartate) 
ASM Aggressive Systemic Mastocytosis
BM Bone Marrow
CD34 Cluster of Differentiation no 34  (cell surface glycoprotein and functions as a 
 cell-cell adhesion factor) 
CD25 Cluster of Differentiation no 25 (interleukin-2 receptor)
C-kit encoding gene for KIT
CM Cutaneous Mastocytosis; mastocytosis only  located in the skin 
CML Chronic Myeloid Leukemia
D816V susbstitution of aspartate to valine in codon 816 (Asp816Val) 
Growth Factor protein capable of stimulating cellular proliferation and cellular differentiation 
Ig Immunoglobulin
ISM Indolent Systemic Mastocytosis 
KIT CD117, c-kit receptor;  cytokine receptor (receptor tyrosine kinase), product 
 of C-kit oncogene
kb kilo base pairs
kD kiloDalton
MCs Mast Cells
MC
TC
 Mast cells connective tissue type
MC
T
 Mast cell mucosal  type
MCL Mast Cell Leukemia  
MF Myelofibrosis
MPD Myeloproliferative Disorder
SCF Stem Cell Factor; (KIT ligand or Steel factor) is a cytokine which binds 
 CD117 (KIT)
SM Systemic Mastocytosis; mastocytosis in one or more extra cutaneous organ
TK Tyrosine Kinase
Tyr Y, Tyrosine 
UP Urticaria Pigmentosa (=maculopapular mastocytosis)
Val V, Valine
WDSM Well-Differentiated Systemic Mastocytosis 
List of abbreviations
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patients with SM [17]. In a pilot study, Droogendijk demon-
strated that imatinib mesylate was effective in patients with SM,
including those with and without the D816V mutation. They
studied 14 patients, of whom ten had D816V mutation. Most
responded to therapy [18]. SM is often complicated by early oste-
oporosis; in one study, osteoporosis in mastocytosis was esti-
mated to be present in up to 30% of cases. Mastocytosis is asso-
ciated with skeletal problems, which include a decrease in bone
density and pathological fractures [19].
Urticaria
Urticaria is characterized by the rapid appearance of wheals that
may be accompanied by angioedema (FIGURE 4). A wheal consists
of a central swelling of variable size, almost invariably surrounded
by an erythema, often with associated itching or sometimes a
burning sensation. The individual lesions have a fleeting nature,
with a duration of usually 1 24 h [20 22]. In small children, urti-
caria can have a blue hue, which often leads to misinterpretation
as urticarial vasculitis or erythema multiforme (FIGURE 5).
Urticaria results from a localized capillary vasodilation and
transudation of protein-rich fluid in the superficial dermis.
Besides histamine, other mediators, including prostaglandins,
leukotrienes, cytokines and chemokines produced at different
times following MC activation also contribute to the changing
character of the urticaria. The mechanism by which MC acti-
vation is induced can be either immunological (IgE mediated,
complement activation components, antiFcHRI autoantibodies
and anti-IgE autoantibodies) or nonimmunological (direct
histamine releasers).
Increasing understanding of the pathomechanisms
involved in urticaria has highlighted the heterogeneity of dif-
ferent subtypes. Recent consensus guidelines distinguish
spontaneous urticaria, physical urticaria, different diseases
related to urticaria for historical reasons and syndromes
including urticaria/angioedema. 
In acute spontaneous urticaria, attacks last less than 6 weeks.
Infection, drugs and food allergy are the main known causes;
however, most cases of acute urticaria remain idiopathic. If
attacks last longer, it is referred to as chronic spontaneous urti-
caria. Attacks may last several months to years. One distin-
guishes immunological and nonimmunological urticaria.
Immunological urticaria is a hypersensitivity reaction mediated
by antibodies and/or T cells, which results in MC activation.
IgE-mediated type I hypersensitivity is a major immunological
pathway associated with MC activation, especially in acute urti-
caria. However, it is not the only mechanism. In particular,
chronic urticaria may result from the binding of IgG autoanti-
bodies to IgE and/or to the receptor for IgE molecules on MCs,
thus corresponding to a type II hypersensitivity reaction.
Approximately 50% of patients with chronic urticaria have
histamine-releasing autoantibodies in their blood. The term
autoimmune urticaria  is increasingly being accepted [23]. In
children, autoimmune urticaria has also been described in
chronic cases. The next most frequent form of long-lasting
urticaria is physical urticaria.
Treatment of urticaria can be divided into three basic
approaches based on the recent review by Zuberbier et al. [21,24].
Acute attacks of urticaria can be managed by short courses of
systemic corticosteroids, but preferably as crisis intervention.
Avoidance, elimination or treatment of the eliciting 
stimulus or cause
This approach is most desirable but, in adults and more rarely
in children, only applicable in a minority of cases. It is per-
formed in IgE-mediated urticaria, such as food allergy and
physical urticaria. In children, most urticaria are caused by
infections and food allergy that are acute in origin and can be
treated more easily [22]. 
Another category that can be treated similarly is physical urti-
caria in adults and children. Factors can be eliminated as much
as possible.Figure 4. Urticaria with normal appearance in a child.
Figure 5. Urticaria with a blue hue often misdiagnosed in 
young children.
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Urticaria results from a localized capillary vasodilation and
transudation of protein-rich fluid in the superficial dermis.
Besides histamine, other mediators, including prostaglandins,
leukotrienes, cytokines and chemokines produced at different
times following MC activation also contribute to the changing
character of the urticaria. The mechanism by which MC acti-
vation is induced can be either immunological (IgE mediated,
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and anti-IgE autoantibodies) or nonimmunological (direct
histamine releasers).
Increasing understanding of the pathomechanisms
involved in urticaria has highlighted the heterogeneity of dif-
ferent subtypes. Recent consensus guidelines distinguish
spontaneous urticaria, physical urticaria, different diseases
related to urticaria for historical reasons and syndromes
including urticaria/angioedema. 
In acute spontaneous urticaria, attacks last less than 6 weeks.
Infection, drugs and food allergy are the main known causes;
however, most cases of acute urticaria remain idiopathic. If
attacks last longer, it is referred to as chronic spontaneous urti-
caria. Attacks may last several months to years. One distin-
guishes immunological and nonimmunological urticaria.
Immunological urticaria is a hypersensitivity reaction mediated
by antibodies and/or T cells, which results in MC activation.
IgE-mediated type I hypersensitivity is a major immunological
pathway associated with MC activation, especially in acute urti-
caria. However, it is not the only mechanism. In particular,
chronic urticaria may result from the binding of IgG autoanti-
bodies to IgE and/or to the receptor for IgE molecules on MCs,
thus corresponding to a type II hypersensitivity reaction.
Approximately 50% of patients with chronic urticaria have
histamine-releasing autoantibodies in their blood. The term
autoimmune urticaria  is increasingly being accepted [23]. In
children, autoimmune urticaria has also been described in
chronic cases. The next most frequent form of long-lasting
urticaria is physical urticaria.
Treatment of urticaria can be divided into three basic
approaches based on the recent review by Zuberbier et al. [21,24].
Acute attacks of urticaria can be managed by short courses of
systemic corticosteroids, but preferably as crisis intervention.
Avoidance, elimination or treatment of the eliciting 
stimulus or cause
This approach is most desirable but, in adults and more rarely
in children, only applicable in a minority of cases. It is per-
formed in IgE-mediated urticaria, such as food allergy and
physical urticaria. In children, most urticaria are caused by
infections and food allergy that are acute in origin and can be
treated more easily [22]. 
Another category that can be treated similarly is physical urti-
caria in adults and children. Factors can be eliminated as much
as possible.Figure 4. Urticaria with normal appearance in a child.
Figure 5. Urticaria with a blue hue often misdiagnosed in 
young children.
Figure 4. Urticaria with normal appearance in a child.
Figure 5. Urticaria with a blue hue often misdiagnosed in young children.
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millimeters to centimeters in diameter. Erythema, swell-
ing, and blister formation as well as itching of the lesions
may occur spontaneously or after stroking or rubbing.
The blistering heals without permanent scarring. The
lesions are generalized and randomly disseminated. The
palms, soles, scalp, and sunlight-exposed areas of the
body are often less affected, especially in older children.
Dermatographism and pruritus may be present, but
these features per se have no diagnostic value.
Complete resolution of the lesions may occur in 10%
of patients and significant improvementmay be expected
in up to 70% of patients by the age of 10 years (9,11,13).
Data on the number of persistent cases of childhood-
onset mastocytosis are limited and range from 25% to
57% (13,14).
The second most common cutaneous presentation of
childhood-onset mastocytosis is solitary mastocytoma
(Fig. 2A) definedby the presence of one to several lesions
(commonly five separate lesions or less) that have char-
acteristics similar to those of urticaria pigmentosa. It is
encountered in 10–35% of the cases of childhood-onset
TABLE 1. Clinical Signs of Mastocytosis
Disease Age predominance Characteristics
Mastocytoma 0–6 months 1–5 red/brown hyperpigmented or skin colored nodules(s)
Urticaria pigmentosa (UP) 3–9 months; most
frequent presentation
Multiple red-brown hyperpigmented macules and papules
Diffuse cutaneous mastocytosis Rare; often at birth Thickened, lichenified skin with papules, rarely without
skin abnormalities; bullae after minimal trauma
Telangiectasia macularis
eruptiva perstans (TMEP)
Adults Numerous hyperpigmented telangiectatic macules
Systemic mastocytosis Adults; rare in children Mast cell infiltrates in skin and internal organs
Mast cell leukemia Adults; rare in children Anemia; mast cells in peripheral blood
Figure 1. Urticaria pigmentosa.
Figure 2. (A) Solitary mastocytoma. (B) Solitary mastocy-
toma, Darier sign positive.
mastocytosis (11,13,15). However, this figure may be an
underestimate, as an asymptomatic solitary lesion may
be overlooked or mistaken for a mole or juvenile xan-
thogranuloma. Of all clinical subtypes of childhood on-
set mastocytosis, solitary mastocytoma invariably
follows amild course with complete resolution, generally
before adulthood.
Diffuse cutaneous mastocytosis (Fig. 3) is rare and
most patients have been described in single case reports.
By definition, the whole skin is involved, although the
central region and the scalp are primarily affected. The
clinical features become prominent at birth or in early
infancy (1,15,16). These consist of widespread sponta-
neous blisteringwith erosions and crusts, various degrees
of erythroderma, strong dermatographism, and itching.
The diagnosis of mastocytosis must be ruled out in
newborns with blistering and bullae. The blisters may be
hemorrhagic in diffuse cutaneousmastocytosis. The skin
may be leathery and thickened, especially in the flexural
regions. In toddlers the skin becomes less reactive, but
diffuse hyperpigmentation and positive dermatogra-
phism may persist into adulthood.
Telangiectasiamacularis eruptiva perstans (TMEP) is
the least common cutaneous manifestation of mastocy-
tosis. The lesions consist of persistent red telangiectatic
areas without any signs of macules or papules. The le-
sions are poorly demarcated and sometimes difficult to
recognize. Darier sign (swelling and redness induced by
rubbing of the lesion) is generally positive (1). As an
entity, it is said to occur only in adults. The clinical fea-
tures overlap with those of UP. TMEP should be dis-
tinguished from telangiectatic UP in which guttate
telangiectatic macules are observed. Underestimation of
its incidence is plausible, especially in children.
SYMPTOMS
Essentially all types of childhood-onset mastocytosis
may be associated with localized and systemic symp-
toms caused by mast cell mediators (Table 2) (1,17). The
most common symptoms are pruritus, redness, and
swelling. These may occur spontaneously or secondarily
after thermal, mechanical, or chemical stimuli. In in-
fants, blistering is common. On rare occasions these
blisters may have hemorrhagic content, as skin mast
cells have been shown to regulate hemostasis (18).
Gastrointestinal complaints are common and consist
primarily of diarrhea and abdominal pains in up to 40%
of children with mastocytosis (10,11,13,19). Hyperacid-
ity and subsequent peptic ulcers secondary to high his-
tamine levels in pediatric mastocytosis have been
TABLE 2. Mast Cell Mediators
Skin specimens Histamine
Leukotriene B4 (LTB4)
5-hydroxyeicosatetraenoic
acid (5-HETE)
Tryptase
Chymase
Heparin
Cutaneous
blister fluid
Histamine
Prostaglandin D2 (PGD2)
Platelet-activating factor (PAF)
Plasma Histamine
a-Tryptase
Urine Histamine
Histamine metabolites
NT-methylhistamine
NT-methylimidazole acetic acid
PGD2 metabolites
9-a-hydroxy-11, 15-dioxo-2,3,4,
5-tetra-norprostane-1,20-dioic acid
9-a, 11 b-dihidroxy-15-oxo-2,
3,18,19-tetranorprost-5-ene-1,
20-dioic acid (PGD-M)
Chondroitin sulfate B
Hyaluronic acid
Arylsulfatases A and B
Figure 3. Diffuse cutaneous mastocytosis.
re 1. rticaria pigmentosa.
igure 2. ) olitary astocytoma.(B) Solitary 
mastocytoma, Darier sign positive.
igure 3. iffuse cutaneous mastocytosis.
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cutaneous mastocytosis with lesions of several centimeters in diameter and solitary mastocytomas do not evolve but 
tend to disappear6.  Pediatric mastocytosis is predominantly encountered in patients during the first 2 years of life. 
Maculopapular mastocytosis is the commonest variant, but this may depend on the setting of the institution. The 
prognosis of pediatric mastocytosis is mostly good 5,7,8. The visible cutaneous abnormalities in CM are frequently of 
major concern to the patients and their family. In about the half of the children the manifestations disappear before, 
during or in late puberty.  As a subtype of pediatric mastocytosis diffuse cutaneous mastocytosis (DCM) remains a 
rarity9,10. The clinical picture may be impressive and treatment options for severe cases include oral steroids and 
PUVA, mild cases may benefit form anti-histamine agents. Eight patients with DCM are reported in this 
communication.  
 
       ….. r  ….PATIENTS AND METHODS……  ..S      
 
The combined group of patients with predominantly cutaneous mastocytosis presently under surveillance of the 
authors consists of 8 patients with DCM.  Consent for publication of data and clinical photographs were obtained 
either from the patients or their parents and approval of the medical ethical committee was obtained. 
Four patients were seen at the Pediatric Dermatology Unit of the department of dermatology Erasmus Medical Center, 
Rotterdam. The remaining 4 patients were seen at the dermatology outpatient clinic of University Medical Center, 
Utrecht, at the outpatient clinic of Radboud University Medical Center, Nijmegen, at the department of pediatrics, 
Onze Lieve Vrouweziekenhuis in Aalst, Belgium, and at the 1st Pediatric Department, Athens University, Aghia Sophia 
Children’s Hospital in Athens. Greece. The follow up ranged from 2 to 19 years, with a mean follow up of 9 years. The 
characteristics of all 8 patients are shown in Tables 1a and 1b.  
The diagnostics included history, physical examination, skin biopsy, serum Tryptase and urinary N-methylhistamine 
levels and abdominal ultrasound11,12. In the cases with a follow up of over 5 years, initial mast cell mediator analysis 
included urinary N-methylhistamine which was later replaced with serum Tryptase as the preferred indicator of mast 
cell activity. The average decline in the level of serum Tryptase was 65% over a period of 4.5 years in seven patients. 
One patient had serum Tryptase level of higher than 200 ng/l which exceeded the range of laboratory test. In this case 
no changes in the level of serum Tryptase were observed. 
 Two cases (Patients no.1 and 8) are described in details. Patient no. 1 represents a typical case starting in the first 
months of life. Bone marrow biopsy was not obtained from this patient. Patient no. 8 represents an impressive case of 
the same disease manifestation illustrating the diversity of DCM. In this case neither bone marrow analysis nor c-kit 
mutation analysis showed significant changes. 
HISTOPATHOLOGY 
Histopathological examination of the skin biopsy in all cases showed the same pattern of a diffuse infiltration of mast 
cells as a broad band under the epidermis, which was accompanied by either a large or a small blister formation. The 
clinically involved skin was somewhat more infiltrated than the not involved skin, but the general histopathological 
picture was the same. 
 
 
Figure 1a and 1b 

 

 
Histopathology of Diffuse Cutaneous Mastocytosis 
(1a H&E staining 100X, 1b Tryptase staining – inset- 400X)
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Figure 1a and 1b. Histopathology of Diffuse Cutaneous 
Mastocytosis (1a H&E staining, 1b Tryptase staining - 
inset 400x).
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Table 1b 
 
Patient 
number 
follow up 
(yrs) 
mediator 
levels# 
Period 
(yrs) c-Kit mutation analysis 
1 9 Nmh -93% 3 n.a. 
2 19 Nmh -28% 5 asp816val 
3 13 Nmh -72% 6 n.a. 
4 4 Tryptase  -58% 3 n.a. 
5 6 Tryptase -22% 1 n.a. 
6 3 Tryptase -83% 3 n.a. 
7 15 Nmh/Tryptase -85% 10 n.a. 
8 2 Tryptase change not esthablished ## 2 negative 
n.a. = information is not available 
Clinical characteristics of eight DCM  cases 
 
Published cases  
* Kuijken I, Bergman W, Oranje AP. Diffuse cutaneous mastocytosis. Ned Tijdschr Geneeskd 2001;145:1527. Dutch. 
** Oranje AP, Soekanto W, Sukardi A, Vuzevski VD, van der Willigen A, Afiani 
HM. Diffuse cutaneous mastocytosis mimicking staphylococcal scalded-skin  syndrome: report of three cases. Pediatr Dermatol 
1991;8:147-51. 
# Note: 
The mast cell mediators urinary N-methylhistamine and serum Tryptase are both valid parameters of mast cell activity in mastocytosis. 
As the markers were not available in all patients at all times, therefore the changes in time of the measured parameters are mentioned. 
## Note: 
The laboratory report did not specify values in excess of 200 µl/l. The initial Tryptase level present in this patient  exceeded of 200 µl/l. 
 
Figure 2 
 
Red large blister type (in patient no 5.) 
Figure 3 
 
 
 
Red large blister type (patient no 1.)
Figure 2. Red large blister type 
                (patient no 5).
Figure 3. Red large blister type 
                (patient no 1).
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Red large blister type (in patient no 5.)
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Red large blister type (patient no 1.)
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Figure 4 
 
 
 
Yellow infiltrated small blister type 
(patient no 7.) 
Figure 5 
 
 
 
Yellow infiltrated small blister type 
(patient no 4.) 
Figure 6 
 
 
 
Yellow infiltrated small blister type extreme presentation (patient no 8.) 
Figure 4. Yellow infiltrated small blister type
                (patient no 7).
Figure 5. Yellow infiltrated small blister type
                (patient no 4).
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Yellow infiltrated small blister type extreme presentation (patient no 8.) 
Figure 6. Yellow infiltrated small blister type extreme  presentation (patient no 8).
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DISCUSSION
In our present study, the numbers of MCs in adults were
determined in biopsies obtained from five different body
sites. Higher numbers of MCs were found in the forearm and
lower leg (distal extremities) compared with those in the
trunk, upper leg, and upper arm (centre and proximal
extremities). Mast cells on the face were not counted in our
study because diagnostic biopsies for mastocytosis are
preferentially not taken from the face. From a pilot study
in 14 patients with mastocytosis, we concluded that the lower
limit for the number of MCs in mastocytosis may be as low as
78 MCs/mm2, which is also lower than the mean number of
MCs in healthy skin (87.8 MCs/mm2). Thus, there was an
overlap in the range of numbers of MCs in mastocytosis and
normal skin.
The first reports on the measurement of MC numbers in
different body sites date to 1950.15 In those early studies,5 6 10
different counting and staining techniques were used and no
differences in the numbers of MCs in relation to the site of
origin of the biopsy were noted. The numbers of MCs were
found to be between 44 and 50 MCs/mm2. The uneven
distribution in the numbers of MCs in different body
sites may be the result of differences in their functional,
environmental, and haemodynamic properties. Although still
controversial, the numbers of MCs do not appear to be related
to variations in the exposure of different body sites to
ultraviolet light.16–20
We confirm the results obtained by Weber et al, who
reported increased numbers of MCs on the face compared with
other body sites and variations in numbers of MCs at different
body sites similar to those reported here.21 The main difference
between their study and ours is that they used the toluidine
blue staining technique. It may be the case that more granules
were stained in our study than that of Weber et al because the
ATA technique is more sensitive than the toluidine blue stain
used in their study. We also used a high magnification (6400)
for analysing stained MCs from a picture on the computer
screen. This may have magnified groups of granules that
would have otherwise remained undetected.
‘‘There was an overlap in the range of numbers of mast
cells in mastocytosis and normal skin’’
Collecting a large number of skin samples, using perile-
sional skin biopsies from BCCs or various dermatological
disorders was useful, making biopsies from healthy indivi-
duals (controls) unnecessary. Cohen and Rogers emphasised
the increased numbers of MCs around BCCs.22 They reported
significant differences between the numbers of MCs in skin
directly adjacent to a BCC compared with the surrounding
skin, independent of the overall inflammatory cell response
in the area. An increase in the numbers of MCs was described
above and around multiple and single dermatofibromas and
other benign epithelial tumours.23 24 In contrast, in other
Figure 3 (A) Normal skin near basal cell carcinoma (original magnification,6100). Mast cells occur in the normal dermis in small numbers as oval to
spindle shaped cells. They are concentrated around the blood vessels. (B) Normal skin of mamma reduction tissue (original magnification,6100). Mast
cells occur in the normal dermis in small numbers as oval to spindle shaped cells. They are concentrated around the blood vessels. (C) Haematoxylin
and eosin staining of mastocytosis (urticaria pigmentosa) (original magnification,6100). Mast cells in the normal skin are indistinguishable from other
perivascular cells. A small amount of granular cytoplasm is seen. (D) Urticaria pigmentosa, dense infiltrate of mast cells in the upper dermis located
directly under the basal membrane. The infiltrate is also more concentrated around the blood vessels (original magnification,6300). (E) Urticaria
pigmentosa: positive staining of the mast cell infiltrate with CD117 (original magnification,6300). (F) Urticaria pigmentosa: positive staining of the
mast cell infiltrate with CD117 (original magnification,6700).
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Figure 3. 
(A) Normal skin ear basal cell carcinoma (original magnification, ×100. Mast cells occur in the 
normal dermis in s all numbers as ov l to spindle shaped cells. They are c ncentrated around 
the blood vessels. 
(B) Normal skin of mamma reduction tissue (original magnification, ×100). Mast cells occur in 
the normal dermis in small numbers as oval to spindle shaped cells. They are concentrated 
around the blood vessels. 
(C) Haematoxylin and eosin staining of mastocytosis (urticaria pigmentosa) (original magnification, 
×100). Mast cells in the normal skin are indistinguishable from other perivascular cells. A 
small amount of granular cytoplasm is seen. 
(D) Urticaria pigmentosa, dense infiltrate of mast cells in the upper dermis located directly under 
the basal membrane. The infiltrate is also more concentrated around the blood vessels (original 
magnification, ×300).
(E) Urticaria pigmentosa: positive staining of the mast cell infiltrate with CD117 (original 
magnification, ×300). 
(F) Urticaria pigmentosa: positive staining of the mast cell infiltrate with CD117 (original 
magnification, ×700).
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had previously developed and described in details else-
where  [9] . The SCORMA Index in the 5 adults ranged 
from 35 to 47 (mean 40), whereas it ranged from 28 to 41 
(mean 35) in the 6 children before wet-wrap treatment. 
The most common subjective symptoms before and after 
treatment are summarized in  table 1 . 
 Prior to this pilot study, wet-wrap treatment with di-
luted corticosteroids was approved by the Medical Ethi-
cal Committee of our institution. After informed con-
sent had been obtained, each patient was treated with 
25% dilution of fluticasone propionate cream 0.05% ap-
plied daily under a wet-wrap occlusion dressing for 6 
weeks. The amount of cream used for the 5 adults ranged 
from 4 to 12 g (average 8 g) daily and for the 6 children 
ranged from 3 to 5 g (average 4 g daily) and were per-
formed according to the finger tip method. The therapy 
compliance was monitored by regularly weighing the 
amount of cream. The patients were evaluated at 3, 6, 12 
and 24 weeks after the start of the treatment. Biochemi-
cal parameters such as routine blood and urine examina-
tion including the levels of urinary N-methylhistamine 
and fasting serum cortisol were monitored at each evalu-
ation. Skin infiltrates were stained using the Leder tech-
nique  [10] . The number of mast cells was also counted in 
lesional skin biopsies from all patients before and 6 weeks 
after treatment. Clinical improvement was assessed 
 using SCORMA. The SCORMA Index in the 5 adults 
ranged from 7 to 41 (mean 27), whereas it ranged from 
15 to 46 (mean 26) in the 6 children after wet-wrap treat-
ment.
 Fig. 1.  a Mastocytosis lesions in a patient 
before treatment with 25% diluted flutica-
sone propionate 0.05% cream under occlu-
sion.  b A partial but clear cosmetic im-
provement in the same patient 24 weeks 
after treatment. 
 Fig. 2.  a A large number of mast cell in a 
histological section of lesional skin biopsy 
before treatment. Leder staining.  ! 160.
 b A decreased number of mast cells in the 
histological section of lesional skin biopsy 
after 6 weeks of treatment. Leder staining. 
 ! 100. 
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Figure 1. 
a. Mastocytosis lesions in a patient before treatment with 25% diluted fluticasone 
propionate 0.05% cream under occlusion.
b. A partial but clear cosmetic improvement in the same patient 24 weeks after 
treatment.
Figur  2. 
a. A large number of mast cells in a histological section of lesional skin biopsy 
before treatment. Leder staining. ×160.
b. A decreased number of mast cells in the histological section of lesional skin 
biopsy after 6 weeks of treatment. Leder staining. ×100.
 Heide  /de Waard-van der Spek  /
den Hollander  /Tank  /Oranje  
Dermatology 2007;214:333–335334
had previously developed and described in details else-
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(mean 35) in the 6 children before wet-wrap treatment. 
The most common subjective symptoms before and after 
treatment are summarized in  table 1 . 
 Prior to this pilot study, wet-wrap treatment with di-
luted corticosteroids was approved by the Medical Ethi-
cal Committee of our institution. After informed con-
sent had been obtained, each patient was treated with 
25% dilution of fluticasone propionate cream 0.05% ap-
plied daily under a wet-wrap occlusion dressing for 6 
weeks. The amount of cream used for the 5 adults ranged 
from 4 to 12 g (average 8 g) daily and for the 6 children 
ranged from 3 to 5 g (average 4 g daily) and were per-
formed according to the finger tip method. The therapy 
compliance was monitored by regularly weighing the 
amount of cream. The patients were evaluated at 3, 6, 12 
and 24 weeks after the start of the treatment. Biochemi-
cal parameters such as routine blood and urine examina-
tion including the levels of urinary N-methylhistamine 
and fasting serum cortisol were monitored at each evalu-
ation. Skin infiltrates were stained using the Leder tech-
nique  [10] . The number of mast cells was also counted in 
lesional skin biopsies from all patients before and 6 weeks 
after treatment. Clinical improvement was assessed 
 using SCORMA. The SCORMA Index in the 5 adults 
ranged from 7 to 41 (mean 27), whereas it ranged from 
15 to 46 (mean 26) in the 6 children after wet-wrap treat-
ment.
 Fig. 1.  a Mastocytosis lesions in a patient 
before treatment with 25% diluted flutica-
sone propionate 0.05% cream under occlu-
sion.  b A partial but clear cosmetic im-
provement in the same patient 24 weeks 
after treatment. 
 Fig. 2.  a A large number of mast cell in a 
histological section of lesional skin biopsy 
before treatment. Leder staini g.  ! 160.
 b A decreased number of mast cells in the 
histological section of lesional skin biopsy 
after 6 weeks of treatment. Leder staining. 
 ! 100. 
